<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS One</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-title-group><journal-title>PLOS One</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, CA USA</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40408335</article-id><article-id pub-id-type="pmc">PMC12101706</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0322144</article-id><article-id pub-id-type="publisher-id">PONE-D-24-18152</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Medical Humanities</subject><subj-group><subject>Medical Journals</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Mental Health and Psychiatry</subject></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and Analysis Methods</subject><subj-group><subject>Research Design</subject><subj-group><subject>Clinical Research Design</subject><subj-group><subject>Survival Analysis</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and Analysis Methods</subject><subj-group><subject>Mathematical and Statistical Techniques</subject><subj-group><subject>Statistical Methods</subject><subj-group><subject>Survival Analysis</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Physical Sciences</subject><subj-group><subject>Mathematics</subject><subj-group><subject>Statistics</subject><subj-group><subject>Statistical Methods</subject><subj-group><subject>Survival Analysis</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Oncology</subject><subj-group><subject>Cancer Treatment</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Pulmonology</subject></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Pain Management</subject></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Oncology</subject></subj-group></subj-group></article-categories><title-group><article-title>Data-driven prior elicitation for Bayes factors in Cox regression for nine subfields in biomedicine</article-title><alt-title alt-title-type="running-head">Priors for Bayes factors in Cox regression</alt-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-8421-090X</contrib-id><name><surname>Linde</surname><given-names>Maximilian</given-names></name><role content-type="http://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role content-type="http://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role content-type="http://credit.niso.org/contributor-roles/software/">Software</role><role content-type="http://credit.niso.org/contributor-roles/visualization/">Visualization</role><role content-type="http://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><xref rid="aff001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="cor001" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name><surname>Jochim</surname><given-names>Laura</given-names></name><role content-type="http://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="aff003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-1660-3642</contrib-id><name><surname>Tendeiro</surname><given-names>Jorge N.</given-names></name><role content-type="http://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role content-type="http://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><role content-type="http://credit.niso.org/contributor-roles/methodology/">Methodology</role><role content-type="http://credit.niso.org/contributor-roles/supervision/">Supervision</role><role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="aff004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-5030-4091</contrib-id><name><surname>van Ravenzwaaij</surname><given-names>Don</given-names></name><role content-type="http://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role content-type="http://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><role content-type="http://credit.niso.org/contributor-roles/methodology/">Methodology</role><role content-type="http://credit.niso.org/contributor-roles/supervision/">Supervision</role><role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="aff002" ref-type="aff">
<sup>2</sup>
</xref></contrib></contrib-group><aff id="aff001"><label>1</label>
<addr-line>GESIS - Leibniz Institute for the Social Sciences, Cologne, Germany</addr-line></aff><aff id="aff002"><label>2</label>
<addr-line>Department of Psychometrics and Statistics, University of Groningen, Groningen, The Netherlands</addr-line></aff><aff id="aff003"><label>3</label>
<addr-line>Utrecht University, Utrecht, The Netherlands</addr-line></aff><aff id="aff004"><label>4</label>
<addr-line>Graduate School of Advanced Science and Engineering, Hiroshima University, Hiroshima, Japan</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>Haunschild</surname><given-names>Robin</given-names></name><role>Editor</role><xref rid="edit1" ref-type="aff"/></contrib></contrib-group><aff id="edit1">
<addr-line>Max Planck Institute for Solid State Research, GERMANY</addr-line>
</aff><author-notes><corresp id="cor001">* E-mail: <email>maximilian.linde@gesis.org</email></corresp><fn fn-type="COI-statement" id="coi001"><p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p></fn></author-notes><pub-date pub-type="epub"><day>23</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>20</volume><issue>5</issue><elocation-id>e0322144</elocation-id><history><date date-type="received"><day>6</day><month>5</month><year>2024</year></date><date date-type="accepted"><day>17</day><month>3</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; 2025 Linde et al</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Linde et al</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="pone.0322144.pdf">
</self-uri><abstract><p>Biomedical research often utilizes Cox regression for the analysis of time-to-event data. The pervasive use of frequentist inference for these analyses implicates that the evidence for or against the presence (or absence) of an effect cannot be directly compared and that researchers must adhere to a predefined sampling plan. As an alternative, the use of Bayes factors improves upon these limitations, which is especially important for costly and time-consuming biomedical studies. However, Bayes factors involve their own difficulty of specifying priors for the parameters of the statistical model. In this article, we develop data-driven priors centered around zero for Cox regression tailored to nine subfields in biomedicine. To this end, we extracted hazard ratios and associated <inline-formula id="pone.0322144.e001"><alternatives><graphic xlink:href="pone.0322144.e001.jpg" id="pone.0322144.e001g" position="anchor"/><mml:math id="M1" display="inline" overflow="scroll"><mml:mrow><mml:mi>x</mml:mi><mml:mi>%</mml:mi></mml:mrow></mml:math></alternatives></inline-formula> confidence intervals from the abstracts of large corpora of already existing studies within the nine biomedical subfields. We used these extracted data to inform priors for the nine subfields. All of our suggested priors are Normal distributions with means of 0 and standard deviations closely scattered around 1. We propose that researchers use these priors as reasonable starting points for their analyses.</p></abstract><funding-group><award-group id="award001"><funding-source>
<institution-wrap><institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/501100003246</institution-id><institution>Nederlandse Organisatie voor Wetenschappelijk Onderzoek</institution></institution-wrap>
</funding-source><award-id>016.Vidi.188.001</award-id><principal-award-recipient>
<contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-5030-4091</contrib-id>
<name><surname>van Ravenzwaaij</surname><given-names>Don</given-names></name>
</principal-award-recipient></award-group><award-group id="award002"><funding-source>
<institution-wrap><institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/501100000646</institution-id><institution>Japan Society for the Promotion of Science London</institution></institution-wrap>
</funding-source><award-id>21K20211</award-id><principal-award-recipient>
<contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-1660-3642</contrib-id>
<name><surname>Tendeiro</surname><given-names>Jorge N.</given-names></name>
</principal-award-recipient></award-group><funding-statement>This research was supported by a Dutch scientific organization VIDI fellowship grant (016.Vidi.188.001) awarded to Don van Ravenzwaaij and a Japanese JSPS KAKENHI grant (21K20211) awarded to Jorge N. Tendeiro. Neither of the funders played any role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement></funding-group><counts><fig-count count="6"/><table-count count="10"/><page-count count="22"/></counts><custom-meta-group><custom-meta id="data-availability"><meta-name>Data Availability</meta-name><meta-value>Data used in section &#x02018;Example Application&#x02019; was shared with the authors by NIAID and may not be distributed beyond the first and last author (for more information, see <ext-link xlink:href="https://accessclinicaldata.niaid.nih.gov/" ext-link-type="uri">https://accessclinicaldata.niaid.nih.gov/</ext-link>). All other data may be obtained from the OSF page associated with the project: <ext-link xlink:href="https://osf.io/ua4ys/" ext-link-type="uri">https://osf.io/ua4ys/</ext-link>.</meta-value></custom-meta></custom-meta-group></article-meta><notes><title>Data Availability</title><p>Data used in section &#x02018;Example Application&#x02019; was shared with the authors by NIAID and may not be distributed beyond the first and last author (for more information, see <ext-link xlink:href="https://accessclinicaldata.niaid.nih.gov/" ext-link-type="uri">https://accessclinicaldata.niaid.nih.gov/</ext-link>). All other data may be obtained from the OSF page associated with the project: <ext-link xlink:href="https://osf.io/ua4ys/" ext-link-type="uri">https://osf.io/ua4ys/</ext-link>.</p></notes></front><body><sec sec-type="intro" id="sec001"><title>Introduction</title><p>The collection and analysis of time-to-event data forms a central part of modern biomedical research (see, e.g., [<xref rid="pone.0322144.ref001" ref-type="bibr">1</xref>&#x02013;<xref rid="pone.0322144.ref006" ref-type="bibr">6</xref>]). In these types of designs, the outcome variable is the time until an event of interest occurs, which is commonly called the survival time. In the medical context, this event of interest could be, for example, death, relapse towards alcoholism, disease/symptom onset, or recovery. Using survival analysis (we refer the interested reader to other sources, which treat survival analysis more thoroughly; e.g., [<xref rid="pone.0322144.ref007" ref-type="bibr">7</xref>&#x02013;<xref rid="pone.0322144.ref015" ref-type="bibr">15</xref>]), it is possible to estimate differences in event rates between conditions, which makes it particularly appealing for clinical trials. For instance, evidence about the effectiveness of an oncological treatment of cancer patients could be gathered by comparing the survival times of patients receiving the treatment to the survival times of patients receiving a placebo or an active control treatment (for examples see [<xref rid="pone.0322144.ref001" ref-type="bibr">1</xref>,<xref rid="pone.0322144.ref016" ref-type="bibr">16</xref>,<xref rid="pone.0322144.ref017" ref-type="bibr">17</xref>]).</p><p>The use of frequentist inference for the analysis of survival data has a long tradition in biomedical research and is still very common today [<xref rid="pone.0322144.ref018" ref-type="bibr">18</xref>]. Classical frequentist inference, however, is not well suited to quantify evidence in favor of the absence of an effect. In addition, frequentist inference requires fixing the study sample size in advance to avoid an inflation of the Type I and/or Type II error rates [<xref rid="pone.0322144.ref019" ref-type="bibr">19</xref>], a downside that can be particularly costly in the realm of resource-intensive biomedical research and clinical trials [<xref rid="pone.0322144.ref018" ref-type="bibr">18</xref>,<xref rid="pone.0322144.ref020" ref-type="bibr">20</xref>,<xref rid="pone.0322144.ref021" ref-type="bibr">21</xref>]. A prominent way to deal with this issue within the frequentist framework is the use of group sequential designs, whereby sequential testing and optional stopping of data collection is permitted at the cost of implementing some procedure that controls the Type I and/or Type II error rates. These designs have a long and successful tradition in biomedicine (e.g., [<xref rid="pone.0322144.ref022" ref-type="bibr">22</xref>]). As an alternative, Bayesian statistics have gained popularity among researchers [<xref rid="pone.0322144.ref023" ref-type="bibr">23</xref>]. In particular, Bayes factors [<xref rid="pone.0322144.ref024" ref-type="bibr">24</xref>&#x02013;<xref rid="pone.0322144.ref027" ref-type="bibr">27</xref>] do not suffer from the two limitations mentioned before and are therefore a valuable alternative for conducting inference in biomedical research [<xref rid="pone.0322144.ref028" ref-type="bibr">28</xref>].</p><p>Bayesian modeling with the goal of either hypothesis testing or parameter estimation requires the specification of a prior distribution for the parameters of the model. The prior expresses one&#x02019;s beliefs about the plausibility of parameter values before observing the data [<xref rid="pone.0322144.ref029" ref-type="bibr">29</xref>&#x02013;<xref rid="pone.0322144.ref031" ref-type="bibr">31</xref>]. Oftentimes, it is notoriously difficult to express these beliefs. Moreover, within Bayesian hypothesis testing, different priors sometimes lead to qualitatively different Bayes factors [<xref rid="pone.0322144.ref030" ref-type="bibr">30</xref>,<xref rid="pone.0322144.ref032" ref-type="bibr">32</xref>&#x02013;<xref rid="pone.0322144.ref036" ref-type="bibr">36</xref>]. As a result, some researchers lament that the use of Bayesian statistics involves subjectivity (e.g., [<xref rid="pone.0322144.ref037" ref-type="bibr">37</xref>]) and that proper guidance is missing, possibly resulting in hesitation to use Bayesian inference. Hence, recommendations for well-established default priors in Bayesian survival analysis - in particular Cox proportional hazards regression (henceforth called Cox regression or Cox model; [<xref rid="pone.0322144.ref038" ref-type="bibr">38</xref>]) - are missing and urgently needed.</p><p>In this article, we propose default priors for Bayesian Cox regression tailored to nine subfields within biomedicine. The construction of these priors harnesses historical records consisting of large corpora of hazard ratios and associated <inline-formula id="pone.0322144.e002"><alternatives><graphic xlink:href="pone.0322144.e002.jpg" id="pone.0322144.e002g" position="anchor"/><mml:math id="M2" display="inline" overflow="scroll"><mml:mrow><mml:mi>x</mml:mi><mml:mi>%</mml:mi></mml:mrow></mml:math></alternatives></inline-formula> confidence intervals from existing studies within the respective subfields. We argue that these proposed priors can be used as reasonable defaults or starting points for biomedical researchers wishing to conduct a Bayesian Cox regression.</p><p>The remainder of this article is structured as follows: First, we provide an overview of Cox regression and Bayes factors. Second, we briefly review how priors can be defined. Third, we explain our process of generating priors for nine subfields in biomedicine and present the corresponding results. Fourth, we reflect on our findings and implications thereof, and conclude with recommendations.</p><sec id="sec002"><title>Bayes factors in Cox regression</title><p>Survival analysis is a statistical method to analyze time-to-event/survival data. Among the many existing forms of survival analysis - for example, Kaplan-Meier product-limit estimator [<xref rid="pone.0322144.ref039" ref-type="bibr">39</xref>], parametric survival analyses (e.g., Exponential, Gompertz, and Weibull), and Cox regression [<xref rid="pone.0322144.ref038" ref-type="bibr">38</xref>] - the latter is used most frequently within biomedicine (e.g., [<xref rid="pone.0322144.ref010" ref-type="bibr">10</xref>]). Therefore, our treatment of priors for survival analysis is limited to the case of Cox regression.</p><p>In Cox regression, the hazard function <inline-formula id="pone.0322144.e003"><alternatives><graphic xlink:href="pone.0322144.e003.jpg" id="pone.0322144.e003g" position="anchor"/><mml:math id="M3" display="inline" overflow="scroll"><mml:mrow><mml:mi>&#x003bb;</mml:mi><mml:mrow><mml:mo fence="true" form="prefix" stretchy="true">(</mml:mo><mml:mi>t</mml:mi><mml:mo fence="true" form="postfix" stretchy="true">)</mml:mo></mml:mrow></mml:mrow></mml:math></alternatives></inline-formula> presents the risk of an event happening in a small time period around a specific time <italic toggle="yes">t</italic> within cases for which the event has not yet happened before time <italic toggle="yes">t</italic> (see, e.g., [<xref rid="pone.0322144.ref007" ref-type="bibr">7</xref>,<xref rid="pone.0322144.ref008" ref-type="bibr">8</xref>]). The specific <inline-formula id="pone.0322144.e004"><alternatives><graphic xlink:href="pone.0322144.e004.jpg" id="pone.0322144.e004g" position="anchor"/><mml:math id="M4" display="inline" overflow="scroll"><mml:mrow><mml:mi>&#x003bb;</mml:mi><mml:mrow><mml:mo fence="true" form="prefix" stretchy="true">(</mml:mo><mml:mi>t</mml:mi><mml:mo fence="true" form="postfix" stretchy="true">)</mml:mo></mml:mrow></mml:mrow></mml:math></alternatives></inline-formula> is allowed to have any shape but must be proportional across all values of an independent variable <italic toggle="yes">x</italic>. Usually, the main goal is not to estimate <inline-formula id="pone.0322144.e005"><alternatives><graphic xlink:href="pone.0322144.e005.jpg" id="pone.0322144.e005g" position="anchor"/><mml:math id="M5" display="inline" overflow="scroll"><mml:mrow><mml:mi>&#x003bb;</mml:mi><mml:mrow><mml:mo fence="true" form="prefix" stretchy="true">(</mml:mo><mml:mi>t</mml:mi><mml:mo fence="true" form="postfix" stretchy="true">)</mml:mo></mml:mrow></mml:mrow></mml:math></alternatives></inline-formula> but rather to estimate the <inline-formula id="pone.0322144.e006"><alternatives><graphic xlink:href="pone.0322144.e006.jpg" id="pone.0322144.e006g" position="anchor"/><mml:math id="M6" display="inline" overflow="scroll"><mml:mrow><mml:mi>&#x003b2;</mml:mi></mml:mrow></mml:math></alternatives></inline-formula> parameter of the Cox model:</p><disp-formula id="pone.0322144.e007"><alternatives><graphic xlink:href="pone.0322144.e007.jpg" id="pone.0322144.e007g" position="anchor"/><mml:math id="M7" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>&#x003bb;</mml:mi><mml:mrow><mml:mo fence="true" form="prefix" stretchy="true">(</mml:mo><mml:mi>t</mml:mi><mml:mo>&#x02223;</mml:mo><mml:mi>x</mml:mi><mml:mo fence="true" form="postfix" stretchy="true">)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mi>&#x003bb;</mml:mi><mml:mrow><mml:mo fence="true" form="prefix" stretchy="true">(</mml:mo><mml:mi>t</mml:mi><mml:mo fence="true" form="postfix" stretchy="true">)</mml:mo></mml:mrow><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mi>x</mml:mi><mml:mi>&#x003b2;</mml:mi></mml:mrow></mml:msup><mml:mtext>.</mml:mtext></mml:mrow></mml:mrow></mml:math></alternatives>
<label>(1)</label></disp-formula><p>Here and throughout, we work with the specific case where <italic toggle="yes">x</italic> is dichotomous and dummy-coded (i.e., there are two conditions, a common situation in biomedical designs). For this scenario, a hazard ratio can be calculated</p><disp-formula id="pone.0322144.e008"><alternatives><graphic xlink:href="pone.0322144.e008.jpg" id="pone.0322144.e008g" position="anchor"/><mml:math id="M8" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:mtext>HR</mml:mtext><mml:mo>=</mml:mo><mml:msup><mml:mi>e</mml:mi><mml:mi>&#x003b2;</mml:mi></mml:msup><mml:mtext>,</mml:mtext></mml:mrow></mml:mrow></mml:math></alternatives>
<label>(2)</label></disp-formula><p>which provides information about the relative hazard rates between conditions.</p><p>In clinical trials, <inline-formula id="pone.0322144.e009"><alternatives><graphic xlink:href="pone.0322144.e009.jpg" id="pone.0322144.e009g" position="anchor"/><mml:math id="M9" display="inline" overflow="scroll"><mml:mrow><mml:mtext>HR</mml:mtext></mml:mrow></mml:math></alternatives></inline-formula> is often the key indicator regarding the effectiveness of a treatment. <inline-formula id="pone.0322144.e010"><alternatives><graphic xlink:href="pone.0322144.e010.jpg" id="pone.0322144.e010g" position="anchor"/><mml:math id="M10" display="inline" overflow="scroll"><mml:mrow><mml:mtext>HR</mml:mtext><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:math></alternatives></inline-formula> (or <inline-formula id="pone.0322144.e011"><alternatives><graphic xlink:href="pone.0322144.e011.jpg" id="pone.0322144.e011g" position="anchor"/><mml:math id="M11" display="inline" overflow="scroll"><mml:mrow><mml:mi>&#x003b2;</mml:mi><mml:mo>=</mml:mo><mml:mn>0</mml:mn></mml:mrow></mml:math></alternatives></inline-formula>) means that the two conditions have the same risk of the event happening at any <italic toggle="yes">t</italic>; <inline-formula id="pone.0322144.e012"><alternatives><graphic xlink:href="pone.0322144.e012.jpg" id="pone.0322144.e012g" position="anchor"/><mml:math id="M12" display="inline" overflow="scroll"><mml:mrow><mml:mtext>HR</mml:mtext><mml:mo>&#x0003e;</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:math></alternatives></inline-formula> (or <inline-formula id="pone.0322144.e013"><alternatives><graphic xlink:href="pone.0322144.e013.jpg" id="pone.0322144.e013g" position="anchor"/><mml:math id="M13" display="inline" overflow="scroll"><mml:mrow><mml:mi>&#x003b2;</mml:mi><mml:mo>&#x0003e;</mml:mo><mml:mn>0</mml:mn></mml:mrow></mml:math></alternatives></inline-formula>) means that the experimental condition has a higher risk of the event happening at any <italic toggle="yes">t</italic>; <inline-formula id="pone.0322144.e014"><alternatives><graphic xlink:href="pone.0322144.e014.jpg" id="pone.0322144.e014g" position="anchor"/><mml:math id="M14" display="inline" overflow="scroll"><mml:mrow><mml:mtext>HR</mml:mtext><mml:mo>&#x0003c;</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:math></alternatives></inline-formula> (or <inline-formula id="pone.0322144.e015"><alternatives><graphic xlink:href="pone.0322144.e015.jpg" id="pone.0322144.e015g" position="anchor"/><mml:math id="M15" display="inline" overflow="scroll"><mml:mrow><mml:mi>&#x003b2;</mml:mi><mml:mo>&#x0003c;</mml:mo><mml:mn>0</mml:mn></mml:mrow></mml:math></alternatives></inline-formula>) means that the control condition has a higher risk of the event happening at any <italic toggle="yes">t</italic>. Frequentist inference on <inline-formula id="pone.0322144.e016"><alternatives><graphic xlink:href="pone.0322144.e016.jpg" id="pone.0322144.e016g" position="anchor"/><mml:math id="M16" display="inline" overflow="scroll"><mml:mrow><mml:mtext>HR</mml:mtext></mml:mrow></mml:math></alternatives></inline-formula> or <inline-formula id="pone.0322144.e017"><alternatives><graphic xlink:href="pone.0322144.e017.jpg" id="pone.0322144.e017g" position="anchor"/><mml:math id="M17" display="inline" overflow="scroll"><mml:mrow><mml:mi>&#x003b2;</mml:mi></mml:mrow></mml:math></alternatives></inline-formula> is then conducted either in the form of null hypothesis significance testing (i.e., test statistic and <italic toggle="yes">p</italic>-value) or in the form of estimation (i.e., a point estimate accompanied with a confidence interval).</p><p>The reliance on frequentist inference [<xref rid="pone.0322144.ref040" ref-type="bibr">40</xref>,<xref rid="pone.0322144.ref041" ref-type="bibr">41</xref>] has some undesirable consequences for biomedical research. Here, we focus on two of these consequences, namely (1) the impossibility to obtain evidence for the null hypothesis and (2) the inability to adjust the sampling plan based on interim results. Concerning (1), it is important to not only determine whether a treatment is working but also whether a treatment is <italic toggle="yes">not</italic> working over and above a placebo effect. The frequentist approach is not suitable for this because it only allows rejecting the hypothesis that there is no effect, but not accepting it (e.g., [<xref rid="pone.0322144.ref035" ref-type="bibr">35</xref>,<xref rid="pone.0322144.ref042" ref-type="bibr">42</xref>&#x02013;<xref rid="pone.0322144.ref046" ref-type="bibr">46</xref>]).</p><p>Concerning (2), the use of frequentist inference prescribes the diligent adherence to a predefined sampling plan, prohibiting to continue or prematurely stop data collection based on interim data analyses (e.g., [<xref rid="pone.0322144.ref047" ref-type="bibr">47</xref>&#x02013;<xref rid="pone.0322144.ref050" ref-type="bibr">50</xref>]). Further criticism is described elsewhere (see, e.g., [<xref rid="pone.0322144.ref041" ref-type="bibr">41</xref>,<xref rid="pone.0322144.ref046" ref-type="bibr">46</xref>,<xref rid="pone.0322144.ref051" ref-type="bibr">51</xref>&#x02013;<xref rid="pone.0322144.ref053" ref-type="bibr">53</xref>]).</p><p>Bayesian testing in the form of Bayes factors permits a direct comparison between the evidence for the null hypothesis that there is no effect and an alternative hypothesis that operationalizes that there is some effect [<xref rid="pone.0322144.ref042" ref-type="bibr">42</xref>]. For instance, with <inline-formula id="pone.0322144.e018"><alternatives><graphic xlink:href="pone.0322144.e018.jpg" id="pone.0322144.e018g" position="anchor"/><mml:math id="M18" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mtext>BF</mml:mtext><mml:mrow><mml:mn>10</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>14</mml:mn></mml:mrow></mml:math></alternatives></inline-formula>, it allows the interpretation that the obtained data is 14 times more likely under the chosen hypothesis that there is some effect compared to the hypothesis that there is no effect; similarly, <inline-formula id="pone.0322144.e019"><alternatives><graphic xlink:href="pone.0322144.e019.jpg" id="pone.0322144.e019g" position="anchor"/><mml:math id="M19" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mtext>BF</mml:mtext><mml:mrow><mml:mn>10</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>0.2</mml:mn></mml:mrow></mml:math></alternatives></inline-formula> indicates that the obtained data is 1/0.2&#x02009;=&#x02009;5 times more likely under the hypothesis that there is no effect compared to the chosen hypothesis that there is some effect.</p><p>Moreover, using Bayes factors, it is legitimate to monitor the results and stop data collection once a predetermined evidence threshold is reached [<xref rid="pone.0322144.ref047" ref-type="bibr">47</xref>&#x02013;<xref rid="pone.0322144.ref050" ref-type="bibr">50</xref>,<xref rid="pone.0322144.ref054" ref-type="bibr">54</xref>,<xref rid="pone.0322144.ref055" ref-type="bibr">55</xref>]. Thus, Bayes factors take the evidence for and against both the null and alternative hypotheses into account, yield more substantial interpretations, and empower researchers to sample just the sufficient amount of cases. These characteristics of Bayes factors are critical for biomedical research as studies (especially clinical trials) can be expensive and time-consuming.</p><p>In the case where there is a point null hypothesis stating that there is no effect</p><disp-formula id="pone.0322144.e020"><alternatives><graphic xlink:href="pone.0322144.e020.jpg" id="pone.0322144.e020g" position="anchor"/><mml:math id="M20" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>&#x0210b;</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mi>:</mml:mi><mml:mspace width="1em"/><mml:mi>&#x003b2;</mml:mi><mml:mo>=</mml:mo><mml:mn>0</mml:mn></mml:mrow></mml:mrow></mml:math></alternatives>
<label>(3)</label></disp-formula><p>and an interval alternative hypothesis stating that there is an effect</p><disp-formula id="pone.0322144.e021"><alternatives><graphic xlink:href="pone.0322144.e021.jpg" id="pone.0322144.e021g" position="anchor"/><mml:math id="M21" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>&#x0210b;</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mi>:</mml:mi><mml:mspace width="1em"/><mml:mi>&#x003b2;</mml:mi><mml:mi>~</mml:mi><mml:mi>f</mml:mi><mml:mrow><mml:mo fence="true" form="prefix" stretchy="true">(</mml:mo><mml:mi>&#x003d5;</mml:mi><mml:mo fence="true" form="postfix" stretchy="true">)</mml:mo></mml:mrow><mml:mtext>,</mml:mtext></mml:mrow></mml:mrow></mml:math></alternatives>
<label>(4)</label></disp-formula><p>the Bayes factor is a ratio of a marginal likelihood and a likelihood evaluated at <inline-formula id="pone.0322144.e022"><alternatives><graphic xlink:href="pone.0322144.e022.jpg" id="pone.0322144.e022g" position="anchor"/><mml:math id="M22" display="inline" overflow="scroll"><mml:mrow><mml:mi>&#x003b2;</mml:mi><mml:mo>=</mml:mo><mml:mn>0</mml:mn></mml:mrow></mml:math></alternatives></inline-formula>. Here, <inline-formula id="pone.0322144.e023"><alternatives><graphic xlink:href="pone.0322144.e023.jpg" id="pone.0322144.e023g" position="anchor"/><mml:math id="M23" display="inline" overflow="scroll"><mml:mrow><mml:mi>f</mml:mi><mml:mrow><mml:mo fence="true" form="prefix" stretchy="true">(</mml:mo><mml:mo>.</mml:mo><mml:mo fence="true" form="postfix" stretchy="true">)</mml:mo></mml:mrow></mml:mrow></mml:math></alternatives></inline-formula> represents any probability density function and <inline-formula id="pone.0322144.e024"><alternatives><graphic xlink:href="pone.0322144.e024.jpg" id="pone.0322144.e024g" position="anchor"/><mml:math id="M24" display="inline" overflow="scroll"><mml:mrow><mml:mi>&#x003d5;</mml:mi></mml:mrow></mml:math></alternatives></inline-formula> the associated parameters. Let <inline-formula id="pone.0322144.e025"><alternatives><graphic xlink:href="pone.0322144.e025.jpg" id="pone.0322144.e025g" position="anchor"/><mml:math id="M25" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mi>&#x003a9;</mml:mi><mml:mn>1</mml:mn></mml:msub></mml:mrow></mml:math></alternatives></inline-formula> be the parameter space under the alternative hypothesis; then the Bayes factor is:</p><disp-formula id="pone.0322144.e026"><alternatives><graphic xlink:href="pone.0322144.e026.jpg" id="pone.0322144.e026g" position="anchor"/><mml:math id="M26" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mtext>BF</mml:mtext><mml:mrow><mml:mn>10</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mfrac><mml:mrow><mml:mi>P</mml:mi><mml:mrow><mml:mo fence="true" form="prefix" stretchy="true">(</mml:mo><mml:mi>D</mml:mi><mml:mo>&#x02223;</mml:mo><mml:msub><mml:mi>&#x0210b;</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo fence="true" form="postfix" stretchy="true">)</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:mi>P</mml:mi><mml:mrow><mml:mo fence="true" form="prefix" stretchy="true">(</mml:mo><mml:mi>D</mml:mi><mml:mo>&#x02223;</mml:mo><mml:msub><mml:mi>&#x0210b;</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo fence="true" form="postfix" stretchy="true">)</mml:mo></mml:mrow></mml:mrow></mml:mfrac></mml:mstyle><mml:mo>=</mml:mo><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mfrac><mml:mrow><mml:msub><mml:mo>&#x0222b;</mml:mo><mml:mrow><mml:mi>&#x003b2;</mml:mi><mml:mo>&#x02208;</mml:mo><mml:msub><mml:mi>&#x003a9;</mml:mi><mml:mn>1</mml:mn></mml:msub></mml:mrow></mml:msub><mml:mover><mml:mover><mml:mrow><mml:mi>f</mml:mi><mml:mrow><mml:mo fence="true" form="prefix" stretchy="true">(</mml:mo><mml:mi>D</mml:mi><mml:mo>&#x02223;</mml:mo><mml:mi>&#x003b2;</mml:mi><mml:mo fence="true" form="postfix" stretchy="true">)</mml:mo></mml:mrow></mml:mrow><mml:mo>&#x023de;</mml:mo></mml:mover><mml:mrow><mml:mtext>Likelihood</mml:mtext></mml:mrow></mml:mover><mml:mover><mml:mover><mml:mrow><mml:mi>f</mml:mi><mml:mrow><mml:mo fence="true" form="prefix" stretchy="true">(</mml:mo><mml:mi>&#x003b2;</mml:mi><mml:mo fence="true" form="postfix" stretchy="true">)</mml:mo></mml:mrow></mml:mrow><mml:mo>&#x023de;</mml:mo></mml:mover><mml:mrow><mml:mtext>Prior</mml:mtext></mml:mrow></mml:mover><mml:mtext>d</mml:mtext><mml:mi>&#x003b2;</mml:mi></mml:mrow><mml:mrow><mml:munder><mml:munder><mml:mrow><mml:mi>f</mml:mi><mml:mrow><mml:mo fence="true" form="prefix" stretchy="true">(</mml:mo><mml:mi>D</mml:mi><mml:mo>&#x02223;</mml:mo><mml:mi>&#x003b2;</mml:mi><mml:mo>=</mml:mo><mml:mn>0</mml:mn><mml:mo fence="true" form="postfix" stretchy="true">)</mml:mo></mml:mrow></mml:mrow><mml:mo>&#x023df;</mml:mo></mml:munder><mml:mrow><mml:mtext>Likelihood&#x000a0;at</mml:mtext><mml:mspace width="1em"/><mml:mi>&#x003b2;</mml:mi><mml:mo>=</mml:mo><mml:mn>0</mml:mn></mml:mrow></mml:munder></mml:mrow></mml:mfrac></mml:mstyle><mml:mtext>.</mml:mtext></mml:mrow></mml:mrow></mml:math></alternatives>
<label>(5)</label></disp-formula><p>In <xref rid="pone.0322144.e026" ref-type="disp-formula">Eq 5</xref>, the integral constitutes a weighted average of the likelihood, with weights supplied by the prior. Depending on the complexity of the underlying statistical model, computing the expression in <xref rid="pone.0322144.e026" ref-type="disp-formula">Eq 5</xref> can be challenging. Through concerted efforts of researchers to develop closed-form solutions and through the explosion of computational power over recent decades that allows applying complex numerical methods (e.g., Monte Carlo sampling and bridge sampling; [<xref rid="pone.0322144.ref056" ref-type="bibr">56</xref>&#x02013;<xref rid="pone.0322144.ref060" ref-type="bibr">60</xref>]), computing the expression in <xref rid="pone.0322144.e026" ref-type="disp-formula">Eq 5</xref> and variants of it has become feasible. These efforts have led to method developments and software implementations for calculating Bayes factors for survival analyses [<xref rid="pone.0322144.ref061" ref-type="bibr">61</xref>&#x02013;<xref rid="pone.0322144.ref064" ref-type="bibr">64</xref>] and many other designs (e.g., [<xref rid="pone.0322144.ref042" ref-type="bibr">42</xref>,<xref rid="pone.0322144.ref053" ref-type="bibr">53</xref>,<xref rid="pone.0322144.ref065" ref-type="bibr">65</xref>&#x02013;<xref rid="pone.0322144.ref071" ref-type="bibr">71</xref>]).</p></sec><sec id="sec003"><title>Choosing priors</title><p>Even though it is possible nowadays to calculate Bayes factors for various sorts of designs, it remains difficult to specify an appropriate prior distribution (or prior for short) for the parameters of interest (cf. <xref rid="pone.0322144.e026" ref-type="disp-formula">Eq 5</xref>). The prior is a probability distribution that is placed on the statistical model&#x02019;s parameters of interest and it expresses belief over the plausibility across all possible parameter values before taking into account new data. In the context of null hypothesis Bayes factor calculations, the prior is one important element of the alternative hypothesis. Even among researchers who advocate Bayesian statistics, there is disagreement on how the prior should be specified (see, e.g., [<xref rid="pone.0322144.ref072" ref-type="bibr">72</xref>,<xref rid="pone.0322144.ref073" ref-type="bibr">73</xref>]).</p><p>Objective Bayesians strive to define non-informative priors that are as &#x0201c;objective&#x0201d; as possible. Objective Bayesians assert that the results of Bayesian analyses should depend only to a minimal extent on the beliefs of different people. They promote default priors that can be used when no other information is available and often seek to find priors that &#x0201c;behave well&#x0201d; and fulfill certain mathematical properties (see, e.g., [<xref rid="pone.0322144.ref074" ref-type="bibr">74</xref>,<xref rid="pone.0322144.ref075" ref-type="bibr">75</xref>] for more details). Subjective Bayesians, on the other hand, counter that the subjective nature of the prior is an integral part of Bayesian analyses. According to them, the prior allows the incorporation of domain knowledge and results from prior studies into Bayesian analyses and therefore permits tests of theories [<xref rid="pone.0322144.ref032" ref-type="bibr">32</xref>,<xref rid="pone.0322144.ref076" ref-type="bibr">76</xref>]. Further, they state that it is questionable whether a truly &#x0201c;objective&#x0201d; prior even exists.</p><p>Recently, the opportunities that well-defined priors open were increasingly recognized in biomedical research. Prior elicitation procedures, in which informed priors are defined by means of using external sources, gained popularity within biomedical research (e.g., [<xref rid="pone.0322144.ref077" ref-type="bibr">77</xref>&#x02013;<xref rid="pone.0322144.ref081" ref-type="bibr">81</xref>]). There are various forms of prior elicitation. For example, through structured interviews, information about prior beliefs can be extracted by one or multiple experts in the respective field, which is subsequently combined into one prior (see, e.g., [<xref rid="pone.0322144.ref079" ref-type="bibr">79</xref>,<xref rid="pone.0322144.ref080" ref-type="bibr">80</xref>,<xref rid="pone.0322144.ref082" ref-type="bibr">82</xref>,<xref rid="pone.0322144.ref083" ref-type="bibr">83</xref>]). Tools like the MATCH software [<xref rid="pone.0322144.ref084" ref-type="bibr">84</xref>] have been developed for this purpose. Alternatively, the results of meta-analyses and prior research in general can be used to create a prior (e.g., [<xref rid="pone.0322144.ref080" ref-type="bibr">80</xref>,<xref rid="pone.0322144.ref085" ref-type="bibr">85</xref>]). That is, researchers could use the overall effect size combined with a measure of uncertainty from a meta-analysis to construct an informed prior for their own analysis; or they could conduct their own literature search and extract the relevant statistics and use them for developing priors. This approach of using prior study results can also be combined with an empirical Bayes approach, which utilizes the current data to create a prior instead of predefining it (e.g., [<xref rid="pone.0322144.ref086" ref-type="bibr">86</xref>]). Such a procedure was proposed by [<xref rid="pone.0322144.ref087" ref-type="bibr">87</xref>].</p><p>In this article, we follow the approach of using results of prior studies to create priors. For this, we conducted our own literature search instead of relying on meta-analyses. The reason for this is that we aim to suggest priors that are generic, such that they apply to entire medical subfields; most meta-analyses do not offer this generality.</p></sec><sec id="sec004"><title>The current study</title><p>In the present article, we develop priors centered around zero for Bayesian Cox regression for nine subfields that we believe are representative for different areas of research within biomedicine. For the construction of these priors we make use of reported hazard ratios and associated <inline-formula id="pone.0322144.e027"><alternatives><graphic xlink:href="pone.0322144.e027.jpg" id="pone.0322144.e027g" position="anchor"/><mml:math id="M27" display="inline" overflow="scroll"><mml:mrow><mml:mi>x</mml:mi><mml:mi>%</mml:mi></mml:mrow></mml:math></alternatives></inline-formula> confidence intervals from large corpora of existing studies. These extracted data are then combined through pooling to generate priors. These priors apply to two-sided alternative hypotheses. Since we are ignorant of the direction of effects, our proposed priors can be truncated at 0 for directional hypotheses.</p></sec></sec><sec sec-type="materials|methods" id="sec005"><title>Methods</title><p>We selected the subfields in biomedicine considered for further investigation based on a taxonomy provided by Scimago (available at <ext-link xlink:href="https://www.scimagojr.com/journalrank.php" ext-link-type="uri">https://www.scimagojr.com/journalrank.php</ext-link>; [<xref rid="pone.0322144.ref088" ref-type="bibr">88</xref>]). On the Scimago website, we used &#x0201c;Medicine&#x0201d; as a subject area, upon which a list of medical subfields were provided (see <xref rid="pone.0322144.g001" ref-type="fig">Fig 1</xref>). Among those, we selected the following nine subfields for further consideration:</p><fig position="float" id="pone.0322144.g001"><object-id pub-id-type="doi">10.1371/journal.pone.0322144.g001</object-id><label>Fig 1</label><caption><title>Settings for extracting top journals from Scimago (available at <ext-link xlink:href="https://www.scimagojr.com/journalrank.php" ext-link-type="uri">https://www.scimagojr.com/journalrank.php</ext-link>; [<xref rid="pone.0322144.ref088" ref-type="bibr">88</xref>]) for one of the nine considered subfields in biomedicine; in this case &#x0201c;Anesthesiology and pain medicine&#x0201d;.</title></caption><graphic xlink:href="pone.0322144.g001" position="float"/></fig><list list-type="order"><list-item><p>Anesthesiology and pain medicine</p></list-item><list-item><p>Cardiology and cardiovascular medicine</p></list-item><list-item><p>Gastroenterology</p></list-item><list-item><p>Hematology</p></list-item><list-item><p>Immunology and allergy</p></list-item><list-item><p>Neurology</p></list-item><list-item><p>Oncology</p></list-item><list-item><p>Psychiatry and mental health</p></list-item><list-item><p>Pulmonary and respiratory medicine</p></list-item></list><p>Our selection was based on three criteria: (1) we aimed to obtain a manageable number of subfields (between eight and twelve); (2) we aimed to obtain subfields with limited overlap; and (3) we aimed to obtain subfields that represent relatively large areas of study within biomedicine. For each of the nine subfields, we obtained a list of the top journals from Scimago. We considered only journals (i.e., neither book series, nor conferences and proceedings, nor trade journals); we considered journals from all regions/countries; and the journal list was based on the year 2022 (see <xref rid="pone.0322144.g001" ref-type="fig">Fig 1</xref> for an example of the settings on the Scimago website for the subfield of &#x0201c;Anesthesiology and pain medicine&#x0201d;). The extraction of the top journals for all nine subfields yielded 2,469 journals in total (see columns 1 and 2 of <xref rid="pone.0322144.t001" ref-type="table">Table 1</xref>). Some subfields shared a set of journals; for example, the journal &#x0201c;Pain&#x0201d; is a top journal for both the subfields of &#x0201c;Anesthesiology and pain medicine&#x0201d; and &#x0201c;Neurology&#x0201d;. We found that there was not a lot of overlap of journals between the subfields, with 2,196 of the 2,469 journals being uniquely assigned to only one subfield.</p><table-wrap position="float" id="pone.0322144.t001"><object-id pub-id-type="doi">10.1371/journal.pone.0322144.t001</object-id><label>Table 1</label><caption><title>Number of used journals and studies for each of the nine subfields within biomedicine.</title></caption><alternatives><graphic xlink:href="pone.0322144.t001" id="pone.0322144.t001g" position="float"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Subfield</th><th align="left" rowspan="1" colspan="1"><inline-formula id="pone.0322144.e028"><alternatives><graphic xlink:href="pone.0322144.e028" id="pone.0322144.e028g" position="anchor"/><mml:math id="M28" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mi mathvariant="bold-italic">N</mml:mi></mml:mrow></mml:mrow></mml:math></alternatives></inline-formula> journals</th><th align="left" rowspan="1" colspan="1"><inline-formula id="pone.0322144.e029"><alternatives><graphic xlink:href="pone.0322144.e029" id="pone.0322144.e029g" position="anchor"/><mml:math id="M29" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mi mathvariant="bold-italic">N</mml:mi></mml:mrow></mml:mrow></mml:math></alternatives></inline-formula> studies</th><th align="left" rowspan="1" colspan="1"><inline-formula id="pone.0322144.e030"><alternatives><graphic xlink:href="pone.0322144.e030" id="pone.0322144.e030g" position="anchor"/><mml:math id="M30" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mi mathvariant="bold-italic">N</mml:mi></mml:mrow></mml:mrow></mml:math></alternatives></inline-formula> studies</th><th align="left" rowspan="1" colspan="1"><inline-formula id="pone.0322144.e031"><alternatives><graphic xlink:href="pone.0322144.e031" id="pone.0322144.e031g" position="anchor"/><mml:math id="M31" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mi mathvariant="bold-italic">N</mml:mi></mml:mrow></mml:mrow></mml:math></alternatives></inline-formula> studies</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">allocated</td><td align="left" rowspan="1" colspan="1">matched</td><td align="left" rowspan="1" colspan="1">considered</td></tr><tr><td align="left" rowspan="1" colspan="1">Anesthesiology and pain medicine</td><td align="left" rowspan="1" colspan="1">44/132</td><td align="left" rowspan="1" colspan="1">360</td><td align="left" rowspan="1" colspan="1">215</td><td align="left" rowspan="1" colspan="1">211</td></tr><tr><td align="left" rowspan="1" colspan="1">Cardiology and cardiovascular medicine</td><td align="left" rowspan="1" colspan="1">230/366</td><td align="left" rowspan="1" colspan="1">10,718</td><td align="left" rowspan="1" colspan="1">6,555</td><td align="left" rowspan="1" colspan="1">6,504</td></tr><tr><td align="left" rowspan="1" colspan="1">Gastroenterology</td><td align="left" rowspan="1" colspan="1">88/157</td><td align="left" rowspan="1" colspan="1">2,088</td><td align="left" rowspan="1" colspan="1">1,311</td><td align="left" rowspan="1" colspan="1">1,300</td></tr><tr><td align="left" rowspan="1" colspan="1">Hematology</td><td align="left" rowspan="1" colspan="1">66/134</td><td align="left" rowspan="1" colspan="1">1,601</td><td align="left" rowspan="1" colspan="1">857</td><td align="left" rowspan="1" colspan="1">849</td></tr><tr><td align="left" rowspan="1" colspan="1">Immunology and allergy</td><td align="left" rowspan="1" colspan="1">82/214</td><td align="left" rowspan="1" colspan="1">1,360</td><td align="left" rowspan="1" colspan="1">839</td><td align="left" rowspan="1" colspan="1">833</td></tr><tr><td align="left" rowspan="1" colspan="1">Neurology</td><td align="left" rowspan="1" colspan="1">178/387</td><td align="left" rowspan="1" colspan="1">2,840</td><td align="left" rowspan="1" colspan="1">1,651</td><td align="left" rowspan="1" colspan="1">1,640</td></tr><tr><td align="left" rowspan="1" colspan="1">Oncology</td><td align="left" rowspan="1" colspan="1">239/373</td><td align="left" rowspan="1" colspan="1">13,163</td><td align="left" rowspan="1" colspan="1">7,741</td><td align="left" rowspan="1" colspan="1">7,684</td></tr><tr><td align="left" rowspan="1" colspan="1">Psychiatry and mental health</td><td align="left" rowspan="1" colspan="1">159/560</td><td align="left" rowspan="1" colspan="1">1,750</td><td align="left" rowspan="1" colspan="1">1,038</td><td align="left" rowspan="1" colspan="1">1,029</td></tr><tr><td align="left" rowspan="1" colspan="1">Pulmonary and respiratory medicine</td><td align="left" rowspan="1" colspan="1">84/146</td><td align="left" rowspan="1" colspan="1">2,551</td><td align="left" rowspan="1" colspan="1">1,561</td><td align="left" rowspan="1" colspan="1">1,548</td></tr><tr><td align="left" rowspan="1" colspan="1">All</td><td align="left" rowspan="1" colspan="1">
<inline-formula id="pone.0322144.e032">
<alternatives><graphic xlink:href="pone.0322144.e032" id="pone.0322144.e032g" position="anchor"/><mml:math id="M32" display="inline" overflow="scroll"><mml:mrow><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mn>170</mml:mn><mml:mo>/</mml:mo><mml:mn>2</mml:mn><mml:mo>,</mml:mo><mml:mn>469</mml:mn></mml:mrow></mml:math></alternatives>
</inline-formula>
</td><td align="left" rowspan="1" colspan="1">
<inline-formula id="pone.0322144.e033">
<alternatives><graphic xlink:href="pone.0322144.e033" id="pone.0322144.e033g" position="anchor"/><mml:math id="M33" display="inline" overflow="scroll"><mml:mrow><mml:mn>36</mml:mn><mml:mo>,</mml:mo><mml:mn>431</mml:mn><mml:mo>/</mml:mo><mml:mn>59</mml:mn><mml:mo>,</mml:mo><mml:mn>646</mml:mn></mml:mrow></mml:math></alternatives>
</inline-formula>
</td><td align="left" rowspan="1" colspan="1">21,768</td><td align="left" rowspan="1" colspan="1">21,598</td></tr></tbody></table></alternatives></table-wrap><p>The first column indicates the subfield, the second column the number of used (i.e., matched between Scopus data and Scimago data) journals (not necessarily unique) from all Scimago journals, the third column the number of studies allocated, the fourth column the number of studies for which there was a match and data extraction was successful, and the fifth column the number of studies remaining after excluding studies that provide flawed results.</p><p>As a separate step, we used Scopus to obtain a list of medical articles. We used the following search query:</p><p>
<monospace>ABS(("hazard ratio" OR hr) AND cox) AND</monospace>
</p><p>
<monospace>SUBJAREA(medi) AND</monospace>
</p><p>
<monospace>PUBYEAR &#x0003e; 1999 AND PUBYEAR &#x0003c; 2021 AND</monospace>
</p><p>
<monospace>(LIMIT-TO(SRCTYPE,"j")) AND</monospace>
</p><p>
<monospace>(LIMIT-TO(PUBSTAGE,"final")) AND</monospace>
</p><p>
<monospace>(LIMIT-TO(DOCTYPE,"ar")) AND</monospace>
</p><p>
<monospace>(LIMIT-TO(LANGUAGE,"English"))</monospace>
</p><p>Only fully published (line 5) articles (line 6) from a journal (line 4) written in English (line 7) were considered. Furthermore, the results had to belong to the field of medicine (line 2) and be published between the years 2000 and 2020, inclusive (line 3). Lastly, the abstracts of the results needed to contain the keywords &#x0201c;hazard ratio&#x0201d; or &#x0201c;HR&#x0201d; and the keyword &#x0201c;Cox&#x0201d;, ignoring case (line 1). Note, however, that this search query was generic such that it did not restrict the results towards one of the nine subfields. The Scopus query yielded 59,669 results, of which 23 could not be exported, leaving 59,646 results in total (see column 3 of <xref rid="pone.0322144.t001" ref-type="table">Table 1</xref>).</p><p>The 59,646 Scopus results were allocated to the nine subfields by matching the journal names indicated by Scopus to the Scimago lists of journal names for the nine subfields. Importantly, a Scopus result could be allocated to multiple subfields as some subfields had journals in common. Before the allocation of Scopus results to the nine subfields, both the Scopus journal names and the Scimago lists of journal names were cleaned and standardized in order to accommodate slight differences in their presentation. This included replacing &#x0201c;&#x00026;&#x0201d; and &#x0201c;&#x00026;&#x0201d; with &#x0201c;AND&#x0201d;, removing all characters that are not alphabetic or white space, repositioning the word &#x0201c;the&#x0201d; (e.g., &#x0201c;Lancet Oncology, The&#x0201d; was turned into &#x0201c;The Lancet Oncology&#x0201d;), and transforming all characters to uppercase. The number of matched journal names relative to the total number of Scimago journal names for the nine subfields are shown in column 2 of <xref rid="pone.0322144.t001" ref-type="table">Table 1</xref> and the number of allocated results for each of the nine subfields can be seen in column 3 of <xref rid="pone.0322144.t001" ref-type="table">Table 1</xref>.</p><p>Once the individual Scopus results were allocated to the nine subfields, we extracted hazard ratios and associated <inline-formula id="pone.0322144.e034"><alternatives><graphic xlink:href="pone.0322144.e034.jpg" id="pone.0322144.e034g" position="anchor"/><mml:math id="M34" display="inline" overflow="scroll"><mml:mrow><mml:mi>x</mml:mi><mml:mi>%</mml:mi></mml:mrow></mml:math></alternatives></inline-formula> confidence intervals from the abstracts of the results. This was done in an automatic fashion through the use of regular expressions (see [<xref rid="pone.0322144.ref089" ref-type="bibr">89</xref>] for the standard reference on regular expressions). We extracted the following information from the abstracts:</p><list list-type="bullet"><list-item><p>Hazard ratio (<inline-formula id="pone.0322144.e035"><alternatives><graphic xlink:href="pone.0322144.e035.jpg" id="pone.0322144.e035g" position="anchor"/><mml:math id="M35" display="inline" overflow="scroll"><mml:mrow><mml:mtext>HR</mml:mtext></mml:mrow></mml:math></alternatives></inline-formula>)</p></list-item><list-item><p>Confidence level of the confidence interval (<inline-formula id="pone.0322144.e036"><alternatives><graphic xlink:href="pone.0322144.e036.jpg" id="pone.0322144.e036g" position="anchor"/><mml:math id="M36" display="inline" overflow="scroll"><mml:mrow><mml:mtext>CI</mml:mtext></mml:mrow></mml:math></alternatives></inline-formula>) for <inline-formula id="pone.0322144.e037"><alternatives><graphic xlink:href="pone.0322144.e037.jpg" id="pone.0322144.e037g" position="anchor"/><mml:math id="M37" display="inline" overflow="scroll"><mml:mrow><mml:mtext>HR</mml:mtext></mml:mrow></mml:math></alternatives></inline-formula> (i.e., <inline-formula id="pone.0322144.e038"><alternatives><graphic xlink:href="pone.0322144.e038.jpg" id="pone.0322144.e038g" position="anchor"/><mml:math id="M38" display="inline" overflow="scroll"><mml:mrow><mml:mn>100</mml:mn><mml:mrow><mml:mo fence="true" form="prefix" stretchy="true">(</mml:mo><mml:mn>1</mml:mn><mml:mo>&#x02212;</mml:mo><mml:mi>&#x003b1;</mml:mi><mml:mo fence="true" form="postfix" stretchy="true">)</mml:mo></mml:mrow></mml:mrow></mml:math></alternatives></inline-formula>)</p></list-item><list-item><p>Lower boundary of the <inline-formula id="pone.0322144.e039"><alternatives><graphic xlink:href="pone.0322144.e039.jpg" id="pone.0322144.e039g" position="anchor"/><mml:math id="M39" display="inline" overflow="scroll"><mml:mrow><mml:mtext>CI</mml:mtext></mml:mrow></mml:math></alternatives></inline-formula> for <inline-formula id="pone.0322144.e040"><alternatives><graphic xlink:href="pone.0322144.e040.jpg" id="pone.0322144.e040g" position="anchor"/><mml:math id="M40" display="inline" overflow="scroll"><mml:mrow><mml:mtext>HR</mml:mtext></mml:mrow></mml:math></alternatives></inline-formula> (<inline-formula id="pone.0322144.e041"><alternatives><graphic xlink:href="pone.0322144.e041.jpg" id="pone.0322144.e041g" position="anchor"/><mml:math id="M41" display="inline" overflow="scroll"><mml:mrow><mml:msup><mml:mtext>HR</mml:mtext><mml:mi>l</mml:mi></mml:msup></mml:mrow></mml:math></alternatives></inline-formula>)</p></list-item><list-item><p>Upper boundary of the <inline-formula id="pone.0322144.e042"><alternatives><graphic xlink:href="pone.0322144.e042.jpg" id="pone.0322144.e042g" position="anchor"/><mml:math id="M42" display="inline" overflow="scroll"><mml:mrow><mml:mtext>CI</mml:mtext></mml:mrow></mml:math></alternatives></inline-formula> for <inline-formula id="pone.0322144.e043"><alternatives><graphic xlink:href="pone.0322144.e043.jpg" id="pone.0322144.e043g" position="anchor"/><mml:math id="M43" display="inline" overflow="scroll"><mml:mrow><mml:mtext>HR</mml:mtext></mml:mrow></mml:math></alternatives></inline-formula> (<inline-formula id="pone.0322144.e044"><alternatives><graphic xlink:href="pone.0322144.e044.jpg" id="pone.0322144.e044g" position="anchor"/><mml:math id="M44" display="inline" overflow="scroll"><mml:mrow><mml:msup><mml:mtext>HR</mml:mtext><mml:mi>u</mml:mi></mml:msup></mml:mrow></mml:math></alternatives></inline-formula>)</p></list-item></list><p>There are several important details about our implemented text-mining procedure. First, we exclusively considered the abstracts for data extraction. In an attempt to ascertain that this did not result in bias in the extracted effect sizes, we randomly sampled 100 articles for which we could match results in the abstract with our regular expression and another 100 articles for which we could not match results in the abstract with our regular expression. For these articles, we applied our regular expression on the main text (i.e., not the abstracts). The effect size distributions from this sample looked very similar, indicating no strong evidence for a bias as a result of focusing our search on abstracts only (see <xref rid="pone.0322144.g005" ref-type="fig">Fig 5</xref> in Appendix A). Second, if the regular expression yielded multiple matches for a given abstract, only the first match was considered; any other matches were discarded. The justification for this decision was that we assumed that the main findings are commonly reported first, followed by secondary or exploratory findings.</p><fig position="float" id="pone.0322144.g002"><object-id pub-id-type="doi">10.1371/journal.pone.0322144.g002</object-id><label>Fig 2</label><caption><title>Prior distributions for the nine subfields, one subfield per panel.</title><p>The histograms show the distribution of <italic toggle="yes">b</italic><sub><italic toggle="yes">i</italic></sub> (and &#x02212;<italic toggle="yes">b</italic><sub><italic toggle="yes">i</italic></sub>), ignoring <inline-formula id="pone.0322144.e091"><alternatives><graphic xlink:href="pone.0322144.e091" id="pone.0322144.e091g" position="anchor"/><mml:math id="M45" display="inline" overflow="scroll"><mml:mrow><mml:mi>S</mml:mi><mml:mi>E</mml:mi><mml:mrow><mml:mo fence="true" form="prefix" stretchy="true">(</mml:mo><mml:msub><mml:mi>b</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo fence="true" form="postfix" stretchy="true">)</mml:mo></mml:mrow></mml:mrow></mml:math></alternatives></inline-formula>. The red curves display the densities of the Normal priors on <inline-formula id="pone.0322144.e092"><alternatives><graphic xlink:href="pone.0322144.e092" id="pone.0322144.e092g" position="anchor"/><mml:math id="M46" display="inline" overflow="scroll"><mml:mrow><mml:mi>&#x003b2;</mml:mi></mml:mrow></mml:math></alternatives></inline-formula>, where <inline-formula id="pone.0322144.e093"><alternatives><graphic xlink:href="pone.0322144.e093" id="pone.0322144.e093g" position="anchor"/><mml:math id="M47" display="inline" overflow="scroll"><mml:mrow><mml:msup><mml:mi>&#x003c3;</mml:mi><mml:mi>p</mml:mi></mml:msup></mml:mrow></mml:math></alternatives></inline-formula> is presented at the top of each panel.</p></caption><graphic xlink:href="pone.0322144.g002" position="float"/></fig><fig position="float" id="pone.0322144.g003"><object-id pub-id-type="doi">10.1371/journal.pone.0322144.g003</object-id><label>Fig 3</label><caption><title>Sensitivity of the pooling method with respect to the choice of <italic toggle="yes">n</italic><sub><italic toggle="yes">i</italic></sub> for the estimation of <inline-formula id="pone.0322144.e101"><alternatives><graphic xlink:href="pone.0322144.e101" id="pone.0322144.e101g" position="anchor"/><mml:math id="M48" display="inline" overflow="scroll"><mml:mrow><mml:msup><mml:mi>&#x003c3;</mml:mi><mml:mi>p</mml:mi></mml:msup></mml:mrow></mml:math></alternatives></inline-formula>.</title><p>The nine panels correspond to the nine subfields. The box plots show <inline-formula id="pone.0322144.e102"><alternatives><graphic xlink:href="pone.0322144.e102" id="pone.0322144.e102g" position="anchor"/><mml:math id="M49" display="inline" overflow="scroll"><mml:mrow><mml:msup><mml:mi>&#x003c3;</mml:mi><mml:mi>p</mml:mi></mml:msup></mml:mrow></mml:math></alternatives></inline-formula> of the priors when each <italic toggle="yes">n</italic><sub><italic toggle="yes">i</italic></sub> is drawn randomly from <inline-formula id="pone.0322144.e103"><alternatives><graphic xlink:href="pone.0322144.e103" id="pone.0322144.e103g" position="anchor"/><mml:math id="M50" display="inline" overflow="scroll"><mml:mrow><mml:mtext>U</mml:mtext><mml:mrow><mml:mo fence="true" form="prefix" stretchy="true">(</mml:mo><mml:mn>10</mml:mn><mml:mo>,</mml:mo><mml:mspace width="1em"/><mml:mn>10000</mml:mn><mml:mo fence="true" form="postfix" stretchy="true">)</mml:mo></mml:mrow></mml:mrow></mml:math></alternatives></inline-formula> (i.e., studies have different sample sizes); this process was repeated 100,000 times.</p></caption><graphic xlink:href="pone.0322144.g003" position="float"/></fig><fig position="float" id="pone.0322144.g004"><object-id pub-id-type="doi">10.1371/journal.pone.0322144.g004</object-id><label>Fig 4</label><caption><title>Results of a Bayesian Cox regression applied to the data set provided by [<xref rid="pone.0322144.ref092" ref-type="bibr">92</xref>].</title><p>The blue and red lines show the development of the Bayes factor as new data enter the study for the &#x0201c;immunology and allergy&#x0201d; and &#x0201c;pulmonary and respiratory medicine&#x0201d; priors. The blue and red lines heavily overlap, so the blue line is hardly visible. The gray lines show the development of the Bayes factor for the sensitivity analysis (i.e., various Normal priors). Data collection is stopped once the Bayes factor exceeds 1/20 or 20.</p></caption><graphic xlink:href="pone.0322144.g004" position="float"/></fig><p>Third, data extraction was only done when all of the four above-mentioned information were available in the abstract. We disregarded abstracts where results were not complete or were presented in any other form. For instance, presentations of a <inline-formula id="pone.0322144.e045"><alternatives><graphic xlink:href="pone.0322144.e045.jpg" id="pone.0322144.e045g" position="anchor"/><mml:math id="M51" display="inline" overflow="scroll"><mml:mrow><mml:mtext>HR</mml:mtext></mml:mrow></mml:math></alternatives></inline-formula> coupled with a <italic toggle="yes">p</italic>-value and potentially a test statistic were ignored. Although this seems like an overly drastic measure, the number of matches was still very high (see column 4 of <xref rid="pone.0322144.t001" ref-type="table">Table 1</xref>). Fourth, we did not distinguish between variations of Cox regression (e.g., multivariate, stratified, multiple predictors).</p><p>Fifth, we allowed various forms of the displayed results. For example, the following variations were all captured by our regular expression: &#x0201c;<inline-formula id="pone.0322144.e046"><alternatives><graphic xlink:href="pone.0322144.e046.jpg" id="pone.0322144.e046g" position="anchor"/><mml:math id="M52" display="inline" overflow="scroll"><mml:mrow><mml:mtext>HR</mml:mtext><mml:mo>=</mml:mo><mml:mn>2.3</mml:mn></mml:mrow></mml:math></alternatives></inline-formula>&#x0201d; (with or without spaces around =), &#x0201c;<inline-formula id="pone.0322144.e047"><alternatives><graphic xlink:href="pone.0322144.e047.jpg" id="pone.0322144.e047g" position="anchor"/><mml:math id="M53" display="inline" overflow="scroll"><mml:mrow><mml:mtext>hazard&#x000a0;ratio</mml:mtext><mml:mo>=</mml:mo><mml:mn>2.3</mml:mn></mml:mrow></mml:math></alternatives></inline-formula>&#x0201d;, &#x0201c;<inline-formula id="pone.0322144.e048"><alternatives><graphic xlink:href="pone.0322144.e048.jpg" id="pone.0322144.e048g" position="anchor"/><mml:math id="M54" display="inline" overflow="scroll"><mml:mrow><mml:mtext>hazards&#x000a0;ratio</mml:mtext><mml:mo>=</mml:mo><mml:mn>2.3</mml:mn></mml:mrow></mml:math></alternatives></inline-formula>&#x0201d;, &#x0201c;<inline-formula id="pone.0322144.e049"><alternatives><graphic xlink:href="pone.0322144.e049.jpg" id="pone.0322144.e049g" position="anchor"/><mml:math id="M55" display="inline" overflow="scroll"><mml:mrow><mml:mtext>hazard&#x000a0;ratios</mml:mtext><mml:mo>=</mml:mo><mml:mn>2.3</mml:mn></mml:mrow></mml:math></alternatives></inline-formula>&#x0201d;, &#x0201c;<inline-formula id="pone.0322144.e050"><alternatives><graphic xlink:href="pone.0322144.e050.jpg" id="pone.0322144.e050g" position="anchor"/><mml:math id="M56" display="inline" overflow="scroll"><mml:mrow><mml:mtext>hazard&#x000a0;ratio</mml:mtext><mml:mrow><mml:mo fence="true" form="prefix" stretchy="true">(</mml:mo><mml:mtext>HR</mml:mtext><mml:mo fence="true" form="postfix" stretchy="true">)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mn>2.3</mml:mn></mml:mrow></mml:math></alternatives></inline-formula>&#x0201d;, &#x0201c;<inline-formula id="pone.0322144.e051"><alternatives><graphic xlink:href="pone.0322144.e051.jpg" id="pone.0322144.e051g" position="anchor"/><mml:math id="M57" display="inline" overflow="scroll"><mml:mrow><mml:mtext>hazards&#x000a0;ratio</mml:mtext><mml:mrow><mml:mo fence="true" form="prefix" stretchy="true">[</mml:mo><mml:mtext>HR</mml:mtext><mml:mo fence="true" form="postfix" stretchy="true">]</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mn>2.3</mml:mn></mml:mrow></mml:math></alternatives></inline-formula>&#x0201d;, &#x0201c;<inline-formula id="pone.0322144.e052"><alternatives><graphic xlink:href="pone.0322144.e052.jpg" id="pone.0322144.e052g" position="anchor"/><mml:math id="M58" display="inline" overflow="scroll"><mml:mrow><mml:mtext>HR</mml:mtext><mml:mi>:</mml:mi><mml:mn>2.3</mml:mn></mml:mrow></mml:math></alternatives></inline-formula>&#x0201d;, &#x0201c;<inline-formula id="pone.0322144.e053"><alternatives><graphic xlink:href="pone.0322144.e053.jpg" id="pone.0322144.e053g" position="anchor"/><mml:math id="M59" display="inline" overflow="scroll"><mml:mrow><mml:mtext>H.R.</mml:mtext><mml:mi>:</mml:mi><mml:mn>2.3</mml:mn></mml:mrow></mml:math></alternatives></inline-formula>&#x0201d;, and many more. Thus, we attempted to make the regular expression as flexible as possible, so that it could capture the maximum amount of valid text, while still maintaining a healthy level of restrictions. For more details, please consult our code, available at <ext-link xlink:href="https://osf.io/ua4ys/" ext-link-type="uri">https://osf.io/ua4ys/</ext-link>. In total, we were able to extract data for 21,768 out of 36,431 results (see column 4 of <xref rid="pone.0322144.t001" ref-type="table">Table 1</xref>).</p><p>We applied additional checks on the extracted data to make sure that both the regular expression worked properly and the information in the abstracts themselves was correct. As a first step, we checked whether the confidence level of the <inline-formula id="pone.0322144.e054"><alternatives><graphic xlink:href="pone.0322144.e054.jpg" id="pone.0322144.e054g" position="anchor"/><mml:math id="M60" display="inline" overflow="scroll"><mml:mrow><mml:mtext>CI</mml:mtext></mml:mrow></mml:math></alternatives></inline-formula> was between 0 and 100. Second, we tested whether <inline-formula id="pone.0322144.e055"><alternatives><graphic xlink:href="pone.0322144.e055.jpg" id="pone.0322144.e055g" position="anchor"/><mml:math id="M61" display="inline" overflow="scroll"><mml:mrow><mml:mtext>HR</mml:mtext></mml:mrow></mml:math></alternatives></inline-formula>, <inline-formula id="pone.0322144.e056"><alternatives><graphic xlink:href="pone.0322144.e056.jpg" id="pone.0322144.e056g" position="anchor"/><mml:math id="M62" display="inline" overflow="scroll"><mml:mrow><mml:msup><mml:mtext>HR</mml:mtext><mml:mi>l</mml:mi></mml:msup></mml:mrow></mml:math></alternatives></inline-formula>, and <inline-formula id="pone.0322144.e057"><alternatives><graphic xlink:href="pone.0322144.e057.jpg" id="pone.0322144.e057g" position="anchor"/><mml:math id="M63" display="inline" overflow="scroll"><mml:mrow><mml:msup><mml:mtext>HR</mml:mtext><mml:mi>u</mml:mi></mml:msup></mml:mrow></mml:math></alternatives></inline-formula> were higher than 0 (because the possible range goes from 0 to <inline-formula id="pone.0322144.e058"><alternatives><graphic xlink:href="pone.0322144.e058.jpg" id="pone.0322144.e058g" position="anchor"/><mml:math id="M64" display="inline" overflow="scroll"><mml:mrow><mml:mo>&#x0221e;</mml:mo></mml:mrow></mml:math></alternatives></inline-formula>). Third, we examined whether the <inline-formula id="pone.0322144.e059"><alternatives><graphic xlink:href="pone.0322144.e059.jpg" id="pone.0322144.e059g" position="anchor"/><mml:math id="M65" display="inline" overflow="scroll"><mml:mrow><mml:mi>log</mml:mi><mml:mtext>HR</mml:mtext></mml:mrow></mml:math></alternatives></inline-formula> was approximately (because of rounding) in the middle of <inline-formula id="pone.0322144.e060"><alternatives><graphic xlink:href="pone.0322144.e060.jpg" id="pone.0322144.e060g" position="anchor"/><mml:math id="M66" display="inline" overflow="scroll"><mml:mrow><mml:msup><mml:mtext>HR</mml:mtext><mml:mi>l</mml:mi></mml:msup></mml:mrow></mml:math></alternatives></inline-formula> and <inline-formula id="pone.0322144.e061"><alternatives><graphic xlink:href="pone.0322144.e061.jpg" id="pone.0322144.e061g" position="anchor"/><mml:math id="M67" display="inline" overflow="scroll"><mml:mrow><mml:msup><mml:mtext>HR</mml:mtext><mml:mi>u</mml:mi></mml:msup></mml:mrow></mml:math></alternatives></inline-formula>. Here, we also excluded results where the <inline-formula id="pone.0322144.e062"><alternatives><graphic xlink:href="pone.0322144.e062.jpg" id="pone.0322144.e062g" position="anchor"/><mml:math id="M68" display="inline" overflow="scroll"><mml:mrow><mml:mi>log</mml:mi><mml:mtext>HR</mml:mtext></mml:mrow></mml:math></alternatives></inline-formula> and at least one of <inline-formula id="pone.0322144.e063"><alternatives><graphic xlink:href="pone.0322144.e063.jpg" id="pone.0322144.e063g" position="anchor"/><mml:math id="M69" display="inline" overflow="scroll"><mml:mrow><mml:msup><mml:mtext>HR</mml:mtext><mml:mi>l</mml:mi></mml:msup></mml:mrow></mml:math></alternatives></inline-formula> or <inline-formula id="pone.0322144.e064"><alternatives><graphic xlink:href="pone.0322144.e064.jpg" id="pone.0322144.e064g" position="anchor"/><mml:math id="M70" display="inline" overflow="scroll"><mml:mrow><mml:msup><mml:mtext>HR</mml:mtext><mml:mi>u</mml:mi></mml:msup></mml:mrow></mml:math></alternatives></inline-formula> had the same value due to rounding. Any extracted data that did not fulfill all of these criteria was discarded. Column 5 of <xref rid="pone.0322144.t001" ref-type="table">Table 1</xref> shows that for all nine subfields only a small number of extracted data had to be excluded (170 out of 21,768 in total), leaving a final number of considered results of 21,598.</p><p>With this step completed, the nine subfields and their hazard ratios and associated <inline-formula id="pone.0322144.e065"><alternatives><graphic xlink:href="pone.0322144.e065.jpg" id="pone.0322144.e065g" position="anchor"/><mml:math id="M71" display="inline" overflow="scroll"><mml:mrow><mml:mi>x</mml:mi><mml:mi>%</mml:mi></mml:mrow></mml:math></alternatives></inline-formula> confidence intervals were considered separately. For each study <italic toggle="yes">i</italic> in <inline-formula id="pone.0322144.e066"><alternatives><graphic xlink:href="pone.0322144.e066.jpg" id="pone.0322144.e066g" position="anchor"/><mml:math id="M72" display="inline" overflow="scroll"><mml:mrow><mml:mi>i</mml:mi><mml:mo>&#x02208;</mml:mo><mml:mrow><mml:mo fence="true" form="prefix" stretchy="true">{</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mspace width="1em"/><mml:mn>2</mml:mn><mml:mo>,</mml:mo><mml:mspace width="1em"/><mml:mo>&#x02026;</mml:mo><mml:mo>,</mml:mo><mml:mspace width="1em"/><mml:mi>N</mml:mi><mml:mo fence="true" form="postfix" stretchy="true">}</mml:mo></mml:mrow></mml:mrow></mml:math></alternatives></inline-formula> within one of the nine subfields (where <italic toggle="yes">N</italic> is the number of studies within one of the nine subfields), the extracted <inline-formula id="pone.0322144.e067"><alternatives><graphic xlink:href="pone.0322144.e067.jpg" id="pone.0322144.e067g" position="anchor"/><mml:math id="M73" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mtext>HR</mml:mtext><mml:mi>i</mml:mi></mml:msub></mml:mrow></mml:math></alternatives></inline-formula> was <inline-formula id="pone.0322144.e068"><alternatives><graphic xlink:href="pone.0322144.e068.jpg" id="pone.0322144.e068g" position="anchor"/><mml:math id="M74" display="inline" overflow="scroll"><mml:mrow><mml:mi>log</mml:mi></mml:mrow></mml:math></alternatives></inline-formula>-transformed (<italic toggle="yes">b</italic><sub><italic toggle="yes">i</italic></sub>). Also, the standard error of <italic toggle="yes">b</italic><sub><italic toggle="yes">i</italic></sub> was calculated based on the confidence interval (e.g., [<xref rid="pone.0322144.ref090" ref-type="bibr">90</xref>]) of <inline-formula id="pone.0322144.e069"><alternatives><graphic xlink:href="pone.0322144.e069.jpg" id="pone.0322144.e069g" position="anchor"/><mml:math id="M75" display="inline" overflow="scroll"><mml:mrow><mml:mtext>HR</mml:mtext></mml:mrow></mml:math></alternatives></inline-formula> (i.e., <inline-formula id="pone.0322144.e070"><alternatives><graphic xlink:href="pone.0322144.e070.jpg" id="pone.0322144.e070g" position="anchor"/><mml:math id="M76" display="inline" overflow="scroll"><mml:mrow><mml:msubsup><mml:mtext>HR</mml:mtext><mml:mi>i</mml:mi><mml:mi>l</mml:mi></mml:msubsup></mml:mrow></mml:math></alternatives></inline-formula> and <inline-formula id="pone.0322144.e071"><alternatives><graphic xlink:href="pone.0322144.e071.jpg" id="pone.0322144.e071g" position="anchor"/><mml:math id="M77" display="inline" overflow="scroll"><mml:mrow><mml:msubsup><mml:mtext>HR</mml:mtext><mml:mi>i</mml:mi><mml:mi>u</mml:mi></mml:msubsup></mml:mrow></mml:math></alternatives></inline-formula>):</p><disp-formula id="pone.0322144.e072"><alternatives><graphic xlink:href="pone.0322144.e072.jpg" id="pone.0322144.e072g" position="anchor"/><mml:math id="M78" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>E</mml:mi><mml:mrow><mml:mo fence="true" form="prefix" stretchy="true">(</mml:mo><mml:msub><mml:mi>b</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo fence="true" form="postfix" stretchy="true">)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mfrac><mml:mrow><mml:mi>log</mml:mi><mml:msubsup><mml:mtext>HR</mml:mtext><mml:mi>i</mml:mi><mml:mi>u</mml:mi></mml:msubsup><mml:mo>&#x02212;</mml:mo><mml:mi>log</mml:mi><mml:msubsup><mml:mtext>HR</mml:mtext><mml:mi>i</mml:mi><mml:mi>l</mml:mi></mml:msubsup></mml:mrow><mml:mrow><mml:mn>2</mml:mn><mml:msubsup><mml:mi>z</mml:mi><mml:mi>i</mml:mi><mml:mo>*</mml:mo></mml:msubsup></mml:mrow></mml:mfrac></mml:mstyle><mml:mtext>,</mml:mtext></mml:mrow></mml:mrow></mml:math></alternatives>
<label>(6)</label></disp-formula><p>where <inline-formula id="pone.0322144.e073"><alternatives><graphic xlink:href="pone.0322144.e073.jpg" id="pone.0322144.e073g" position="anchor"/><mml:math id="M79" display="inline" overflow="scroll"><mml:mrow><mml:msubsup><mml:mi>z</mml:mi><mml:mi>i</mml:mi><mml:mo>*</mml:mo></mml:msubsup><mml:mo>=</mml:mo><mml:mi>Q</mml:mi><mml:mrow><mml:mo fence="true" form="prefix" stretchy="true">(</mml:mo><mml:mn>1</mml:mn><mml:mo>&#x02212;</mml:mo><mml:msub><mml:mi>&#x003b1;</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>/</mml:mo><mml:mn>2</mml:mn><mml:mo fence="true" form="postfix" stretchy="true">)</mml:mo></mml:mrow></mml:mrow></mml:math></alternatives></inline-formula> and <inline-formula id="pone.0322144.e074"><alternatives><graphic xlink:href="pone.0322144.e074.jpg" id="pone.0322144.e074g" position="anchor"/><mml:math id="M80" display="inline" overflow="scroll"><mml:mrow><mml:mi>Q</mml:mi><mml:mrow><mml:mo fence="true" form="prefix" stretchy="true">(</mml:mo><mml:mo>.</mml:mo><mml:mo fence="true" form="postfix" stretchy="true">)</mml:mo></mml:mrow></mml:mrow></mml:math></alternatives></inline-formula> is the quantile function of the standard Normal distribution. The sign of <italic toggle="yes">b</italic><sub><italic toggle="yes">i</italic></sub>, however, is meaningless because it depends on how the independent variable is coded. For instance, commonly the control condition is coded with 0 and the experimental condition with 1; occasionally, the opposite is the case, which would reverse the sign of <italic toggle="yes">b</italic><sub><italic toggle="yes">i</italic></sub>. We take this arbitrariness into account in any further calculations.</p><p>The obtained <italic toggle="yes">b</italic><sub><italic toggle="yes">i</italic></sub> and <inline-formula id="pone.0322144.e075"><alternatives><graphic xlink:href="pone.0322144.e075.jpg" id="pone.0322144.e075g" position="anchor"/><mml:math id="M81" display="inline" overflow="scroll"><mml:mrow><mml:mi>S</mml:mi><mml:mi>E</mml:mi><mml:mrow><mml:mo fence="true" form="prefix" stretchy="true">(</mml:mo><mml:msub><mml:mi>b</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo fence="true" form="postfix" stretchy="true">)</mml:mo></mml:mrow></mml:mrow></mml:math></alternatives></inline-formula> within a subfield could then be used for the construction of a prior for each subfield separately. We decided to use the Normal distribution for the prior. To obtain a prior, we combined the data through pooling (e.g., [<xref rid="pone.0322144.ref090" ref-type="bibr">90</xref>]). Using this procedure, <italic toggle="yes">b</italic><sub><italic toggle="yes">i</italic></sub> and <inline-formula id="pone.0322144.e076"><alternatives><graphic xlink:href="pone.0322144.e076.jpg" id="pone.0322144.e076g" position="anchor"/><mml:math id="M82" display="inline" overflow="scroll"><mml:mrow><mml:mi>S</mml:mi><mml:mi>E</mml:mi><mml:mrow><mml:mo fence="true" form="prefix" stretchy="true">(</mml:mo><mml:msub><mml:mi>b</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo fence="true" form="postfix" stretchy="true">)</mml:mo></mml:mrow></mml:mrow></mml:math></alternatives></inline-formula> were treated as coming from separate samples that were combined into a single pooled sample. One desirable feature of this pooling method is that <italic toggle="yes">b</italic><sub><italic toggle="yes">i</italic></sub> values with higher <inline-formula id="pone.0322144.e077"><alternatives><graphic xlink:href="pone.0322144.e077.jpg" id="pone.0322144.e077g" position="anchor"/><mml:math id="M83" display="inline" overflow="scroll"><mml:mrow><mml:mi>S</mml:mi><mml:mi>E</mml:mi><mml:mrow><mml:mo fence="true" form="prefix" stretchy="true">(</mml:mo><mml:msub><mml:mi>b</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo fence="true" form="postfix" stretchy="true">)</mml:mo></mml:mrow></mml:mrow></mml:math></alternatives></inline-formula> are central to (rather than discarded for) the calculation of the pooled standard error. In other words, the <inline-formula id="pone.0322144.e078"><alternatives><graphic xlink:href="pone.0322144.e078.jpg" id="pone.0322144.e078g" position="anchor"/><mml:math id="M84" display="inline" overflow="scroll"><mml:mrow><mml:mi>S</mml:mi><mml:mi>E</mml:mi><mml:mrow><mml:mo fence="true" form="prefix" stretchy="true">(</mml:mo><mml:msub><mml:mi>b</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo fence="true" form="postfix" stretchy="true">)</mml:mo></mml:mrow></mml:mrow></mml:math></alternatives></inline-formula> around the <italic toggle="yes">b</italic><sub><italic toggle="yes">i</italic></sub> values had a direct influence on the calculation of the pooled standard error: All else being equal, the higher the <inline-formula id="pone.0322144.e079"><alternatives><graphic xlink:href="pone.0322144.e079.jpg" id="pone.0322144.e079g" position="anchor"/><mml:math id="M85" display="inline" overflow="scroll"><mml:mrow><mml:mi>S</mml:mi><mml:mi>E</mml:mi><mml:mrow><mml:mo fence="true" form="prefix" stretchy="true">(</mml:mo><mml:msub><mml:mi>b</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo fence="true" form="postfix" stretchy="true">)</mml:mo></mml:mrow></mml:mrow></mml:math></alternatives></inline-formula> of a sample, the more it would increase the pooled standard error. We deemed this behavior desirable since we wanted the prior to reflect uncertainty. The resulting mean and standard error of a single pooled sample served as the mean and standard deviation of the prior.</p><p>We decided against using the inverse-variance weighting procedure that is commonly used in meta-analyses (see, e.g., [<xref rid="pone.0322144.ref091" ref-type="bibr">91</xref>]). The reason for this was that the prior would get increasingly narrow as the corpus of considered studies increases. In addition, <italic toggle="yes">b</italic><sub><italic toggle="yes">i</italic></sub> with high <inline-formula id="pone.0322144.e080"><alternatives><graphic xlink:href="pone.0322144.e080.jpg" id="pone.0322144.e080g" position="anchor"/><mml:math id="M86" display="inline" overflow="scroll"><mml:mrow><mml:mi>S</mml:mi><mml:mi>E</mml:mi><mml:mrow><mml:mo fence="true" form="prefix" stretchy="true">(</mml:mo><mml:msub><mml:mi>b</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo fence="true" form="postfix" stretchy="true">)</mml:mo></mml:mrow></mml:mrow></mml:math></alternatives></inline-formula> values have a relatively low influence (they are less diagnostic in determining the mean), which was undesirable for our purposes of trying to estimate the spread of the prior. Also, we decided to not use the partly empirical Bayes procedure described in [<xref rid="pone.0322144.ref087" ref-type="bibr">87</xref>] because the nature of it prescribes that the current data (i.e., not only the corpus of prior studies) is used to determine the prior.</p><p>Assuming a constant <italic toggle="yes">n</italic> across studies <italic toggle="yes">i</italic> and taking into consideration the arbitrariness of the sign of <italic toggle="yes">b</italic><sub><italic toggle="yes">i</italic></sub> by using both <italic toggle="yes">b</italic><sub><italic toggle="yes">i</italic></sub> and &#x02212;<italic toggle="yes">b</italic><sub><italic toggle="yes">i</italic></sub> for each study <italic toggle="yes">i</italic>, we can compute the mean <inline-formula id="pone.0322144.e081"><alternatives><graphic xlink:href="pone.0322144.e081.jpg" id="pone.0322144.e081g" position="anchor"/><mml:math id="M87" display="inline" overflow="scroll"><mml:mrow><mml:msup><mml:mi>&#x003bc;</mml:mi><mml:mi>p</mml:mi></mml:msup></mml:mrow></mml:math></alternatives></inline-formula> of the prior (cf. [<xref rid="pone.0322144.ref090" ref-type="bibr">90</xref>]). Since we consider both <italic toggle="yes">b</italic><sub><italic toggle="yes">i</italic></sub> and &#x02212;<italic toggle="yes">b</italic><sub><italic toggle="yes">i</italic></sub> for each study <italic toggle="yes">i</italic>, <inline-formula id="pone.0322144.e082"><alternatives><graphic xlink:href="pone.0322144.e082.jpg" id="pone.0322144.e082g" position="anchor"/><mml:math id="M88" display="inline" overflow="scroll"><mml:mrow><mml:msup><mml:mi>&#x003bc;</mml:mi><mml:mi>p</mml:mi></mml:msup></mml:mrow></mml:math></alternatives></inline-formula> must necessarily be 0:</p><disp-formula id="pone.0322144.e083"><alternatives><graphic xlink:href="pone.0322144.e083.jpg" id="pone.0322144.e083g" position="anchor"/><mml:math id="M89" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:msup><mml:mi>&#x003bc;</mml:mi><mml:mi>p</mml:mi></mml:msup><mml:mo>=</mml:mo><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mfrac><mml:mrow><mml:mi>n</mml:mi><mml:msubsup><mml:mo>&#x02211;</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>N</mml:mi></mml:msubsup><mml:msub><mml:mi>b</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:mi>n</mml:mi><mml:msubsup><mml:mo>&#x02211;</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>N</mml:mi></mml:msubsup><mml:mo>&#x02212;</mml:mo><mml:msub><mml:mi>b</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mrow><mml:mrow><mml:mn>2</mml:mn><mml:mi>N</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:mfrac></mml:mstyle><mml:mo>=</mml:mo><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mfrac><mml:mrow><mml:msubsup><mml:mo>&#x02211;</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>N</mml:mi></mml:msubsup><mml:msub><mml:mi>b</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>&#x02212;</mml:mo><mml:msub><mml:mi>b</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mrow><mml:mrow><mml:mn>2</mml:mn><mml:mi>N</mml:mi></mml:mrow></mml:mfrac></mml:mstyle><mml:mo>=</mml:mo><mml:mn>0</mml:mn><mml:mtext>.</mml:mtext></mml:mrow></mml:mrow></mml:math></alternatives>
<label>(7)</label></disp-formula><p>Similarly, we can compute the standard deviation of the prior <inline-formula id="pone.0322144.e084"><alternatives><graphic xlink:href="pone.0322144.e084.jpg" id="pone.0322144.e084g" position="anchor"/><mml:math id="M90" display="inline" overflow="scroll"><mml:mrow><mml:msup><mml:mi>&#x003c3;</mml:mi><mml:mi>p</mml:mi></mml:msup></mml:mrow></mml:math></alternatives></inline-formula>:</p><disp-formula id="pone.0322144.e085"><alternatives><graphic xlink:href="pone.0322144.e085.jpg" id="pone.0322144.e085g" position="anchor"/><mml:math id="M91" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:msup><mml:mi>&#x003c3;</mml:mi><mml:mi>p</mml:mi></mml:msup><mml:mo>=</mml:mo><mml:msqrt><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mfrac><mml:mrow><mml:mrow><mml:mo fence="true" form="prefix" stretchy="true">(</mml:mo><mml:mi>n</mml:mi><mml:mo>&#x02212;</mml:mo><mml:mn>1</mml:mn><mml:mo fence="true" form="postfix" stretchy="true">)</mml:mo></mml:mrow><mml:msubsup><mml:mo>&#x02211;</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>N</mml:mi></mml:msubsup><mml:mi>S</mml:mi><mml:mi>E</mml:mi><mml:msup><mml:mrow><mml:mo fence="true" form="prefix" stretchy="true">(</mml:mo><mml:msub><mml:mi>b</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo fence="true" form="postfix" stretchy="true">)</mml:mo></mml:mrow><mml:mn>2</mml:mn></mml:msup><mml:mo>+</mml:mo><mml:mi>n</mml:mi><mml:msubsup><mml:mo>&#x02211;</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>N</mml:mi></mml:msubsup><mml:msubsup><mml:mi>b</mml:mi><mml:mi>i</mml:mi><mml:mn>2</mml:mn></mml:msubsup></mml:mrow><mml:mrow><mml:mi>N</mml:mi><mml:mi>n</mml:mi><mml:mo>&#x02212;</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:mfrac></mml:mstyle></mml:mrow></mml:msqrt><mml:mtext>.</mml:mtext></mml:mrow></mml:mrow></mml:math></alternatives>
<label>(8)</label></disp-formula><p>In essence, Eq (<xref rid="pone.0322144.e085" ref-type="disp-formula">8</xref>) sums up <inline-formula id="pone.0322144.e086"><alternatives><graphic xlink:href="pone.0322144.e086.jpg" id="pone.0322144.e086g" position="anchor"/><mml:math id="M92" display="inline" overflow="scroll"><mml:mrow><mml:mi>S</mml:mi><mml:mi>E</mml:mi><mml:mo fence="true" form="prefix" stretchy="true">(</mml:mo><mml:msub><mml:mi>b</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:msup><mml:mo fence="true" form="postfix" stretchy="true">)</mml:mo><mml:mn>2</mml:mn></mml:msup></mml:mrow></mml:math></alternatives></inline-formula> and it sums up <inline-formula id="pone.0322144.e087"><alternatives><graphic xlink:href="pone.0322144.e087.jpg" id="pone.0322144.e087g" position="anchor"/><mml:math id="M93" display="inline" overflow="scroll"><mml:mrow><mml:msubsup><mml:mi>b</mml:mi><mml:mi>i</mml:mi><mml:mn>2</mml:mn></mml:msubsup></mml:mrow></mml:math></alternatives></inline-formula>. Thus, all else being equal, <inline-formula id="pone.0322144.e088"><alternatives><graphic xlink:href="pone.0322144.e088.jpg" id="pone.0322144.e088g" position="anchor"/><mml:math id="M94" display="inline" overflow="scroll"><mml:mrow><mml:msup><mml:mi>&#x003c3;</mml:mi><mml:mi>p</mml:mi></mml:msup></mml:mrow></mml:math></alternatives></inline-formula> increases as any of the two quantities increases. Note that our extracted information did not provide information on the sample size <italic toggle="yes">n</italic><sub><italic toggle="yes">i</italic></sub> within each study. We used an arbitrary sample size of <italic toggle="yes">n</italic>&#x02009;=&#x02009;200 for all <italic toggle="yes">n</italic><sub><italic toggle="yes">i</italic></sub>. However, in order to verify the robustness of the assumption of equal sample size per study, we randomly varied <italic toggle="yes">n</italic><sub><italic toggle="yes">i</italic></sub> across studies, so that it could take on values sampled from <inline-formula id="pone.0322144.e089"><alternatives><graphic xlink:href="pone.0322144.e089.jpg" id="pone.0322144.e089g" position="anchor"/><mml:math id="M95" display="inline" overflow="scroll"><mml:mrow><mml:mtext>U</mml:mtext><mml:mrow><mml:mo fence="true" form="prefix" stretchy="true">(</mml:mo><mml:mn>10</mml:mn><mml:mo>,</mml:mo><mml:mspace width="1em"/><mml:mn>10000</mml:mn><mml:mo fence="true" form="postfix" stretchy="true">)</mml:mo></mml:mrow></mml:mrow></mml:math></alternatives></inline-formula>. We repeated this procedure 100,000 times to accommodate many possible arrangements of <italic toggle="yes">n</italic><sub><italic toggle="yes">i</italic></sub>.</p></sec><sec sec-type="results" id="sec006"><title>Results</title><p>The results for the construction of the Normal priors for the nine subfields through the pooling method [<xref rid="pone.0322144.ref090" ref-type="bibr">90</xref>] can be seen in <xref rid="pone.0322144.g002" ref-type="fig">Fig 2</xref>. The panels represent the nine subfields. Histograms show the distributions of <italic toggle="yes">b</italic><sub><italic toggle="yes">i</italic></sub> (and &#x02212;<italic toggle="yes">b</italic><sub><italic toggle="yes">i</italic></sub>) for the different corpora, independent of <inline-formula id="pone.0322144.e090"><alternatives><graphic xlink:href="pone.0322144.e090.jpg" id="pone.0322144.e090g" position="anchor"/><mml:math id="M96" display="inline" overflow="scroll"><mml:mrow><mml:mi>S</mml:mi><mml:mi>E</mml:mi><mml:mrow><mml:mo fence="true" form="prefix" stretchy="true">(</mml:mo><mml:msub><mml:mi>b</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo fence="true" form="postfix" stretchy="true">)</mml:mo></mml:mrow></mml:mrow></mml:math></alternatives></inline-formula>. The red curves show the priors resulting from the application of the pooling method [<xref rid="pone.0322144.ref090" ref-type="bibr">90</xref>]. Descriptive statistics can be found in Appendix <xref rid="sec010" ref-type="sec">B</xref>.</p><p>For all nine subfields, the center of the Normal prior was located at <inline-formula id="pone.0322144.e094"><alternatives><graphic xlink:href="pone.0322144.e094.jpg" id="pone.0322144.e094g" position="anchor"/><mml:math id="M97" display="inline" overflow="scroll"><mml:mrow><mml:msup><mml:mi>&#x003bc;</mml:mi><mml:mi>p</mml:mi></mml:msup><mml:mo>=</mml:mo><mml:mn>0</mml:mn></mml:mrow></mml:math></alternatives></inline-formula> as a necessary consequence of our decision to ignore the sign of <italic toggle="yes">b</italic><sub><italic toggle="yes">i</italic></sub>. The more interesting parameter of the Normal prior is the standard deviation <inline-formula id="pone.0322144.e095"><alternatives><graphic xlink:href="pone.0322144.e095.jpg" id="pone.0322144.e095g" position="anchor"/><mml:math id="M98" display="inline" overflow="scroll"><mml:mrow><mml:msup><mml:mi>&#x003c3;</mml:mi><mml:mi>p</mml:mi></mml:msup></mml:mrow></mml:math></alternatives></inline-formula> because it reflects both the effect sizes and the uncertainties around them based on past studies within a subfield. From the histograms and the Normal priors it can be seen that the effect sizes, and therefore also the Normal priors, were similar across the nine subfields. <inline-formula id="pone.0322144.e096"><alternatives><graphic xlink:href="pone.0322144.e096.jpg" id="pone.0322144.e096g" position="anchor"/><mml:math id="M99" display="inline" overflow="scroll"><mml:mrow><mml:msup><mml:mi>&#x003c3;</mml:mi><mml:mi>p</mml:mi></mml:msup></mml:mrow></mml:math></alternatives></inline-formula> ranged between 0.915 for &#x0201c;Psychiatry and mental health&#x0201d; and 1.079 for &#x0201c;Gastroenterology&#x0201d;.</p><p>Since the calculation of <inline-formula id="pone.0322144.e097"><alternatives><graphic xlink:href="pone.0322144.e097.jpg" id="pone.0322144.e097g" position="anchor"/><mml:math id="M100" display="inline" overflow="scroll"><mml:mrow><mml:msup><mml:mi>&#x003c3;</mml:mi><mml:mi>p</mml:mi></mml:msup></mml:mrow></mml:math></alternatives></inline-formula> through the pooling method [<xref rid="pone.0322144.ref090" ref-type="bibr">90</xref>] was based on an arbitrary choice of <italic toggle="yes">n</italic>&#x02009;=&#x02009;200 that was the same for all studies within a corpus of a specific subfield, we also investigated the dependence of <inline-formula id="pone.0322144.e098"><alternatives><graphic xlink:href="pone.0322144.e098.jpg" id="pone.0322144.e098g" position="anchor"/><mml:math id="M101" display="inline" overflow="scroll"><mml:mrow><mml:msup><mml:mi>&#x003c3;</mml:mi><mml:mi>p</mml:mi></mml:msup></mml:mrow></mml:math></alternatives></inline-formula> on <italic toggle="yes">n</italic>. <xref rid="pone.0322144.g003" ref-type="fig">Fig 3</xref> shows this dependence, where the panels represent the different subfields. The box plots represent the variation of <inline-formula id="pone.0322144.e099"><alternatives><graphic xlink:href="pone.0322144.e099.jpg" id="pone.0322144.e099g" position="anchor"/><mml:math id="M102" display="inline" overflow="scroll"><mml:mrow><mml:msup><mml:mi>&#x003c3;</mml:mi><mml:mi>p</mml:mi></mml:msup></mml:mrow></mml:math></alternatives></inline-formula> as a function of <italic toggle="yes">n</italic><sub><italic toggle="yes">i</italic></sub>, where <italic toggle="yes">n</italic><sub><italic toggle="yes">i</italic></sub> for each study <italic toggle="yes">i</italic> was sampled from <inline-formula id="pone.0322144.e100"><alternatives><graphic xlink:href="pone.0322144.e100.jpg" id="pone.0322144.e100g" position="anchor"/><mml:math id="M103" display="inline" overflow="scroll"><mml:mrow><mml:mtext>U</mml:mtext><mml:mrow><mml:mo fence="true" form="prefix" stretchy="true">(</mml:mo><mml:mn>10</mml:mn><mml:mo>,</mml:mo><mml:mspace width="1em"/><mml:mn>10000</mml:mn><mml:mo fence="true" form="postfix" stretchy="true">)</mml:mo></mml:mrow></mml:mrow></mml:math></alternatives></inline-formula> (i.e., different sample sizes were possible across studies), over 100,000 repetitions.</p><p>When <italic toggle="yes">n</italic><sub><italic toggle="yes">i</italic></sub> were allowed to vary across studies, some variation in <inline-formula id="pone.0322144.e104"><alternatives><graphic xlink:href="pone.0322144.e104.jpg" id="pone.0322144.e104g" position="anchor"/><mml:math id="M104" display="inline" overflow="scroll"><mml:mrow><mml:msup><mml:mi>&#x003c3;</mml:mi><mml:mi>p</mml:mi></mml:msup></mml:mrow></mml:math></alternatives></inline-formula> was observed, as shown by the box plots. Still, the variation in <inline-formula id="pone.0322144.e105"><alternatives><graphic xlink:href="pone.0322144.e105.jpg" id="pone.0322144.e105g" position="anchor"/><mml:math id="M105" display="inline" overflow="scroll"><mml:mrow><mml:msup><mml:mi>&#x003c3;</mml:mi><mml:mi>p</mml:mi></mml:msup></mml:mrow></mml:math></alternatives></inline-formula> was not radical enough to question our heuristic of using <italic toggle="yes">n</italic>&#x02009;=&#x02009;200 for all studies within a corpus of a subfield.</p><sec id="sec007"><title>Example application</title><p>To illustrate how the obtained priors can be used, we conducted a Bayesian Cox regression on a medical data set, which is described in [<xref rid="pone.0322144.ref092" ref-type="bibr">92</xref>]. In this study, the authors aimed to examine a drug called Remdesivir, which promised to be beneficial for treating patients with Covid-19. The study included <inline-formula id="pone.0322144.e106"><alternatives><graphic xlink:href="pone.0322144.e106.jpg" id="pone.0322144.e106g" position="anchor"/><mml:math id="M106" display="inline" overflow="scroll"><mml:mrow><mml:mi>n</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mn>062</mml:mn></mml:mrow></mml:math></alternatives></inline-formula> participants, of which <italic toggle="yes">n</italic><sub><italic toggle="yes">c</italic></sub>&#x02009;=&#x02009;521 were randomly placed in the placebo condition and <italic toggle="yes">n</italic><sub><italic toggle="yes">e</italic></sub>&#x02009;=&#x02009;541 in the Remdesivir condition. All participants had a Covid-19 infection. The primary analysis focused on the amount of time until participants recovered.</p><p>It can be argued that this study falls both in the realm of &#x0201c;immunology and allergy&#x0201d; as well as &#x0201c;pulmonary and respiratory medicine&#x0201d; (i.e., <inline-formula id="pone.0322144.e107"><alternatives><graphic xlink:href="pone.0322144.e107.jpg" id="pone.0322144.e107g" position="anchor"/><mml:math id="M107" display="inline" overflow="scroll"><mml:mrow><mml:msup><mml:mi>&#x003c3;</mml:mi><mml:mi>p</mml:mi></mml:msup><mml:mo>=</mml:mo><mml:mn>1.023</mml:mn></mml:mrow></mml:math></alternatives></inline-formula> and <inline-formula id="pone.0322144.e108"><alternatives><graphic xlink:href="pone.0322144.e108.jpg" id="pone.0322144.e108g" position="anchor"/><mml:math id="M108" display="inline" overflow="scroll"><mml:mrow><mml:msup><mml:mi>&#x003c3;</mml:mi><mml:mi>p</mml:mi></mml:msup><mml:mo>=</mml:mo><mml:mn>0.999</mml:mn></mml:mrow></mml:math></alternatives></inline-formula>, respectively). Therefore, we conducted our analyses with both priors. Furthermore, we think that it is always good practice to conduct sensitivity analyses. So, we further extended our used priors to entail Normal priors centered on <inline-formula id="pone.0322144.e109"><alternatives><graphic xlink:href="pone.0322144.e109.jpg" id="pone.0322144.e109g" position="anchor"/><mml:math id="M109" display="inline" overflow="scroll"><mml:mrow><mml:msup><mml:mi>&#x003bc;</mml:mi><mml:mi>p</mml:mi></mml:msup><mml:mo>=</mml:mo><mml:mn>0</mml:mn></mml:mrow></mml:math></alternatives></inline-formula> with <inline-formula id="pone.0322144.e110"><alternatives><graphic xlink:href="pone.0322144.e110.jpg" id="pone.0322144.e110g" position="anchor"/><mml:math id="M110" display="inline" overflow="scroll"><mml:mrow><mml:msup><mml:mi>&#x003c3;</mml:mi><mml:mi>p</mml:mi></mml:msup><mml:mo>&#x02208;</mml:mo><mml:mrow><mml:mo fence="true" form="prefix" stretchy="true">{</mml:mo><mml:mn>0.3</mml:mn><mml:mo>,</mml:mo><mml:mn>0.4</mml:mn><mml:mo>,</mml:mo><mml:mo>.</mml:mo><mml:mo>.</mml:mo><mml:mo>.</mml:mo><mml:mo>,</mml:mo><mml:mn>1.7</mml:mn><mml:mo fence="true" form="postfix" stretchy="true">}</mml:mo></mml:mrow></mml:mrow></mml:math></alternatives></inline-formula>. We argued that a major advantage of Bayesian statistics is to monitor and optionally stop data collection based on interim results. We demonstrate this procedure on the basis of the data set by [<xref rid="pone.0322144.ref092" ref-type="bibr">92</xref>]. Unfortunately, the data file does not record the order in which participants entered the study. However, for the purposes of this demonstration, we deemed it appropriate to simply take a random order. In essence, we pretend that the study is still ongoing and we stop data collection once the resulting Bayes factor falls outside the decision threshold of 1/20 or 20. In general, the choice for a specific decision threshold should be tailored to the research at hand. There are scenarios where the priority lies with more certainty and scenarios where the priority lies with more efficiency. However, researchers should be aware of the tradeoff between certainty and resource demands; the more certain we want to be, the more cases must be sampled. Lastly, for our analysis we use a one-sided positive alternative hypothesis because it is hypothesized that patients receiving Remdesivir recover quicker than patients receiving a placebo.</p><p><xref rid="pone.0322144.g004" ref-type="fig">Fig 4</xref> shows the development of the Bayes factors as new data enter the study for various priors. The blue and red lines correspond to the &#x0201c;immunology and allergy&#x0201d; and &#x0201c;pulmonary and respiratory medicine&#x0201d; priors and the gray lines to the priors used in the sensitivity analyses. It can be seen that all Bayes factor trajectories cross the upper threshold of 20 at some point, demonstrating the robustness of the findings. For some extreme priors, the upper threshold is already crossed at about 300 observations.</p></sec></sec><sec sec-type="conclusions" id="sec008"><title>Discussion</title><p>Survival analysis, and in particular Cox regression [<xref rid="pone.0322144.ref038" ref-type="bibr">38</xref>], is an indispensable statistical tool for biomedical research. The ubiquitous frequentist framework is limited in that it cannot quantify evidence in favor of the null hypothesis that there is no effect [<xref rid="pone.0322144.ref042" ref-type="bibr">42</xref>] and in that it does not allow continuing or stopping data collection based on interim analyses [<xref rid="pone.0322144.ref047" ref-type="bibr">47</xref>&#x02013;<xref rid="pone.0322144.ref050" ref-type="bibr">50</xref>,<xref rid="pone.0322144.ref054" ref-type="bibr">54</xref>,<xref rid="pone.0322144.ref055" ref-type="bibr">55</xref>]. Bayes factors remedy these shortcomings and permit intuitive interpretations. Nevertheless, the specification of priors that are required for Bayesian analyses can be difficult.</p><p>In this paper, we have developed priors for the <inline-formula id="pone.0322144.e111"><alternatives><graphic xlink:href="pone.0322144.e111.jpg" id="pone.0322144.e111g" position="anchor"/><mml:math id="M111" display="inline" overflow="scroll"><mml:mrow><mml:mi>&#x003b2;</mml:mi></mml:mrow></mml:math></alternatives></inline-formula> parameter in Cox regression for nine subfields in biomedicine (see column 1 in <xref rid="pone.0322144.t001" ref-type="table">Table 1</xref>). These priors were informed by large corpora of already existing studies within the respective subfields and therefore provide reasonable approximations to the to-be-expected effect sizes and uncertainties thereof. For all nine subfields, we decided to use a Normal prior, which is centered on <inline-formula id="pone.0322144.e112"><alternatives><graphic xlink:href="pone.0322144.e112.jpg" id="pone.0322144.e112g" position="anchor"/><mml:math id="M112" display="inline" overflow="scroll"><mml:mrow><mml:msup><mml:mi>&#x003bc;</mml:mi><mml:mi>p</mml:mi></mml:msup><mml:mo>=</mml:mo><mml:mn>0</mml:mn></mml:mrow></mml:math></alternatives></inline-formula>. We found very similar standard deviations for the Normal priors across the nine subfields, ranging from <inline-formula id="pone.0322144.e113"><alternatives><graphic xlink:href="pone.0322144.e113.jpg" id="pone.0322144.e113g" position="anchor"/><mml:math id="M113" display="inline" overflow="scroll"><mml:mrow><mml:msup><mml:mi>&#x003c3;</mml:mi><mml:mi>p</mml:mi></mml:msup><mml:mo>=</mml:mo><mml:mn>0.915</mml:mn></mml:mrow></mml:math></alternatives></inline-formula> for &#x0201c;Psychiatry and mental health&#x0201d; to <inline-formula id="pone.0322144.e114"><alternatives><graphic xlink:href="pone.0322144.e114.jpg" id="pone.0322144.e114g" position="anchor"/><mml:math id="M114" display="inline" overflow="scroll"><mml:mrow><mml:msup><mml:mi>&#x003c3;</mml:mi><mml:mi>p</mml:mi></mml:msup><mml:mo>=</mml:mo><mml:mn>1.079</mml:mn></mml:mrow></mml:math></alternatives></inline-formula> for &#x0201c;Gastroenterology&#x0201d;, suggesting considerable similarities across subfields. Since our developed priors differ only slightly across the nine subfields, we believe that it is reasonable to use a standard Normal prior (i.e., <inline-formula id="pone.0322144.e115"><alternatives><graphic xlink:href="pone.0322144.e115.jpg" id="pone.0322144.e115g" position="anchor"/><mml:math id="M115" display="inline" overflow="scroll"><mml:mrow><mml:mtext>N</mml:mtext><mml:mrow><mml:mo fence="true" form="prefix" stretchy="true">(</mml:mo><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mspace width="1em"/><mml:mn>1</mml:mn><mml:mo fence="true" form="postfix" stretchy="true">)</mml:mo></mml:mrow></mml:mrow></mml:math></alternatives></inline-formula>) for all nine subfields, forming a compromise among the nine individual priors, as a starting point. Still, any choice of prior is always arbitrary to some degree. Therefore, we urge researchers to complement their analysis using a specific prior with sensitivity analyses (e.g., [<xref rid="pone.0322144.ref031" ref-type="bibr">31</xref>,<xref rid="pone.0322144.ref093" ref-type="bibr">93</xref>&#x02013;<xref rid="pone.0322144.ref095" ref-type="bibr">95</xref>]), in which parameters of the prior are systematically varied and even entirely different (reasonable) priors are chosen, in order to examine the robustness of the resulting Bayes factors.</p><p>We caution the reader to not take our proposed priors to be set in stone. The choice of prior always depends to some extent on the goals of the researcher. For example, it might not always be desirable for the prior to accurately reflect expected effects. Sometimes, the focus might be on ensuring sufficient shrinkage of the parameter estimate (e.g., [<xref rid="pone.0322144.ref087" ref-type="bibr">87</xref>,<xref rid="pone.0322144.ref096" ref-type="bibr">96</xref>,<xref rid="pone.0322144.ref097" ref-type="bibr">97</xref>]). Furthermore, we strongly advice researchers to only apply these priors in settings where they are appropriate. That is, these priors should only be applied in Cox regressions. We discourage the transfer of these priors to other methods, such as meta analysis or linear regression. In addition, our developed priors represent expected effect sizes of entire medical fields at a very global level. It is likely that researchers often have access to information that is more tailored to their research question. In that case, we encourage researchers to utilize this more informed and problem-specific information for the construction of a prior. We also want to highlight that researchers should define their prior, including the priors for any sensitivity analyses, before they inspect the data. Trying out multiple priors and then reporting those few that yield favorable results, is bad scientific practice.</p><p>Moreover, our process of arriving at the priors contained decisions, assumptions, and heuristics that might be questioned. First, the allocation of the articles to the nine subfields based alone on the journal is a drastic heuristic. A proportion of the articles is therefore probably classified into the wrong subfield. Second, the regular expression that we created to extract hazard ratios and associated <inline-formula id="pone.0322144.e116"><alternatives><graphic xlink:href="pone.0322144.e116.jpg" id="pone.0322144.e116g" position="anchor"/><mml:math id="M116" display="inline" overflow="scroll"><mml:mrow><mml:mi>x</mml:mi><mml:mi>%</mml:mi></mml:mrow></mml:math></alternatives></inline-formula> confidence intervals from the abstracts of the articles might have been biased to some extent. Some journals have very specific reporting guidelines for the abstracts, which might not have been captured by our regular expression. Thus, it is possible that certain journals were systematically underrepresented in our results. We investigated this potential bias by examining the number of articles that remain after conducting the processing steps shown in <xref rid="pone.0322144.t001" ref-type="table">Table 1</xref> for each journal in each field. We did not find convincing evidence for a systematic underrepresentation of certain journals (see Appendix <xref rid="sec010" ref-type="sec">C</xref>). Third, we only matched abstracts where a hazard ratio is combined with a confidence interval but not abstracts where a hazard ratio is combined with a <italic toggle="yes">p</italic>-value. We made this decision because <italic toggle="yes">p</italic>-values often do not map directly onto the confidence intervals. Additional information on how the <italic toggle="yes">p</italic>-value was calculated would be needed, which is rarely available in abstracts. Fourth, for the Cox regression analyses, we did not differentiate between different types of predictors (e.g., categorical, continuous) and types of analyses (e.g., stratified, multivariate), leaving open the possibility that certain nuances are ignored by our calculations. Fifth, our results are predicated on articles that have come up in the Scopus search engine. Any articles that were published in predatory journals, but that were somehow not screened out as such (see e.g., <ext-link xlink:href="https://www.elsevier.com/connect/the-guardians-of-scopus" ext-link-type="uri">https://www.elsevier.com/connect/the-guardians-of-scopus</ext-link>), may have introduced bias in the estimate of effect size variance, because of lack of proper peer review. Sixth, we assumed that HR refers to hazard ratio in the abstracts. However, HR could also be an abbreviation for other terms like heart rate. To mitigate this concern, we manually screened a random sample of 88 articles for which we could obtain a match and found that in all cases HR corresponded to hazard ratio.</p><p>It is clear that our proposed priors for Bayesian Cox regressions are very generic, such that one individual prior accommodates an entire subfield (or even all nine subfields if we are willing to accept the standard Normal prior). These priors might still be appropriate approximations for smaller specializations within subfields. However, in these cases it might be worthwhile to obtain more informed and precise priors that are tailored to these smaller subfields.</p><sec sec-type="conclusions" id="sec009"><title>Conclusion</title><p>The analysis of time-to-event data with Cox regression [<xref rid="pone.0322144.ref038" ref-type="bibr">38</xref>] is pervasive in biomedical research. Cox regression combined with Bayes factors has much to offer over traditional frequentist inference because it allows researchers to directly contrast the evidence for the null and alternative hypotheses [<xref rid="pone.0322144.ref042" ref-type="bibr">42</xref>] and because it allows monitoring results during data collection and continue or stop at any time [<xref rid="pone.0322144.ref047" ref-type="bibr">47</xref>&#x02013;<xref rid="pone.0322144.ref050" ref-type="bibr">50</xref>,<xref rid="pone.0322144.ref054" ref-type="bibr">54</xref>,<xref rid="pone.0322144.ref055" ref-type="bibr">55</xref>]. These characteristics of Bayes factors have the potential to reduce the waste of scarce resources in biomedical research and especially clinical trials [<xref rid="pone.0322144.ref053" ref-type="bibr">53</xref>,<xref rid="pone.0322144.ref098" ref-type="bibr">98</xref>]. However, the specification of priors for these Bayesian analyses can be challenging and be perceived as overly subjective. We propose default priors in Cox regression that are informed by large corpora of already existing studies for nine subfields. These priors are all Normal distributions centered on 0 with standard deviations that are close to 1. They can be used as a default or starting point for medical researchers and can be augmented with sensitivity analyses.</p></sec></sec><sec id="sec010"><title>Appendix A: Comparison of abstract and main text matches</title><p>To mitigate the possibility that the effect size distributions are biased, we took our database of articles found on Scopus that matched any of the journals listed in Scimago, yielding 36,431 articles (see <xref rid="pone.0322144.t001" ref-type="table">Table 1</xref> in the manuscript). Of those articles, we randomly sampled 100 articles for which we could not match results in the abstract with our regular expression (no-match group); and we randomly sampled 100 articles for which we could match results in the abstract with our regular expression (match group). Then, we tried to obtain the full texts of these 200 articles. We were able to obtain 86 full texts for the no-match group and 88 full texts for the match group (some articles were not accessible to us). We transformed the PDF files into txt files using the pdftotext command from the Xpdfreader tool <ext-link xlink:href="https://www.xpdfreader.com/" ext-link-type="uri">https://www.xpdfreader.com/</ext-link>. Then we manually removed the abstracts from the txt files. Subsequently, we used the same regular expression to match results in the main text of the txt files. <xref rid="pone.0322144.g005" ref-type="fig">Fig 5</xref> shows a plot that compares the effect size distributions for extracted results from the abstracts and the main text. As can be seen, the effect size distributions look similar across the different panels, providing evidence that there is probably no strong bias.</p></sec><sec id="sec011"><title>1. Descriptive statistics for medical fields</title><p>See <xref rid="pone.0322144.t002" ref-type="table">Tables 2</xref>, <xref rid="pone.0322144.t003" ref-type="table">3</xref>, <xref rid="pone.0322144.t004" ref-type="table">4</xref>, <xref rid="pone.0322144.t005" ref-type="table">5</xref>, 6, 7, 8, 9, and 10.</p><table-wrap position="float" id="pone.0322144.t002"><object-id pub-id-type="doi">10.1371/journal.pone.0322144.t002</object-id><label>Table 2</label><caption><title>Descriptive statistics for Anesthesiology and pain medicine.</title></caption><alternatives><graphic xlink:href="pone.0322144.t002" id="pone.0322144.t002g" position="float"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">b</italic>
</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">SE(b)</italic>
</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">b</italic>
<sup>2</sup>
</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">SE(b)</italic>
<sup>2</sup>
</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Min</td><td align="left" rowspan="1" colspan="1">-2.120</td><td align="left" rowspan="1" colspan="1">0.002</td><td align="left" rowspan="1" colspan="1">0.000</td><td align="left" rowspan="1" colspan="1">0.000</td></tr><tr><td align="left" rowspan="1" colspan="1">1st Qu.</td><td align="left" rowspan="1" colspan="1">-0.010</td><td align="left" rowspan="1" colspan="1">0.069</td><td align="left" rowspan="1" colspan="1">0.043</td><td align="left" rowspan="1" colspan="1">0.005</td></tr><tr><td align="left" rowspan="1" colspan="1">Median</td><td align="left" rowspan="1" colspan="1">0.336</td><td align="left" rowspan="1" colspan="1">0.164</td><td align="left" rowspan="1" colspan="1">0.261</td><td align="left" rowspan="1" colspan="1">0.027</td></tr><tr><td align="left" rowspan="1" colspan="1">Mean</td><td align="left" rowspan="1" colspan="1">0.388</td><td align="left" rowspan="1" colspan="1">0.219</td><td align="left" rowspan="1" colspan="1">0.804</td><td align="left" rowspan="1" colspan="1">0.089</td></tr><tr><td align="left" rowspan="1" colspan="1">3rd Qu.</td><td align="left" rowspan="1" colspan="1">0.782</td><td align="left" rowspan="1" colspan="1">0.308</td><td align="left" rowspan="1" colspan="1">0.781</td><td align="left" rowspan="1" colspan="1">0.095</td></tr><tr><td align="left" rowspan="1" colspan="1">Max</td><td align="left" rowspan="1" colspan="1">2.896</td><td align="left" rowspan="1" colspan="1">1.211</td><td align="left" rowspan="1" colspan="1">8.386</td><td align="left" rowspan="1" colspan="1">1.468</td></tr></tbody></table></alternatives></table-wrap><table-wrap position="float" id="pone.0322144.t003"><object-id pub-id-type="doi">10.1371/journal.pone.0322144.t003</object-id><label>Table 3</label><caption><title>Descriptive statistics for Cardiology and cardiovascular medicine.</title></caption><alternatives><graphic xlink:href="pone.0322144.t003" id="pone.0322144.t003g" position="float"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">b</italic>
</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">SE(b)</italic>
</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">b</italic>
<sup>2</sup>
</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">SE(b)</italic>
<sup>2</sup>
</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Min</td><td align="left" rowspan="1" colspan="1">-4.247</td><td align="left" rowspan="1" colspan="1">0.000</td><td align="left" rowspan="1" colspan="1">0.000</td><td align="left" rowspan="1" colspan="1">0.000</td></tr><tr><td align="left" rowspan="1" colspan="1">1st Qu.</td><td align="left" rowspan="1" colspan="1">-0.041</td><td align="left" rowspan="1" colspan="1">0.086</td><td align="left" rowspan="1" colspan="1">0.061</td><td align="left" rowspan="1" colspan="1">0.007</td></tr><tr><td align="left" rowspan="1" colspan="1">Median</td><td align="left" rowspan="1" colspan="1">0.365</td><td align="left" rowspan="1" colspan="1">0.184</td><td align="left" rowspan="1" colspan="1">0.278</td><td align="left" rowspan="1" colspan="1">0.034</td></tr><tr><td align="left" rowspan="1" colspan="1">y Mean</td><td align="left" rowspan="1" colspan="1">0.407</td><td align="left" rowspan="1" colspan="1">0.238</td><td align="left" rowspan="1" colspan="1">0.824</td><td align="left" rowspan="1" colspan="1">0.099</td></tr><tr><td align="left" rowspan="1" colspan="1">3rd Qu.</td><td align="left" rowspan="1" colspan="1">0.854</td><td align="left" rowspan="1" colspan="1">0.332</td><td align="left" rowspan="1" colspan="1">0.935</td><td align="left" rowspan="1" colspan="1">0.110</td></tr><tr><td align="left" rowspan="1" colspan="1">Max</td><td align="left" rowspan="1" colspan="1">4.800</td><td align="left" rowspan="1" colspan="1">1.883</td><td align="left" rowspan="1" colspan="1">23.039</td><td align="left" rowspan="1" colspan="1">3.547</td></tr></tbody></table></alternatives></table-wrap><table-wrap position="float" id="pone.0322144.t004"><object-id pub-id-type="doi">10.1371/journal.pone.0322144.t004</object-id><label>Table 4</label><caption><title>Descriptive statistics for Gastroenterology.</title></caption><alternatives><graphic xlink:href="pone.0322144.t004" id="pone.0322144.t004g" position="float"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">b</italic>
</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">SE(b)</italic>
</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">b</italic>
<sup>2</sup>
</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">SE(b)</italic>
<sup>2</sup>
</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Min</td><td align="left" rowspan="1" colspan="1">-3.507</td><td align="left" rowspan="1" colspan="1">0.000</td><td align="left" rowspan="1" colspan="1">0.000</td><td align="left" rowspan="1" colspan="1">0.000</td></tr><tr><td align="left" rowspan="1" colspan="1">1st Qu.</td><td align="left" rowspan="1" colspan="1">-0.174</td><td align="left" rowspan="1" colspan="1">0.110</td><td align="left" rowspan="1" colspan="1">0.090</td><td align="left" rowspan="1" colspan="1">0.012</td></tr><tr><td align="left" rowspan="1" colspan="1">Median</td><td align="left" rowspan="1" colspan="1">0.389</td><td align="left" rowspan="1" colspan="1">0.219</td><td align="left" rowspan="1" colspan="1">0.426</td><td align="left" rowspan="1" colspan="1">0.048</td></tr><tr><td align="left" rowspan="1" colspan="1">Mean</td><td align="left" rowspan="1" colspan="1">0.393</td><td align="left" rowspan="1" colspan="1">0.285</td><td align="left" rowspan="1" colspan="1">1.027</td><td align="left" rowspan="1" colspan="1">0.137</td></tr><tr><td align="left" rowspan="1" colspan="1">3rd Qu.</td><td align="left" rowspan="1" colspan="1">0.968</td><td align="left" rowspan="1" colspan="1">0.389</td><td align="left" rowspan="1" colspan="1">1.264</td><td align="left" rowspan="1" colspan="1">0.152</td></tr><tr><td align="left" rowspan="1" colspan="1">Max</td><td align="left" rowspan="1" colspan="1">3.459</td><td align="left" rowspan="1" colspan="1">1.274</td><td align="left" rowspan="1" colspan="1">12.296</td><td align="left" rowspan="1" colspan="1">1.623</td></tr></tbody></table></alternatives></table-wrap><table-wrap position="float" id="pone.0322144.t005"><object-id pub-id-type="doi">10.1371/journal.pone.0322144.t005</object-id><label>Table 5</label><caption><title>Descriptive statistics for Hematology.</title></caption><alternatives><graphic xlink:href="pone.0322144.t005" id="pone.0322144.t005g" position="float"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">b</italic>
</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">SE(b)</italic>
</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">b</italic>
<sup>2</sup>
</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">SE(b)</italic>
<sup>2</sup>
</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Min</td><td align="left" rowspan="1" colspan="1">-3.219</td><td align="left" rowspan="1" colspan="1">0.001</td><td align="left" rowspan="1" colspan="1">0.000</td><td align="left" rowspan="1" colspan="1">0.000</td></tr><tr><td align="left" rowspan="1" colspan="1">1st Qu.</td><td align="left" rowspan="1" colspan="1">-0.174</td><td align="left" rowspan="1" colspan="1">0.119</td><td align="left" rowspan="1" colspan="1">0.083</td><td align="left" rowspan="1" colspan="1">0.014</td></tr><tr><td align="left" rowspan="1" colspan="1">Median</td><td align="left" rowspan="1" colspan="1">0.378</td><td align="left" rowspan="1" colspan="1">0.225</td><td align="left" rowspan="1" colspan="1">0.380</td><td align="left" rowspan="1" colspan="1">0.051</td></tr><tr><td align="left" rowspan="1" colspan="1">Mean</td><td align="left" rowspan="1" colspan="1">0.398</td><td align="left" rowspan="1" colspan="1">0.275</td><td align="left" rowspan="1" colspan="1">1.029</td><td align="left" rowspan="1" colspan="1">0.123</td></tr><tr><td align="left" rowspan="1" colspan="1">3rd Qu.</td><td align="left" rowspan="1" colspan="1">0.916</td><td align="left" rowspan="1" colspan="1">0.377</td><td align="left" rowspan="1" colspan="1">1.148</td><td align="left" rowspan="1" colspan="1">0.142</td></tr><tr><td align="left" rowspan="1" colspan="1">Max</td><td align="left" rowspan="1" colspan="1">4.806</td><td align="left" rowspan="1" colspan="1">1.332</td><td align="left" rowspan="1" colspan="1">23.102</td><td align="left" rowspan="1" colspan="1">1.773</td></tr></tbody></table></alternatives></table-wrap></sec><sec id="sec012"><title>2. Article retention rate across processing steps</title><p>We further investigated the possibility that certain journals are underrepresented in our results by examining the article retention rates over processing steps across fields and journals. In particular, looking at <xref rid="pone.0322144.t001" ref-type="table">Table 1</xref>, it can be seen that there are three processing steps involved: First, Scopus articles are selected based on whether they match the Scimago journal names. Second, articles are selected for which we could obtain a match for the regular expression. Third, of the matched articles, we filtered out articles for which our regular expression yielded ambiguous/wrong results. <xref rid="pone.0322144.g006" ref-type="fig">Fig 6</xref> shows the proportion of articles remaining in a specific field (panels) and journal (lines) when transitioning from the first to the second step (S1) and from the second to the third step (S2). However, journals for which the number of articles is 0 at some processing step are filtered out because the division with 0 is problematic. It can be seen that there is some variation between journals at S1 for all fields. This variation decreases drastically at S2 for all fields.</p><fig position="float" id="pone.0322144.g005"><object-id pub-id-type="doi">10.1371/journal.pone.0322144.g005</object-id><label>Fig 5</label><caption><title>Effect size distributions for effect sizes matched in the abstract or main text of a sample of 200 articles.</title></caption><graphic xlink:href="pone.0322144.g005" position="float"/></fig><fig position="float" id="pone.0322144.g006"><object-id pub-id-type="doi">10.1371/journal.pone.0322144.g006</object-id><label>Fig 6</label><caption><title>Proportion of articles remaining in a specific field (panels) and journal (lines) when transitioning from the first to the second step (S1) and from the second to the third step (S2).</title><p>Note that journals for which the number of articles is 0 at some processing step were not considered here.</p></caption><graphic xlink:href="pone.0322144.g006" position="float"/></fig><table-wrap position="float" id="pone.0322144.t006"><object-id pub-id-type="doi">10.1371/journal.pone.0322144.t006</object-id><label>Table 6</label><caption><title>Descriptive statistics for Immunology and allergy.</title></caption><alternatives><graphic xlink:href="pone.0322144.t006" id="pone.0322144.t006g" position="float"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">b</italic>
</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">SE(b)</italic>
</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">b</italic>
<sup>2</sup>
</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">SE(b)</italic>
<sup>2</sup>
</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Min</td><td align="left" rowspan="1" colspan="1">-2.996</td><td align="left" rowspan="1" colspan="1">0.001</td><td align="left" rowspan="1" colspan="1">0.000</td><td align="left" rowspan="1" colspan="1">0.000</td></tr><tr><td align="left" rowspan="1" colspan="1">1st Qu.</td><td align="left" rowspan="1" colspan="1">-0.128</td><td align="left" rowspan="1" colspan="1">0.105</td><td align="left" rowspan="1" colspan="1">0.069</td><td align="left" rowspan="1" colspan="1">0.011</td></tr><tr><td align="left" rowspan="1" colspan="1">Median</td><td align="left" rowspan="1" colspan="1">0.351</td><td align="left" rowspan="1" colspan="1">0.207</td><td align="left" rowspan="1" colspan="1">0.345</td><td align="left" rowspan="1" colspan="1">0.043</td></tr><tr><td align="left" rowspan="1" colspan="1">Mean</td><td align="left" rowspan="1" colspan="1">0.361</td><td align="left" rowspan="1" colspan="1">0.259</td><td align="left" rowspan="1" colspan="1">0.937</td><td align="left" rowspan="1" colspan="1">0.110</td></tr><tr><td align="left" rowspan="1" colspan="1">3rd Qu.</td><td align="left" rowspan="1" colspan="1">0.880</td><td align="left" rowspan="1" colspan="1">0.365</td><td align="left" rowspan="1" colspan="1">1.156</td><td align="left" rowspan="1" colspan="1">0.133</td></tr><tr><td align="left" rowspan="1" colspan="1">Max</td><td align="left" rowspan="1" colspan="1">4.248</td><td align="left" rowspan="1" colspan="1">1.145</td><td align="left" rowspan="1" colspan="1">18.050</td><td align="left" rowspan="1" colspan="1">1.311</td></tr></tbody></table></alternatives></table-wrap><table-wrap position="float" id="pone.0322144.t007"><object-id pub-id-type="doi">10.1371/journal.pone.0322144.t007</object-id><label>Table 7</label><caption><title>Descriptive statistics for Neurology.</title></caption><alternatives><graphic xlink:href="pone.0322144.t007" id="pone.0322144.t007g" position="float"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">b</italic>
</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">SE(b)</italic>
</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">b</italic>
<sup>2</sup>
</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">SE(b)</italic>
<sup>2</sup>
</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Min</td><td align="left" rowspan="1" colspan="1">-4.605</td><td align="left" rowspan="1" colspan="1">0.001</td><td align="left" rowspan="1" colspan="1">0.000</td><td align="left" rowspan="1" colspan="1">0.000</td></tr><tr><td align="left" rowspan="1" colspan="1">1st Qu.</td><td align="left" rowspan="1" colspan="1">0.010</td><td align="left" rowspan="1" colspan="1">0.101</td><td align="left" rowspan="1" colspan="1">0.090</td><td align="left" rowspan="1" colspan="1">0.010</td></tr><tr><td align="left" rowspan="1" colspan="1">Median</td><td align="left" rowspan="1" colspan="1">0.425</td><td align="left" rowspan="1" colspan="1">0.202</td><td align="left" rowspan="1" colspan="1">0.339</td><td align="left" rowspan="1" colspan="1">0.041</td></tr><tr><td align="left" rowspan="1" colspan="1">Mean</td><td align="left" rowspan="1" colspan="1">0.446</td><td align="left" rowspan="1" colspan="1">0.255</td><td align="left" rowspan="1" colspan="1">0.978</td><td align="left" rowspan="1" colspan="1">0.115</td></tr><tr><td align="left" rowspan="1" colspan="1">3rd Qu.</td><td align="left" rowspan="1" colspan="1">0.916</td><td align="left" rowspan="1" colspan="1">0.348</td><td align="left" rowspan="1" colspan="1">1.060</td><td align="left" rowspan="1" colspan="1">0.121</td></tr><tr><td align="left" rowspan="1" colspan="1">Max</td><td align="left" rowspan="1" colspan="1">4.726</td><td align="left" rowspan="1" colspan="1">1.799</td><td align="left" rowspan="1" colspan="1">22.331</td><td align="left" rowspan="1" colspan="1">3.236</td></tr></tbody></table></alternatives></table-wrap><table-wrap position="float" id="pone.0322144.t008"><object-id pub-id-type="doi">10.1371/journal.pone.0322144.t008</object-id><label>Table 8</label><caption><title>Descriptive statistics for Oncology.</title></caption><alternatives><graphic xlink:href="pone.0322144.t008" id="pone.0322144.t008g" position="float"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">b</italic>
</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">SE(b)</italic>
</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">b</italic>
<sup>2</sup>
</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">SE(b)</italic>
<sup>2</sup>
</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Min</td><td align="left" rowspan="1" colspan="1">-5.809</td><td align="left" rowspan="1" colspan="1">0.001</td><td align="left" rowspan="1" colspan="1">0.000</td><td align="left" rowspan="1" colspan="1">0.000</td></tr><tr><td align="left" rowspan="1" colspan="1">1st Qu.</td><td align="left" rowspan="1" colspan="1">-0.288</td><td align="left" rowspan="1" colspan="1">0.106</td><td align="left" rowspan="1" colspan="1">0.081</td><td align="left" rowspan="1" colspan="1">0.011</td></tr><tr><td align="left" rowspan="1" colspan="1">Median</td><td align="left" rowspan="1" colspan="1">0.285</td><td align="left" rowspan="1" colspan="1">0.206</td><td align="left" rowspan="1" colspan="1">0.316</td><td align="left" rowspan="1" colspan="1">0.042</td></tr><tr><td align="left" rowspan="1" colspan="1">Mean</td><td align="left" rowspan="1" colspan="1">0.263</td><td align="left" rowspan="1" colspan="1">0.252</td><td align="left" rowspan="1" colspan="1">0.830</td><td align="left" rowspan="1" colspan="1">0.107</td></tr><tr><td align="left" rowspan="1" colspan="1">3rd Qu.</td><td align="left" rowspan="1" colspan="1">0.765</td><td align="left" rowspan="1" colspan="1">0.338</td><td align="left" rowspan="1" colspan="1">0.856</td><td align="left" rowspan="1" colspan="1">0.115</td></tr><tr><td align="left" rowspan="1" colspan="1">Max</td><td align="left" rowspan="1" colspan="1">5.955</td><td align="left" rowspan="1" colspan="1">2.784</td><td align="left" rowspan="1" colspan="1">35.466</td><td align="left" rowspan="1" colspan="1">7.749</td></tr></tbody></table></alternatives></table-wrap><table-wrap position="float" id="pone.0322144.t009"><object-id pub-id-type="doi">10.1371/journal.pone.0322144.t009</object-id><label>Table 9</label><caption><title>Descriptive statistics for Psychiatry and mental health.</title></caption><alternatives><graphic xlink:href="pone.0322144.t009" id="pone.0322144.t009g" position="float"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">b</italic>
</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">SE(b)</italic>
</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">b</italic>
<sup>2</sup>
</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">SE(b)</italic>
<sup>2</sup>
</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Min</td><td align="left" rowspan="1" colspan="1">-2.659</td><td align="left" rowspan="1" colspan="1">0.001</td><td align="left" rowspan="1" colspan="1">0.000</td><td align="left" rowspan="1" colspan="1">0.000</td></tr><tr><td align="left" rowspan="1" colspan="1">1st Qu.</td><td align="left" rowspan="1" colspan="1">0.068</td><td align="left" rowspan="1" colspan="1">0.069</td><td align="left" rowspan="1" colspan="1">0.062</td><td align="left" rowspan="1" colspan="1">0.005</td></tr><tr><td align="left" rowspan="1" colspan="1">Median</td><td align="left" rowspan="1" colspan="1">0.392</td><td align="left" rowspan="1" colspan="1">0.151</td><td align="left" rowspan="1" colspan="1">0.261</td><td align="left" rowspan="1" colspan="1">0.023</td></tr><tr><td align="left" rowspan="1" colspan="1">Mean</td><td align="left" rowspan="1" colspan="1">0.454</td><td align="left" rowspan="1" colspan="1">0.194</td><td align="left" rowspan="1" colspan="1">0.768</td><td align="left" rowspan="1" colspan="1">0.070</td></tr><tr><td align="left" rowspan="1" colspan="1">3rd Qu.</td><td align="left" rowspan="1" colspan="1">0.815</td><td align="left" rowspan="1" colspan="1">0.259</td><td align="left" rowspan="1" colspan="1">0.840</td><td align="left" rowspan="1" colspan="1">0.067</td></tr><tr><td align="left" rowspan="1" colspan="1">Max</td><td align="left" rowspan="1" colspan="1">3.886</td><td align="left" rowspan="1" colspan="1">1.428</td><td align="left" rowspan="1" colspan="1">15.099</td><td align="left" rowspan="1" colspan="1">2.040</td></tr></tbody></table></alternatives></table-wrap><table-wrap position="float" id="pone.0322144.t010"><object-id pub-id-type="doi">10.1371/journal.pone.0322144.t010</object-id><label>Table 10</label><caption><title>Descriptive statistics for Pulmonary and respiratory medicine.</title></caption><alternatives><graphic xlink:href="pone.0322144.t010" id="pone.0322144.t010g" position="float"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">b</italic>
</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">SE(b)</italic>
</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">b</italic>
<sup>2</sup>
</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">SE(b)</italic>
<sup>2</sup>
</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Min</td><td align="left" rowspan="1" colspan="1">-3.507</td><td align="left" rowspan="1" colspan="1">0.000</td><td align="left" rowspan="1" colspan="1">0.000</td><td align="left" rowspan="1" colspan="1">0.000</td></tr><tr><td align="left" rowspan="1" colspan="1">1st Qu.</td><td align="left" rowspan="1" colspan="1">-0.136</td><td align="left" rowspan="1" colspan="1">0.093</td><td align="left" rowspan="1" colspan="1">0.068</td><td align="left" rowspan="1" colspan="1">0.009</td></tr><tr><td align="left" rowspan="1" colspan="1">Median</td><td align="left" rowspan="1" colspan="1">0.351</td><td align="left" rowspan="1" colspan="1">0.203</td><td align="left" rowspan="1" colspan="1">0.336</td><td align="left" rowspan="1" colspan="1">0.041</td></tr><tr><td align="left" rowspan="1" colspan="1">Mean</td><td align="left" rowspan="1" colspan="1">0.378</td><td align="left" rowspan="1" colspan="1">0.255</td><td align="left" rowspan="1" colspan="1">0.886</td><td align="left" rowspan="1" colspan="1">0.112</td></tr><tr><td align="left" rowspan="1" colspan="1">3rd Qu.</td><td align="left" rowspan="1" colspan="1">0.884</td><td align="left" rowspan="1" colspan="1">0.357</td><td align="left" rowspan="1" colspan="1">1.012</td><td align="left" rowspan="1" colspan="1">0.127</td></tr><tr><td align="left" rowspan="1" colspan="1">Max</td><td align="left" rowspan="1" colspan="1">3.728</td><td align="left" rowspan="1" colspan="1">1.499</td><td align="left" rowspan="1" colspan="1">13.899</td><td align="left" rowspan="1" colspan="1">2.246</td></tr></tbody></table></alternatives></table-wrap></sec></body><back><ref-list><title>References</title><ref id="pone.0322144.ref001"><label>1</label><mixed-citation publication-type="journal"><name><surname>Stupp</surname><given-names>R</given-names></name>, <name><surname>Hegi</surname><given-names>ME</given-names></name>, <name><surname>Mason</surname><given-names>WP</given-names></name>, <name><surname>van den Bent</surname><given-names>MJ</given-names></name>, <name><surname>Taphoorn</surname><given-names>MJB</given-names></name>, <name><surname>Janzer</surname><given-names>RC</given-names></name>, <etal>et al</etal>. <article-title>Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial</article-title>. <source>Lancet Oncol</source>. <year>2009</year>;<volume>10</volume>(<issue>5</issue>):<fpage>459</fpage>&#x02013;<lpage>66</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/S1470-2045(09)70025-7</pub-id>
<pub-id pub-id-type="pmid">19269895</pub-id>
</mixed-citation></ref><ref id="pone.0322144.ref002"><label>2</label><mixed-citation publication-type="journal"><name><surname>D&#x02019;Agostino</surname><given-names>RB Sr</given-names></name>, <name><surname>Vasan</surname><given-names>RS</given-names></name>, <name><surname>Pencina</surname><given-names>MJ</given-names></name>, <name><surname>Wolf</surname><given-names>PA</given-names></name>, <name><surname>Cobain</surname><given-names>M</given-names></name>, <name><surname>Massaro</surname><given-names>JM</given-names></name>, <etal>et al</etal>. <article-title>General cardiovascular risk profile for use in primary care: the Framingham Heart Study</article-title>. <source>Circulation</source>. <year>2008</year>;<volume>117</volume>(<issue>6</issue>):<fpage>743</fpage>&#x02013;<lpage>53</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.107.699579</pub-id>
<pub-id pub-id-type="pmid">18212285</pub-id>
</mixed-citation></ref><ref id="pone.0322144.ref003"><label>3</label><mixed-citation publication-type="journal"><name><surname>Kenchaiah</surname><given-names>S</given-names></name>, <name><surname>Evans</surname><given-names>JC</given-names></name>, <name><surname>Levy</surname><given-names>D</given-names></name>, <name><surname>Wilson</surname><given-names>PWF</given-names></name>, <name><surname>Benjamin</surname><given-names>EJ</given-names></name>, <name><surname>Larson</surname><given-names>MG</given-names></name>, <etal>et al</etal>. <article-title>Obesity and the risk of heart failure</article-title>. <source>N Engl J Med</source>. <year>2002</year>;<volume>347</volume>(<issue>5</issue>):<fpage>305</fpage>&#x02013;<lpage>13</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1056/NEJMoa020245</pub-id>
<pub-id pub-id-type="pmid">12151467</pub-id>
</mixed-citation></ref><ref id="pone.0322144.ref004"><label>4</label><mixed-citation publication-type="journal"><name><surname>Boney</surname><given-names>CM</given-names></name>, <name><surname>Verma</surname><given-names>A</given-names></name>, <name><surname>Tucker</surname><given-names>R</given-names></name>, <name><surname>Vohr</surname><given-names>BR</given-names></name>. <article-title>Metabolic syndrome in childhood: association with birth weight, maternal obesity, and gestational diabetes mellitus</article-title>. <source>Pediatrics</source>. <year>2005</year>;<volume>115</volume>(<issue>3</issue>):<fpage>290</fpage>&#x02013;<lpage>6</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1542/peds.2004-1808</pub-id>
<pub-id pub-id-type="pmid">15741354</pub-id>
</mixed-citation></ref><ref id="pone.0322144.ref005"><label>5</label><mixed-citation publication-type="journal"><name><surname>Diener</surname><given-names>HC</given-names></name>, <name><surname>Bogousslavsky</surname><given-names>J</given-names></name>, <name><surname>Brass</surname><given-names>LM</given-names></name>, <name><surname>Cimminiello</surname><given-names>C</given-names></name>, <name><surname>Csiba</surname><given-names>L</given-names></name>, <name><surname>Kaste</surname><given-names>M</given-names></name>, <etal>et al</etal>. <article-title>Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial.</article-title>
<source>The Lancet</source>. <year>2004</year>;<volume>364</volume>(<issue>9431</issue>):<fpage>331</fpage>&#x02013;<lpage>7</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/S0140-6736(04)16721-4</pub-id></mixed-citation></ref><ref id="pone.0322144.ref006"><label>6</label><mixed-citation publication-type="journal"><name><surname>Singh</surname><given-names>R</given-names></name>, <name><surname>Mukhopadhyay</surname><given-names>K</given-names></name>. <article-title>Survival analysis in clinical trials: basics and must know areas</article-title>. <source>Perspect Clin Res</source>. <year>2011</year>;<volume>2</volume>(<issue>4</issue>):<fpage>145</fpage>&#x02013;<lpage>8</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.4103/2229-3485.86872</pub-id>
<pub-id pub-id-type="pmid">22145125</pub-id>
</mixed-citation></ref><ref id="pone.0322144.ref007"><label>7</label><mixed-citation publication-type="book"><name><surname>Harrell</surname><given-names>FE</given-names></name>. <source>Regression modeling strategies: with applications to linear models, logistic regression, and survival analysis</source>. <edition>2nd ed</edition>. <publisher-loc>New York, NY</publisher-loc>: <publisher-name>Springer</publisher-name>; <year>2015</year>.</mixed-citation></ref><ref id="pone.0322144.ref008"><label>8</label><mixed-citation publication-type="journal"><name><surname>Clark</surname><given-names>TG</given-names></name>, <name><surname>Bradburn</surname><given-names>MJ</given-names></name>, <name><surname>Love</surname><given-names>SB</given-names></name>, <name><surname>Altman</surname><given-names>DG</given-names></name>. <article-title>Survival analysis part I: basic concepts and first analyses</article-title>. <source>Br J Cancer</source>. <year>2003</year>;<volume>89</volume>(<issue>2</issue>):<fpage>232</fpage>&#x02013;<lpage>8</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/sj.bjc.6601118</pub-id><pub-id pub-id-type="pmid">12865907</pub-id>
</mixed-citation></ref><ref id="pone.0322144.ref009"><label>9</label><mixed-citation publication-type="journal"><name><surname>Clark</surname><given-names>TG</given-names></name>, <name><surname>Bradburn</surname><given-names>MJ</given-names></name>, <name><surname>Love</surname><given-names>SB</given-names></name>, <name><surname>Altman</surname><given-names>DG</given-names></name>. <article-title>Survival analysis part IV: further concepts and methods in survival analysis</article-title>. <source>Br J Cancer</source>. <year>2003</year>;<volume>89</volume>(<issue>5</issue>):<fpage>781</fpage>&#x02013;<lpage>6</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/sj.bjc.6601117</pub-id>
<pub-id pub-id-type="pmid">12942105</pub-id>
</mixed-citation></ref><ref id="pone.0322144.ref010"><label>10</label><mixed-citation publication-type="journal"><name><surname>Bradburn</surname><given-names>MJ</given-names></name>, <name><surname>Clark</surname><given-names>TG</given-names></name>, <name><surname>Love</surname><given-names>SB</given-names></name>, <name><surname>Altman</surname><given-names>DG</given-names></name>. <article-title>Survival analysis part II: multivariate data analysis - an introduction to concepts and methods</article-title>. <source>Br J Cancer</source>. <year>2003</year>;<volume>89</volume>(<issue>3</issue>):<fpage>431</fpage>&#x02013;<lpage>6</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/sj.bjc.6601119</pub-id>
<pub-id pub-id-type="pmid">12888808</pub-id>
</mixed-citation></ref><ref id="pone.0322144.ref011"><label>11</label><mixed-citation publication-type="journal"><name><surname>Bradburn</surname><given-names>MJ</given-names></name>, <name><surname>Clark</surname><given-names>TG</given-names></name>, <name><surname>Love</surname><given-names>SB</given-names></name>, <name><surname>Altman</surname><given-names>DG</given-names></name>. <article-title>Survival analysis Part III: multivariate data analysis - choosing a model and assessing its adequacy and fit</article-title>. <source>Br J Cancer</source>. <year>2003</year>;<volume>89</volume>(<issue>4</issue>):<fpage>605</fpage>&#x02013;<lpage>11</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/sj.bjc.6601120</pub-id>
<pub-id pub-id-type="pmid">12915864</pub-id>
</mixed-citation></ref><ref id="pone.0322144.ref012"><label>12</label><mixed-citation publication-type="book"><name><surname>Hosmer</surname><given-names>DW</given-names></name>, <name><surname>Lemeshow</surname><given-names>S</given-names></name>, <name><surname>May</surname><given-names>S</given-names></name>. <source>Applied survival analysis: regression modeling of time-to-event data</source>. <edition>2nd ed</edition>. <publisher-loc>Hoboken, NJ</publisher-loc>: <publisher-name>Wiley</publisher-name>; <year>2008</year>.</mixed-citation></ref><ref id="pone.0322144.ref013"><label>13</label><mixed-citation publication-type="book"><name><surname>Klein</surname><given-names>JP</given-names></name>, <name><surname>Moeschberger</surname><given-names>ML</given-names></name>. <source>Survival analysis: techniques for censored and truncated data</source>. <publisher-name>Springer</publisher-name>: <publisher-loc>New York, NY</publisher-loc>; <year>1997</year>.</mixed-citation></ref><ref id="pone.0322144.ref014"><label>14</label><mixed-citation publication-type="book"><name><surname>Therneau</surname><given-names>TM</given-names></name>, <name><surname>Grambsch</surname><given-names>PM</given-names></name>. <source>Modeling survival data: extending the Cox model</source>. <publisher-loc>New York, NY</publisher-loc>: <publisher-name>Springer</publisher-name>; <year>2000</year>.</mixed-citation></ref><ref id="pone.0322144.ref015"><label>15</label><mixed-citation publication-type="book"><name><surname>Collett</surname><given-names>D</given-names></name>. <source>Modelling survival data in medical research</source>. <edition>3rd ed</edition>. <publisher-loc>Boca Raton, FL</publisher-loc>: <publisher-name>CRC Press</publisher-name>; <year>2015</year>.</mixed-citation></ref><ref id="pone.0322144.ref016"><label>16</label><mixed-citation publication-type="journal"><name><surname>Kantoff</surname><given-names>PW</given-names></name>, <name><surname>Higano</surname><given-names>CS</given-names></name>, <name><surname>Shore</surname><given-names>ND</given-names></name>, <name><surname>Berger</surname><given-names>ER</given-names></name>, <name><surname>Small</surname><given-names>EJ</given-names></name>, <name><surname>Penson</surname><given-names>DF</given-names></name>, <etal>et al</etal>. <article-title>Sipuleucel-T immunotherapy for castration-resistant prostate cancer</article-title>. <source>N Engl J Med</source>. <year>2010</year>;<volume>363</volume>(<issue>5</issue>):<fpage>411</fpage>&#x02013;<lpage>22</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1056/NEJMoa1001294</pub-id>
<pub-id pub-id-type="pmid">20818862</pub-id>
</mixed-citation></ref><ref id="pone.0322144.ref017"><label>17</label><mixed-citation publication-type="journal"><name><surname>Rinke</surname><given-names>A</given-names></name>, <name><surname>M&#x000fc;ller</surname><given-names>H-H</given-names></name>, <name><surname>Schade-Brittinger</surname><given-names>C</given-names></name>, <name><surname>Klose</surname><given-names>K-J</given-names></name>, <name><surname>Barth</surname><given-names>P</given-names></name>, <name><surname>Wied</surname><given-names>M</given-names></name>, <etal>et al</etal>. <article-title>Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group</article-title>. <source>J Clin Oncol</source>. <year>2009</year>;<volume>27</volume>(<issue>28</issue>):<fpage>4656</fpage>&#x02013;<lpage>63</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1200/JCO.2009.22.8510</pub-id>
<pub-id pub-id-type="pmid">19704057</pub-id>
</mixed-citation></ref><ref id="pone.0322144.ref018"><label>18</label><mixed-citation publication-type="journal"><name><surname>Brard</surname><given-names>C</given-names></name>, <name><surname>Le Teuff</surname><given-names>G</given-names></name>, <name><surname>Le Deley</surname><given-names>M-C</given-names></name>, <name><surname>Hampson</surname><given-names>LV</given-names></name>. <article-title>Bayesian survival analysis in clinical trials: what methods are used in practice?</article-title>
<source>Clin Trials</source>. <year>2017</year>;<volume>14</volume>(<issue>1</issue>):<fpage>78</fpage>&#x02013;<lpage>87</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1177/1740774516673362</pub-id>
<pub-id pub-id-type="pmid">27729499</pub-id>
</mixed-citation></ref><ref id="pone.0322144.ref019"><label>19</label><mixed-citation publication-type="journal"><name><surname>Yu</surname><given-names>EC</given-names></name>, <name><surname>Sprenger</surname><given-names>AM</given-names></name>, <name><surname>Thomas</surname><given-names>RP</given-names></name>, <name><surname>Dougherty</surname><given-names>MR</given-names></name>. <article-title>When decision heuristics and science collide.</article-title>
<source>Psychonom Bull Rev</source>. <year>2014</year>;<volume>21</volume>:<fpage>268</fpage>&#x02013;<lpage>82</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.3758/s13423-013-0495-z</pub-id></mixed-citation></ref><ref id="pone.0322144.ref020"><label>20</label><mixed-citation publication-type="journal"><name><surname>Berry</surname><given-names>DA</given-names></name>. <article-title>Bayesian clinical trials</article-title>. <source>Nat Rev Drug Discov</source>. <year>2006</year>;<volume>5</volume>(<issue>1</issue>):<fpage>27</fpage>&#x02013;<lpage>36</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/nrd1927.</pub-id><pub-id pub-id-type="pmid">16485344</pub-id>
</mixed-citation></ref><ref id="pone.0322144.ref021"><label>21</label><mixed-citation publication-type="journal"><name><surname>Moye</surname><given-names>LA</given-names></name>. <article-title>Bayesians in clinical trials: asleep at the switch.</article-title>
<source>Statist Med</source>. <year>2008</year>;<volume>27</volume>(<issue>4</issue>):<fpage>469</fpage>&#x02013;<lpage>82</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1002/sim.2928</pub-id></mixed-citation></ref><ref id="pone.0322144.ref022"><label>22</label><mixed-citation publication-type="journal"><name><surname>Pocock</surname><given-names>SJ</given-names></name>. <article-title>Group sequential methods in the design and analysis of clinical trials</article-title>. <source>Biometrika</source>. <year>1977</year>;<volume>64</volume>(<issue>2</issue>):<fpage>191</fpage>&#x02013;<lpage>9</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1093/biomet/64.2.191</pub-id></mixed-citation></ref><ref id="pone.0322144.ref023"><label>23</label><mixed-citation publication-type="journal"><name><surname>van de Schoot</surname><given-names>R</given-names></name>, <name><surname>Winter</surname><given-names>SD</given-names></name>, <name><surname>Ryan</surname><given-names>O</given-names></name>, <name><surname>Zondervan-Zwijnenburg</surname><given-names>M</given-names></name>, <name><surname>Depaoli</surname><given-names>S</given-names></name>. <article-title>A systematic review of Bayesian articles in psychology: the last 25 years</article-title>. <source>Psychol Methods</source>. <year>2017</year>; <volume>22</volume>(<issue>2</issue>):<fpage>217</fpage>&#x02013;<lpage>39</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1037/met0000100.supp</pub-id><pub-id pub-id-type="pmid">28594224</pub-id>
</mixed-citation></ref><ref id="pone.0322144.ref024"><label>24</label><mixed-citation publication-type="book"><name><surname>Jeffreys</surname><given-names>H</given-names></name>. <source>Theory of probability</source>. <publisher-loc>Oxford, UK</publisher-loc>: <publisher-name>The Clarendon Press</publisher-name>; <year>1939</year>.</mixed-citation></ref><ref id="pone.0322144.ref025"><label>25</label><mixed-citation publication-type="book"><name><surname>Jeffreys</surname><given-names>H</given-names></name>. <source>Theory of probability</source>. <edition>2nd ed</edition>. <publisher-loc>Oxford, UK</publisher-loc>: <publisher-name>The Clarendon Press</publisher-name>; <year>1948</year>.</mixed-citation></ref><ref id="pone.0322144.ref026"><label>26</label><mixed-citation publication-type="book"><name><surname>Jeffreys</surname><given-names>H</given-names></name>. <source>Theory of probability</source>. <edition>3rd ed</edition>. <publisher-loc>Oxford, UK</publisher-loc>: <publisher-name>Oxford University Press</publisher-name>; <year>1961</year>.</mixed-citation></ref><ref id="pone.0322144.ref027"><label>27</label><mixed-citation publication-type="journal"><name><surname>Kass</surname><given-names>RE</given-names></name>, <name><surname>Raftery</surname><given-names>AE</given-names></name>. <article-title>Bayes factors.</article-title>
<source>J Am Statist Assoc</source>. <year>1995</year>;<volume>90</volume>(<issue>430</issue>):<fpage>773</fpage>&#x02013;<lpage>95</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.2307/2291091</pub-id></mixed-citation></ref><ref id="pone.0322144.ref028"><label>28</label><mixed-citation publication-type="journal"><name><surname>Goodman</surname><given-names>S</given-names></name>. <article-title>Toward evidence-based medical statistics. 2: the Bayes factor</article-title>. <source>Ann Intern Med</source>. <year>1999</year>;<volume>130</volume>(<issue>12</issue>):<fpage>1005</fpage>&#x02013;<lpage>13</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.7326/0003-4819-130-12-199906150-00019</pub-id>
<pub-id pub-id-type="pmid">10383350</pub-id>
</mixed-citation></ref><ref id="pone.0322144.ref029"><label>29</label><mixed-citation publication-type="journal"><name><surname>Kruschke</surname><given-names>JK</given-names></name>. <article-title>Bayesian data analysis</article-title>. <source>Wiley Interdiscip Rev Cogn Sci</source>. <year>2010</year>;1(5):658&#x02013;<lpage>76</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1002/wcs.72</pub-id>
<pub-id pub-id-type="pmid">26271651</pub-id>
</mixed-citation></ref><ref id="pone.0322144.ref030"><label>30</label><mixed-citation publication-type="journal"><name><surname>Kruschke</surname><given-names>JK</given-names></name>, <name><surname>Liddell</surname><given-names>TM</given-names></name>. <article-title>Bayesian data analysis for newcomers</article-title>. <source>Psychon Bull Rev</source>. <year>2018</year>;<volume>25</volume>(<issue>1</issue>):<fpage>155</fpage>&#x02013;<lpage>77</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.3758/s13423-017-1272-1</pub-id>
<pub-id pub-id-type="pmid">28405907</pub-id>
</mixed-citation></ref><ref id="pone.0322144.ref031"><label>31</label><mixed-citation publication-type="book"><name><surname>Kruschke</surname><given-names>JK</given-names></name>. <source>Doing Bayesian data analysis: a tutorial with R, JAGS, and Stan</source>. <edition>2nd ed</edition>. <publisher-loc>Boston, MA</publisher-loc>: <publisher-name>Academic Press</publisher-name>; <year>2015</year>.</mixed-citation></ref><ref id="pone.0322144.ref032"><label>32</label><mixed-citation publication-type="journal"><name><surname>Vanpaemel</surname><given-names>W</given-names></name>. <article-title>Prior sensitivity in theory testing: an apologia for the Bayes factor</article-title>. <source>J Math Psychol</source>. <year>2010</year>;<volume>54</volume>(<issue>6</issue>):<fpage>491</fpage>&#x02013;<lpage>8</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.jmp.2010.07.003</pub-id></mixed-citation></ref><ref id="pone.0322144.ref033"><label>33</label><mixed-citation publication-type="journal"><name><surname>Sinharay</surname><given-names>S</given-names></name>, <name><surname>Stern</surname><given-names>HS</given-names></name>. <article-title>On the sensitivity of Bayes factors to the prior distributions</article-title>. <source>Am Statist</source>. <year>2002</year>;<volume>56</volume>(<issue>3</issue>):<fpage>196</fpage>&#x02013;<lpage>201</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1198/000313002137</pub-id></mixed-citation></ref><ref id="pone.0322144.ref034"><label>34</label><mixed-citation publication-type="journal"><name><surname>Liu</surname><given-names>CC</given-names></name>, <name><surname>Aitkin</surname><given-names>M</given-names></name>. <article-title>Bayes factors: prior sensitivity and model generalizability</article-title>. <source>J Math Psychol</source>. <year>2008</year>;<volume>52</volume>(<issue>6</issue>):<fpage>362</fpage>&#x02013;<lpage>75</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.jmp.2008.03.002</pub-id></mixed-citation></ref><ref id="pone.0322144.ref035"><label>35</label><mixed-citation publication-type="journal"><name><surname>Gallistel</surname><given-names>CR</given-names></name>. <article-title>The importance of proving the null</article-title>. <source>Psychol Rev</source>. <year>2009</year>;<volume>116</volume>(<issue>2</issue>):<fpage>439</fpage>&#x02013;<lpage>53</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1037/a0015251</pub-id>
<pub-id pub-id-type="pmid">19348549</pub-id>
</mixed-citation></ref><ref id="pone.0322144.ref036"><label>36</label><mixed-citation publication-type="journal"><name><surname>Tendeiro</surname><given-names>JN</given-names></name>, <name><surname>Kiers</surname><given-names>HAL</given-names></name>. <article-title>A review of issues about null hypothesis Bayesian testing</article-title>. <source>Psychol Methods</source>. <year>2019</year>;<volume>24</volume>(<issue>6</issue>):<fpage>774</fpage>&#x02013;<lpage>95</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1037/met0000221</pub-id><pub-id pub-id-type="pmid">31094544</pub-id>
</mixed-citation></ref><ref id="pone.0322144.ref037"><label>37</label><mixed-citation publication-type="journal"><name><surname>Efron</surname><given-names>B</given-names></name>. <article-title>Why isn&#x02019;t everyone a Bayesian?</article-title>
<source>Am Statist</source>. <year>1986</year>;<volume>40</volume>(<issue>1</issue>):<fpage>1</fpage>&#x02013;<lpage>5</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.2307/2683105</pub-id></mixed-citation></ref><ref id="pone.0322144.ref038"><label>38</label><mixed-citation publication-type="journal"><name><surname>Cox</surname><given-names>DR</given-names></name>. <article-title>Regression models and life-tables.</article-title>
<source>J Roy Statist Soc Ser B: Statist Methodol</source>. <year>1972</year>;<volume>34</volume>(<issue>2</issue>):<fpage>187</fpage>&#x02013;<lpage>202</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1111/j.2517-6161.1972.tb00899.x</pub-id></mixed-citation></ref><ref id="pone.0322144.ref039"><label>39</label><mixed-citation publication-type="journal"><name><surname>Kaplan</surname><given-names>EL</given-names></name>, <name><surname>Meier</surname><given-names>P</given-names></name>. <article-title>Nonparametric estimation from incomplete observations.</article-title>
<source>J Am Statist Assoc</source>. <year>1958</year>;<volume>53</volume>(<issue>282</issue>):<fpage>457</fpage>&#x02013;<lpage>81</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1080/01621459.1958.10501452</pub-id></mixed-citation></ref><ref id="pone.0322144.ref040"><label>40</label><mixed-citation publication-type="journal"><name><surname>Chavalarias</surname><given-names>D</given-names></name>, <name><surname>Wallach</surname><given-names>JD</given-names></name>, <name><surname>Li</surname><given-names>AHT</given-names></name>, <name><surname>Ioannidis</surname><given-names>JPA</given-names></name>. <article-title>Evolution of reporting P values in the biomedical literature, 1990&#x02013;2015</article-title>. <source>JAMA</source>. <year>2016</year>;<volume>315</volume>(<issue>11</issue>):<fpage>1141</fpage>&#x02013;<lpage>8</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1001/jama.2016.1952</pub-id>
<pub-id pub-id-type="pmid">26978209</pub-id>
</mixed-citation></ref><ref id="pone.0322144.ref041"><label>41</label><mixed-citation publication-type="journal"><name><surname>Goodman</surname><given-names>SN</given-names></name>. <article-title>Toward evidence-based medical statistics. 1: the p value fallacy.</article-title>
<source>Annal Intern Med</source>. <year>1999</year>;<volume>130</volume>(<issue>12</issue>):<fpage>995</fpage>&#x02013;<lpage>1004</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.7326/0003-4819-130-12-199906150-00008</pub-id>
<pub-id pub-id-type="pmid">10383371</pub-id>
</mixed-citation></ref><ref id="pone.0322144.ref042"><label>42</label><mixed-citation publication-type="journal"><name><surname>Rouder</surname><given-names>JN</given-names></name>, <name><surname>Speckman</surname><given-names>PL</given-names></name>, <name><surname>Sun</surname><given-names>D</given-names></name>, <name><surname>Morey</surname><given-names>RD</given-names></name>, <name><surname>Iverson</surname><given-names>G</given-names></name>. <article-title>Bayesian t tests for accepting and rejecting the null hypothesis.</article-title>
<source>Psychonom Bull Rev</source>. <year>2009</year>;<volume>16</volume>(<issue>2</issue>):<fpage>225</fpage>&#x02013;<lpage>37</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.3758/PBR.16.2.225</pub-id></mixed-citation></ref><ref id="pone.0322144.ref043"><label>43</label><mixed-citation publication-type="journal"><name><surname>Bakan</surname><given-names>D</given-names></name>. <article-title>The test of significance in psychological research</article-title>. <source>Psychol Bull</source>. <year>1966</year>;<volume>66</volume>(<issue>6</issue>):<fpage>423</fpage>&#x02013;<lpage>37</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1037/h0020412.</pub-id><pub-id pub-id-type="pmid">5974619</pub-id>
</mixed-citation></ref><ref id="pone.0322144.ref044"><label>44</label><mixed-citation publication-type="journal"><name><surname>Ioannidis</surname><given-names>JPA</given-names></name>. <article-title>Why most published research findings are false</article-title>. <source>PLoS Med</source>. <year>2005</year>;<volume>2</volume>(<issue>8</issue>):e124. <comment>doi: </comment><pub-id pub-id-type="doi">10.1371/journal.pmed.0020124</pub-id>
<pub-id pub-id-type="pmid">16060722</pub-id>
</mixed-citation></ref><ref id="pone.0322144.ref045"><label>45</label><mixed-citation publication-type="journal"><name><surname>Hoekstra</surname><given-names>R</given-names></name>, <name><surname>Monden</surname><given-names>R</given-names></name>, <name><surname>van Ravenzwaaij</surname><given-names>D</given-names></name>, <name><surname>Wagenmakers</surname><given-names>EJ</given-names></name>. <article-title>Bayesian reanalysis of null results reported in medicine: strong yet variable evidence for the absence of treatment effects</article-title>. <source>PLoS ONE</source>. <year>2018</year>;<volume>13</volume>(<issue>4</issue>):e0195474. <comment>doi: </comment><pub-id pub-id-type="doi">10.1371/journal.pone.0195474</pub-id>
<pub-id pub-id-type="pmid">29694370</pub-id>
</mixed-citation></ref><ref id="pone.0322144.ref046"><label>46</label><mixed-citation publication-type="journal"><name><surname>Wagenmakers</surname><given-names>EJ. A</given-names></name>
<article-title>practical solution to the pervasive problems of p values</article-title>. <source>Psychon Bull Rev</source>. <year>2007</year>;<volume>14</volume>(<issue>5</issue>):<fpage>779</fpage>&#x02013;<lpage>804</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.3758/BF03194105</pub-id><pub-id pub-id-type="pmid">18087943</pub-id>
</mixed-citation></ref><ref id="pone.0322144.ref047"><label>47</label><mixed-citation publication-type="journal"><name><surname>Armitage</surname><given-names>P</given-names></name>, <name><surname>McPherson</surname><given-names>CK</given-names></name>, <name><surname>Rowe</surname><given-names>BC</given-names></name>. <article-title>Repeated significance tests on accumulating data.</article-title>
<source>J Roy Statist Soc Ser A (Gen)</source>. <year>1969</year>;<volume>132</volume>(<issue>2</issue>):<fpage>235</fpage>&#x02013;<lpage>44</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.2307/2343787</pub-id></mixed-citation></ref><ref id="pone.0322144.ref048"><label>48</label><mixed-citation publication-type="journal"><name><surname>Rouder</surname><given-names>JN</given-names></name>. <article-title>Optional stopping: no problem for Bayesians</article-title>. <source>Psychon Bull Rev</source>. <year>2014</year>;<volume>21</volume>(<issue>2</issue>):<fpage>301</fpage>&#x02013;<lpage>8</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.3758/s13423-014-0595-4</pub-id><pub-id pub-id-type="pmid">24659049</pub-id>
</mixed-citation></ref><ref id="pone.0322144.ref049"><label>49</label><mixed-citation publication-type="journal"><name><surname>Tendeiro</surname><given-names>JN</given-names></name>, <name><surname>Kiers</surname><given-names>HAL</given-names></name>, <name><surname>van Ravenzwaaij</surname><given-names>D</given-names></name>. <article-title>Worked-out examples of the adequacy of Bayesian optional stopping</article-title>. <source>Psychon Bull Rev</source>. <year>2022</year>;<volume>29</volume>(<issue>1</issue>):<fpage>70</fpage>&#x02013;<lpage>87</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.3758/s13423-021-01962-5</pub-id>
<pub-id pub-id-type="pmid">34254263</pub-id>
</mixed-citation></ref><ref id="pone.0322144.ref050"><label>50</label><mixed-citation publication-type="journal"><name><surname>Sch&#x000f6;nbrodt</surname><given-names>FD</given-names></name>, <name><surname>Wagenmakers</surname><given-names>EJ</given-names></name>, <name><surname>Zehetleitner</surname><given-names>M</given-names></name>, <name><surname>Perugini</surname><given-names>M</given-names></name>. <article-title>Sequential hypothesis testing with Bayes factors: efficiently testing mean differences</article-title>. <source>Psychol Methods</source>. <year>2017</year>;<volume>22</volume>(<issue>2</issue>):<fpage>322</fpage>&#x02013;<lpage>39</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1037/met0000061</pub-id><pub-id pub-id-type="pmid">26651986</pub-id>
</mixed-citation></ref><ref id="pone.0322144.ref051"><label>51</label><mixed-citation publication-type="journal"><collab>International Committee of Medical Journal Editors</collab>. <article-title>Uniform requirements for manuscripts submitted to biomedical journals</article-title>. <source>Pathology</source>. <year>1997</year>;<volume>29</volume>(<issue>4</issue>):<fpage>441</fpage>&#x02013;<lpage>7</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1080/00313029700169515</pub-id></mixed-citation></ref><ref id="pone.0322144.ref052"><label>52</label><mixed-citation publication-type="journal"><name><surname>Rennie</surname><given-names>D</given-names></name>. <article-title>Vive la diff&#x000e9;rence (p less than 0.05)</article-title>. <source>N Engl J Med</source>. <year>1978</year>;<volume>299</volume>:<fpage>828</fpage>&#x02013;<lpage>9</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1056/NEJM197810122991509</pub-id>
<pub-id pub-id-type="pmid">692566</pub-id>
</mixed-citation></ref><ref id="pone.0322144.ref053"><label>53</label><mixed-citation publication-type="journal"><name><surname>van Ravenzwaaij</surname><given-names>D</given-names></name>, <name><surname>Monden</surname><given-names>R</given-names></name>, <name><surname>Tendeiro</surname><given-names>JN</given-names></name>, <name><surname>Ioannidis</surname><given-names>JPA</given-names></name>. <article-title>Bayes factors for superiority, non-inferiority, and equivalence designs</article-title>. <source>BMC Med Res Methodol</source>. <year>2019</year>;<volume>19</volume>(<issue>1</issue>):<fpage>71</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1186/s12874-019-0699-7</pub-id>
<pub-id pub-id-type="pmid">30925900</pub-id>
</mixed-citation></ref><ref id="pone.0322144.ref054"><label>54</label><mixed-citation publication-type="journal"><name><surname>Sch&#x000f6;nbrodt</surname><given-names>FD</given-names></name>, <name><surname>Wagenmakers</surname><given-names>EJ</given-names></name>. <article-title>Bayes factor design analysis: planning for compelling evidence</article-title>. <source>Psychon Bull Rev</source>. <year>2018</year>;<volume>25</volume>(<issue>1</issue>):<fpage>128</fpage>&#x02013;<lpage>42</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.3758/s13423-017-1230-y</pub-id>
<pub-id pub-id-type="pmid">28251595</pub-id>
</mixed-citation></ref><ref id="pone.0322144.ref055"><label>55</label><mixed-citation publication-type="journal"><name><surname>Stefan</surname><given-names>AM</given-names></name>, <name><surname>Sch&#x000f6;nbrodt</surname><given-names>FD</given-names></name>, <name><surname>Evans</surname><given-names>NJ</given-names></name>, <name><surname>Wagenmakers</surname><given-names>EJ</given-names></name>. <article-title>Efficiency in sequential testing: comparing the sequential probability ratio test and the sequential Bayes factor test</article-title>. <source>Behav Res Methods</source>. <year>2022</year>;<volume>54</volume>(<issue>6</issue>):<fpage>3100</fpage>&#x02013;<lpage>17</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.3758/s13428-021-01754-8</pub-id><pub-id pub-id-type="pmid">35233752</pub-id>
</mixed-citation></ref><ref id="pone.0322144.ref056"><label>56</label><mixed-citation publication-type="journal"><name><surname>Gronau</surname><given-names>QF</given-names></name>, <name><surname>Sarafoglou</surname><given-names>A</given-names></name>, <name><surname>Matzke</surname><given-names>D</given-names></name>, <name><surname>Ly</surname><given-names>A</given-names></name>, <name><surname>Boehm</surname><given-names>U</given-names></name>, <name><surname>Marsman</surname><given-names>M</given-names></name>, <etal>et al</etal>. <article-title>A tutorial on bridge sampling</article-title>. <source>J Math Psychol</source>. <year>2017</year>;<volume>81</volume>:<fpage>80</fpage>&#x02013;<lpage>97</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.jmp.2017.09.005</pub-id>
<pub-id pub-id-type="pmid">29200501</pub-id>
</mixed-citation></ref><ref id="pone.0322144.ref057"><label>57</label><mixed-citation publication-type="journal"><name><surname>van Ravenzwaaij</surname><given-names>D</given-names></name>, <name><surname>Cassey</surname><given-names>P</given-names></name>, <name><surname>Brown</surname><given-names>SD</given-names></name>. <article-title>A simple introduction to Markov Chain Monte-Carlo sampling</article-title>. <source>Psychon Bull Rev</source>. <year>2018</year>;<volume>25</volume>(<issue>1</issue>):<fpage>143</fpage>&#x02013;<lpage>54</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.3758/s13423-016-1015-8</pub-id>
<pub-id pub-id-type="pmid">26968853</pub-id>
</mixed-citation></ref><ref id="pone.0322144.ref058"><label>58</label><mixed-citation publication-type="book"><name><surname>Gilks</surname><given-names>WR</given-names></name>, <name><surname>Richardson</surname><given-names>S</given-names></name>, <name><surname>Spiegelhalter</surname><given-names>D</given-names></name>. <source>Markov chain Monte Carlo in practice</source>. <publisher-loc>Boca Raton, FL</publisher-loc>: <publisher-name>Chapman &#x00026; Hall/CRC</publisher-name>; <year>1995</year>.</mixed-citation></ref><ref id="pone.0322144.ref059"><label>59</label><mixed-citation publication-type="book"><name><surname>Brooks</surname><given-names>S</given-names></name>, <name><surname>Gelman</surname><given-names>A</given-names></name>, <name><surname>Jones</surname><given-names>GL</given-names></name>, <name><surname>Meng</surname><given-names>XL</given-names></name>. <source>Handbook of Markov chain Monte Carlo</source>. <publisher-loc>New York, NY</publisher-loc>: <publisher-name>Chapman &#x00026; Hall/CRC</publisher-name>; <year>2011</year>.</mixed-citation></ref><ref id="pone.0322144.ref060"><label>60</label><mixed-citation publication-type="preprint"><name><surname>Betancourt</surname><given-names>M</given-names></name>. <article-title>A conceptual introduction to Hamiltonian Monte Carlo;</article-title>
<year>2018</year>. Available from: <ext-link xlink:href="https://arxiv.org/abs/1701.02434" ext-link-type="uri">https://arxiv.org/abs/1701.02434</ext-link></mixed-citation></ref><ref id="pone.0322144.ref061"><label>61</label><mixed-citation publication-type="journal"><name><surname>Barto&#x00161;</surname><given-names>F</given-names></name>, <name><surname>Aust</surname><given-names>F</given-names></name>, <name><surname>Haaf</surname><given-names>JM</given-names></name>. <article-title>Informed Bayesian survival analysis</article-title>. <source>BMC Med Res Methodol</source>. <year>2022</year>;<volume>22</volume>(<issue>1</issue>):<fpage>238</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1186/s12874-022-01676-9</pub-id>
<pub-id pub-id-type="pmid">36088281</pub-id>
</mixed-citation></ref><ref id="pone.0322144.ref062"><label>62</label><mixed-citation publication-type="other">Linde M, Tendeiro JN, van Ravenzwaaij D. Bayes factors for two-group comparisons in Cox regression. 2022.</mixed-citation></ref><ref id="pone.0322144.ref063"><label>63</label><mixed-citation publication-type="other">Linde M, van Ravenzwaaij D, Tendeiro JN. Baymedr: computation of Bayes factors for common biomedical designs. 2022. Available from: <ext-link xlink:href="https://github.com/maxlinde/baymedr" ext-link-type="uri">https://github.com/maxlinde/baymedr</ext-link></mixed-citation></ref><ref id="pone.0322144.ref064"><label>64</label><mixed-citation publication-type="other">Barto&#x00161; F. RoBSA: an R package for robust Bayesian survival analyses; 2022. Available from: <ext-link xlink:href="https://CRAN.R-project.org/package" ext-link-type="uri">https://CRAN.R-project.org/package=RoBSA</ext-link></mixed-citation></ref><ref id="pone.0322144.ref065"><label>65</label><mixed-citation publication-type="journal"><name><surname>Rouder</surname><given-names>JN</given-names></name>, <name><surname>Morey</surname><given-names>RD</given-names></name>, <name><surname>Speckman</surname><given-names>PL</given-names></name>, <name><surname>Province</surname><given-names>JM</given-names></name>. <article-title>Default Bayes factors for ANOVA designs</article-title>. <source>J Math Psychol</source>. <year>2012</year>;<volume>56</volume>(<issue>2</issue>):<fpage>356</fpage>&#x02013;<lpage>74</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.jmp.2012.08.001</pub-id></mixed-citation></ref><ref id="pone.0322144.ref066"><label>66</label><mixed-citation publication-type="journal"><name><surname>Gronau</surname><given-names>QF</given-names></name>, <name><surname>Ly</surname><given-names>A</given-names></name>, <name><surname>Wagenmakers</surname><given-names>EJ</given-names></name>. <article-title>Informed Bayesian t-tests</article-title>. <source>Am Statist</source>. <year>2020</year>;<volume>74</volume>(<issue>2</issue>):<fpage>137</fpage>&#x02013;<lpage>43</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1080/00031305.2018.1562983</pub-id></mixed-citation></ref><ref id="pone.0322144.ref067"><label>67</label><mixed-citation publication-type="other">Morey R, Rouder J. BayesFactor: computation of Bayes factors for common designs. 2018. Available from: <ext-link xlink:href="https://CRAN.R-project.org/package" ext-link-type="uri">https://CRAN.R-project.org/package=BayesFactor</ext-link></mixed-citation></ref><ref id="pone.0322144.ref068"><label>68</label><mixed-citation publication-type="other">Gu X, Hoijtink H, Mulder J, van Lissa CJ. Bain: Bayes factors for informative hypotheses. 2021. Available from: <ext-link xlink:href="https://CRAN.R-project.org/package" ext-link-type="uri">https://CRAN.R-project.org/package=bain</ext-link></mixed-citation></ref><ref id="pone.0322144.ref069"><label>69</label><mixed-citation publication-type="journal"><name><surname>van Lissa</surname><given-names>CJ</given-names></name>, <name><surname>Gu</surname><given-names>X</given-names></name>, <name><surname>Mulder</surname><given-names>J</given-names></name>, <name><surname>Rosseel</surname><given-names>Y</given-names></name>, <name><surname>van Zundert</surname><given-names>C</given-names></name>, <name><surname>Hoijtink</surname><given-names>H</given-names></name>. <article-title>Teacher&#x02019;s corner: evaluating informative hypotheses using the Bayes factor in structural equation models.</article-title>
<source>Struct Eq Model: Multidiscip J</source>. <year>2021</year>;<volume>28</volume>(<issue>2</issue>):<fpage>292</fpage>&#x02013;<lpage>301</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1080/10705511.2020.1745644</pub-id></mixed-citation></ref><ref id="pone.0322144.ref070"><label>70</label><mixed-citation publication-type="preprint"><name><surname>Heck</surname><given-names>DW</given-names></name>, <name><surname>Boehm</surname><given-names>U</given-names></name>, <name><surname>B&#x000f6;ing-Messing</surname><given-names>F</given-names></name>, <name><surname>B&#x000fc;rkner</surname><given-names>PC</given-names></name>, <name><surname>Derks</surname><given-names>K</given-names></name>, <name><surname>Dienes</surname><given-names>Z</given-names></name>, <etal>et al</etal>. A review of applications of the Bayes factor in psychological research. <year>2020</year>. Available from: <ext-link xlink:href="https://psyarxiv.com/cu43g" ext-link-type="uri">https://psyarxiv.com/cu43g</ext-link></mixed-citation></ref><ref id="pone.0322144.ref071"><label>71</label><mixed-citation publication-type="other">JASP Team. JASP (Version 0.17.2). 2023. Available from: <ext-link xlink:href="https://jasp-stats.org/" ext-link-type="uri">https://jasp-stats.org/</ext-link></mixed-citation></ref><ref id="pone.0322144.ref072"><label>72</label><mixed-citation publication-type="journal"><name><surname>Berger</surname><given-names>J</given-names></name>. <article-title>The case for objective Bayesian analysis</article-title>. <source>Bayesian Anal</source>. <year>2006</year>;<volume>1</volume>(<issue>3</issue>):<fpage>385</fpage>&#x02013;<lpage>402</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1214/06-BA115</pub-id></mixed-citation></ref><ref id="pone.0322144.ref073"><label>73</label><mixed-citation publication-type="journal"><name><surname>Goldstein</surname><given-names>M</given-names></name>. <article-title>Subjective Bayesian analysis: principles and practice</article-title>. <source>Bayesian Anal</source>. <year>2006</year>;<volume>1</volume>(<issue>3</issue>):<fpage>403</fpage>&#x02013;<lpage>20</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1214/06-BA116</pub-id></mixed-citation></ref><ref id="pone.0322144.ref074"><label>74</label><mixed-citation publication-type="journal"><name><surname>Bayarri</surname><given-names>MJ</given-names></name>, <name><surname>Berger</surname><given-names>JO</given-names></name>, <name><surname>Forte</surname><given-names>A</given-names></name>, <name><surname>Garc&#x000ed;a-Donato</surname><given-names>G</given-names></name>. <article-title>Criteria for Bayesian model choice with application to variable selection.</article-title>
<source>Ann Statist</source>. <year>2012</year>;<volume>40</volume>(<issue>3</issue>):<fpage>1550</fpage>&#x02013;<lpage>77</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1214/12-AOS1013</pub-id></mixed-citation></ref><ref id="pone.0322144.ref075"><label>75</label><mixed-citation publication-type="journal"><name><surname>Consonni</surname><given-names>G</given-names></name>, <name><surname>Fouskakis</surname><given-names>D</given-names></name>, <name><surname>Liseo</surname><given-names>B</given-names></name>, <name><surname>Ntzoufras</surname><given-names>I</given-names></name>. <article-title>Prior distributions for objective Bayesian analysis</article-title>. <source>Bayesian Anal</source>. <year>2018</year>;<volume>13</volume>(<issue>2</issue>):<fpage>627</fpage>&#x02013;<lpage>79</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1214/18-ba1103</pub-id></mixed-citation></ref><ref id="pone.0322144.ref076"><label>76</label><mixed-citation publication-type="journal"><name><surname>Dienes</surname><given-names>Z</given-names></name>. <article-title>Bayesian versus orthodox statistics: which side are you on?</article-title>
<source>Perspect Psychol Sci</source>. <year>2011</year>;<volume>6</volume>(<issue>3</issue>):<fpage>274</fpage>&#x02013;<lpage>90</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1177/1745691611406920</pub-id><pub-id pub-id-type="pmid">26168518</pub-id>
</mixed-citation></ref><ref id="pone.0322144.ref077"><label>77</label><mixed-citation publication-type="journal"><name><surname>Thall</surname><given-names>PF</given-names></name>, <name><surname>Cook</surname><given-names>JD</given-names></name>. <article-title>Dose-finding based on efficacy-toxicity trade-offs</article-title>. <source>Biometrics</source>. <year>2004</year>;<volume>60</volume>(<issue>3</issue>):<fpage>684</fpage>&#x02013;<lpage>93</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1111/j.0006-341X.2004.00218.x</pub-id><pub-id pub-id-type="pmid">15339291</pub-id>
</mixed-citation></ref><ref id="pone.0322144.ref078"><label>78</label><mixed-citation publication-type="journal"><name><surname>Guo</surname><given-names>B</given-names></name>, <name><surname>Park</surname><given-names>Y</given-names></name>, <name><surname>Liu</surname><given-names>S</given-names></name>. <article-title>A utility-based Bayesian Phase I&#x02013;II design for immunotherapy trials with progression-free survival end points</article-title>. <source>J Roy Statist Soc Ser C: Appl Statist</source>. <year>2019</year>;<volume>68</volume>(<issue>2</issue>):<fpage>411</fpage>&#x02013;<lpage>25</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1111/rssc.12288</pub-id></mixed-citation></ref><ref id="pone.0322144.ref079"><label>79</label><mixed-citation publication-type="journal"><name><surname>Johnson</surname><given-names>SR</given-names></name>, <name><surname>Tomlinson</surname><given-names>GA</given-names></name>, <name><surname>Hawker</surname><given-names>GA</given-names></name>, <name><surname>Granton</surname><given-names>JT</given-names></name>, <name><surname>Feldman</surname><given-names>BM</given-names></name>. <article-title>Methods to elicit beliefs for Bayesian priors: a systematic review</article-title>. <source>J Clin Epidemiol</source>. <year>2010</year>;<volume>63</volume>:<fpage>355</fpage>&#x02013;<lpage>69</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.jclinepi.2009.06.003</pub-id>
<pub-id pub-id-type="pmid">19716263</pub-id>
</mixed-citation></ref><ref id="pone.0322144.ref080"><label>80</label><mixed-citation publication-type="journal"><name><surname>van de Schoot</surname><given-names>R</given-names></name>, <name><surname>Sijbrandij</surname><given-names>M</given-names></name>, <name><surname>Depaoli</surname><given-names>S</given-names></name>, <name><surname>Winter</surname><given-names>SD</given-names></name>, <name><surname>Olff</surname><given-names>M</given-names></name>, <name><surname>van Loey</surname><given-names>NE</given-names></name>. <article-title>Bayesian PTSD-trajectory analysis with informed priors based on a systematic literature search and expert elicitation.</article-title>
<source>Multiv Behav Res</source>. <year>2018</year>;<volume>53</volume>(<issue>2</issue>):<fpage>267</fpage>&#x02013;<lpage>91</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1080/00273171.2017.1412293</pub-id></mixed-citation></ref><ref id="pone.0322144.ref081"><label>81</label><mixed-citation publication-type="journal"><name><surname>Zondervan-Zwijnenburg</surname><given-names>M</given-names></name>, <name><surname>Peeters</surname><given-names>M</given-names></name>, <name><surname>Depaoli</surname><given-names>S</given-names></name>, <name><surname>van de Schoot</surname><given-names>R</given-names></name>. <article-title>Where do priors come from? Applying guidelines to construct informative priors in small sample research</article-title>. <source>Res Hum Develop</source>. <year>2017</year>;<volume>14</volume>(<issue>4</issue>):<fpage>305</fpage>&#x02013;<lpage>20</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1080/15427609.2017.1370966</pub-id></mixed-citation></ref><ref id="pone.0322144.ref082"><label>82</label><mixed-citation publication-type="journal"><name><surname>Stefan</surname><given-names>AM</given-names></name>, <name><surname>Evans</surname><given-names>NJ</given-names></name>, <name><surname>Wagenmakers</surname><given-names>EJ</given-names></name>. <article-title>Practical challenges and methodological flexibility in prior elicitation</article-title>. <source>Psychol Methods</source>. <year>2022</year>;<volume>27</volume>(<issue>2</issue>):<fpage>177</fpage>&#x02013;<lpage>97</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1037/met0000354</pub-id>
<pub-id pub-id-type="pmid">32940511</pub-id>
</mixed-citation></ref><ref id="pone.0322144.ref083"><label>83</label><mixed-citation publication-type="book"><name><surname>O&#x02019;Hagan</surname><given-names>A</given-names></name>, <name><surname>Buck</surname><given-names>CE</given-names></name>, <name><surname>Daneshkhah</surname><given-names>A</given-names></name>, <name><surname>Eiser</surname><given-names>JR</given-names></name>, <name><surname>Garthwaite</surname><given-names>PH</given-names></name>, <name><surname>Jenkinson</surname><given-names>DJ</given-names></name>, <etal>et al</etal>. <source>Uncertain judgements: eliciting experts&#x02019; probabilities</source>. <publisher-loc>Chichester, UK</publisher-loc>: <publisher-name>John Wiley &#x00026; Sons</publisher-name>; <year>2006</year>.</mixed-citation></ref><ref id="pone.0322144.ref084"><label>84</label><mixed-citation publication-type="journal"><name><surname>Morris</surname><given-names>DE</given-names></name>, <name><surname>Oakley</surname><given-names>JE</given-names></name>, <name><surname>Crowe</surname><given-names>JA</given-names></name>. <article-title>A Web-based tool for eliciting probability distributions from experts</article-title>. <source>Environ Model Softw</source>. <year>2014</year>;<volume>52</volume>:<fpage>1</fpage>&#x02013;<lpage>4</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.envsoft.2013.10.010</pub-id></mixed-citation></ref><ref id="pone.0322144.ref085"><label>85</label><mixed-citation publication-type="journal"><name><surname>Rietbergen</surname><given-names>C</given-names></name>, <name><surname>Klugkist</surname><given-names>I</given-names></name>, <name><surname>Janssen</surname><given-names>KJM</given-names></name>, <name><surname>Moons</surname><given-names>KGM</given-names></name>, <name><surname>Hoijtink</surname><given-names>HJA</given-names></name>. <article-title>Incorporation of historical data in the analysis of randomized therapeutic trials</article-title>. <source>Contemp Clin Trials</source>. <year>2011</year>;<volume>32</volume>(<issue>6</issue>):<fpage>848</fpage>&#x02013;<lpage>55</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.cct.2011.06.002</pub-id>
<pub-id pub-id-type="pmid">21729767</pub-id>
</mixed-citation></ref><ref id="pone.0322144.ref086"><label>86</label><mixed-citation publication-type="journal"><name><surname>Casella</surname><given-names>G</given-names></name>. <article-title>An introduction to empirical Bayes data analysis</article-title>. <source>Am Statist.</source>
<year>1985</year>;<volume>39</volume>(<issue>2</issue>):<fpage>83</fpage>&#x02013;<lpage>7</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1080/00031305.1985.10479400</pub-id></mixed-citation></ref><ref id="pone.0322144.ref087"><label>87</label><mixed-citation publication-type="journal"><name><surname>van Zwet</surname><given-names>E</given-names></name>, <name><surname>Gelman</surname><given-names>A</given-names></name>. <article-title>A proposal for informative default priors scaled by the standard error of estimates</article-title>. <source>Am Statist</source>. <year>2022</year>;<volume>76</volume>(<issue>1</issue>):<fpage>1</fpage>&#x02013;<lpage>9</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1080/00031305.2021.1938225</pub-id></mixed-citation></ref><ref id="pone.0322144.ref088"><label>88</label><mixed-citation publication-type="other">SCImago. SJR - SCImago Journal &#x00026; Country Rank [Portal]; n.d. Available from: <ext-link xlink:href="http://www.scimagojr.com" ext-link-type="uri">http://www.scimagojr.com</ext-link></mixed-citation></ref><ref id="pone.0322144.ref089"><label>89</label><mixed-citation publication-type="book"><name><surname>Friedl</surname><given-names>JEF</given-names></name>. <source>Mastering regular expressions</source>. <edition>4th ed</edition>. <publisher-loc>Sebastopol, CA</publisher-loc>: <publisher-name>O&#x02019;Reilly Media</publisher-name>; <year>2006</year>.</mixed-citation></ref><ref id="pone.0322144.ref090"><label>90</label><mixed-citation publication-type="book"><name><surname>Higgins</surname><given-names>JPT</given-names></name>, <name><surname>Li</surname><given-names>T</given-names></name>, <name><surname>Deeks</surname><given-names>JJ.</given-names></name>
<article-title>Choosing effect measures and computing estimates of effect.</article-title> In: <name><surname>Higgins</surname><given-names>JPT</given-names></name>, <name><surname>Thomas</surname><given-names>J</given-names></name>, <name><surname>Chandler</surname><given-names>J</given-names></name>, <name><surname>Cumpston</surname><given-names>M</given-names></name>, <name><surname>Li</surname><given-names>T</given-names></name>, <name><surname>Matthew</surname><given-names>PJ</given-names></name>, <etal>et al.,</etal> editors. <source>Cochrane handbook for systematic reviews of interventions</source>. <edition>2nd ed</edition>. <publisher-loc>Chichester, UK</publisher-loc>: <publisher-name>John Wiley &#x00026; Sons</publisher-name>; <year>2019</year>. pp. <fpage>143</fpage>&#x02013;<lpage>76</lpage>.</mixed-citation></ref><ref id="pone.0322144.ref091"><label>91</label><mixed-citation publication-type="book"><name><surname>Borenstein</surname><given-names>M</given-names></name>, <name><surname>Hedges</surname><given-names>LV</given-names></name>, <name><surname>Higgins</surname><given-names>JPT</given-names></name>, <name><surname>Rothstein</surname><given-names>HR</given-names></name>. <source>Introduction to meta-analysis</source>. <edition>2nd ed</edition>. <publisher-loc>Hoboken, NJ</publisher-loc>: <publisher-name>John Wiley &#x00026; Sons</publisher-name>; <year>2021</year>.</mixed-citation></ref><ref id="pone.0322144.ref092"><label>92</label><mixed-citation publication-type="journal"><name><surname>Beigel</surname><given-names>JH</given-names></name>, <name><surname>Tomashek</surname><given-names>KM</given-names></name>, <name><surname>Dodd</surname><given-names>LE</given-names></name>, <name><surname>Mehta</surname><given-names>AK</given-names></name>, <name><surname>Zingman</surname><given-names>BS</given-names></name>, <name><surname>Kalil</surname><given-names>AC</given-names></name>, <etal>et al</etal>. <article-title>Remdesivir for the treatment of Covid-19 - final report</article-title>. <source>N Engl J Med</source>. <year>2020</year>;<volume>383</volume>(<issue>19</issue>):<fpage>1813</fpage>&#x02013;<lpage>26</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1056/NEJMoa2007764</pub-id>
<pub-id pub-id-type="pmid">32445440</pub-id>
</mixed-citation></ref><ref id="pone.0322144.ref093"><label>93</label><mixed-citation publication-type="journal"><name><surname>Berger</surname><given-names>JO</given-names></name>, <name><surname>Moreno</surname><given-names>E</given-names></name>, <name><surname>Pericchi</surname><given-names>LR</given-names></name>, <name><surname>Bayarri</surname><given-names>MJ</given-names></name>, <name><surname>Bernardo</surname><given-names>JM</given-names></name>, <name><surname>Cano</surname><given-names>JA</given-names></name>, <etal>et al</etal>. <article-title>An overview of robust Bayesian analysis</article-title>. <source>Test</source>. <year>1994</year>;<volume>3</volume>(<issue>1</issue>):<fpage>5</fpage>&#x02013;<lpage>124</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1007/bf02562676</pub-id></mixed-citation></ref><ref id="pone.0322144.ref094"><label>94</label><mixed-citation publication-type="journal"><name><surname>Du</surname><given-names>H</given-names></name>, <name><surname>Edwards</surname><given-names>MC</given-names></name>, <name><surname>Zhang</surname><given-names>Z</given-names></name>. <article-title>Bayes factor in one-sample tests of means with a sensitivity analysis: a discussion of separate prior distributions</article-title>. <source>Behav Res Methods</source>. <year>2019</year>;<volume>51</volume>(<issue>5</issue>):<fpage>1998</fpage>&#x02013;<lpage>2021</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.3758/s13428-019-01262-w</pub-id>
<pub-id pub-id-type="pmid">31161425</pub-id>
</mixed-citation></ref><ref id="pone.0322144.ref095"><label>95</label><mixed-citation publication-type="journal"><name><surname>Depaoli</surname><given-names>S</given-names></name>, <name><surname>van de Schoot</surname><given-names>R</given-names></name>. <article-title>Improving transparency and replication in Bayesian statistics: the WAMBS-checklist</article-title>. <source>Psychol Methods</source>. <year>2017</year>;<volume>22</volume>(<issue>2</issue>):<fpage>240</fpage>&#x02013;<lpage>61</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1037/met0000065</pub-id>
<pub-id pub-id-type="pmid">26690773</pub-id>
</mixed-citation></ref><ref id="pone.0322144.ref096"><label>96</label><mixed-citation publication-type="journal"><name><surname>van Erp</surname><given-names>S</given-names></name>, <name><surname>Oberski</surname><given-names>DL</given-names></name>, <name><surname>Mulder</surname><given-names>J</given-names></name>. <article-title>Shrinkage priors for Bayesian penalized regression</article-title>. <source>J Math Psychol</source>. <year>2019</year>;<volume>89</volume>:<fpage>31</fpage>&#x02013;<lpage>50</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.jmp.2018.12.004</pub-id></mixed-citation></ref><ref id="pone.0322144.ref097"><label>97</label><mixed-citation publication-type="journal"><name><surname>Park</surname><given-names>T</given-names></name>, <name><surname>Casella</surname><given-names>G</given-names></name>. <article-title>The Bayesian Lasso.</article-title>
<source>J Am Statist Assoc</source>. <year>2008</year>;<volume>103</volume>(<issue>482</issue>):<fpage>681</fpage>&#x02013;<lpage>6</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1198/016214508000000337</pub-id></mixed-citation></ref><ref id="pone.0322144.ref098"><label>98</label><mixed-citation publication-type="journal"><name><surname>Macleod</surname><given-names>MR</given-names></name>, <name><surname>Michie</surname><given-names>S</given-names></name>, <name><surname>Roberts</surname><given-names>I</given-names></name>, <name><surname>Dirnagl</surname><given-names>U</given-names></name>, <name><surname>Chalmers</surname><given-names>I</given-names></name>, <name><surname>Ioannidis</surname><given-names>JPA</given-names></name>, <etal>et al</etal>. <article-title>Biomedical research: increasing value, reducing waste</article-title>. <source>The Lancet</source>. <year>2014</year>;<volume>383</volume>(<issue>9912</issue>):<fpage>101</fpage>&#x02013;<lpage>4</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/S0140-6736(13)62329-6</pub-id>
<pub-id pub-id-type="pmid">24411643</pub-id>
</mixed-citation></ref></ref-list></back><sub-article article-type="author-comment" id="pone.0322144.r001" specific-use="rebutted-decision-letter-unavailable"><front-stub><article-id pub-id-type="doi">10.1371/journal.pone.0322144.r001</article-id><title-group><article-title>Author response to Decision Letter 0</article-title></title-group><custom-meta-group><custom-meta><meta-name>Submission Version</meta-name><meta-value>0</meta-value></custom-meta></custom-meta-group></front-stub><body><p>
<named-content content-type="author-response-date">6 May 2024</named-content>
</p></body></sub-article><sub-article article-type="aggregated-review-documents" id="pone.0322144.r002" specific-use="decision-letter"><front-stub><article-id pub-id-type="doi">10.1371/journal.pone.0322144.r002</article-id><title-group><article-title>Decision Letter 0</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Haunschild</surname><given-names>Robin</given-names></name><role>Academic Editor</role></contrib></contrib-group><permissions><copyright-statement>&#x000a9; 2025 Robin Haunschild</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Robin Haunschild</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><related-article ext-link-type="doi" xlink:href="10.1371/journal.pone.0322144" id="rel-obj002" related-article-type="reviewed-article"/><custom-meta-group><custom-meta><meta-name>Submission Version</meta-name><meta-value>0</meta-value></custom-meta></custom-meta-group></front-stub><body><p>
<named-content content-type="letter-date">7 Aug 2024</named-content>
</p><p><!--<div>-->PONE-D-24-18152<!--</div>--><!--<div>-->Data-driven prior elicitation for Bayes factors in Cox regression for nine subfields in biomedicine<!--</div>--><!--<div>-->PLOS ONE</p><p>Dear Dr. Linde,</p><p>Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE&#x02019;s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.</p><p>Please submit your revised manuscript by Sep 21 2024 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at&#x000a0;<email>plosone@plos.org</email>. When you're ready to submit your revision, log on to <ext-link xlink:href="https://www.editorialmanager.com/pone/" ext-link-type="uri">https://www.editorialmanager.com/pone/</ext-link> and select the 'Submissions Needing Revision' folder to locate your manuscript file.</p><p>Please include the following items when submitting your revised manuscript:<!--</div>--></p><p><list list-type="bullet"><list-item><p>A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.</p></list-item><list-item><p>A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.</p></list-item><list-item><p>An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.</p></list-item></list>
</p><p>If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.</p><p>If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: <ext-link xlink:href="https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols" ext-link-type="uri">https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols</ext-link>. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at <ext-link xlink:href="https://plos.org/protocols?utm_medium=editorial-email&#x00026;utm_source=authorletters&#x00026;utm_campaign=protocols" ext-link-type="uri">https://plos.org/protocols?utm_medium=editorial-email&#x00026;utm_source=authorletters&#x00026;utm_campaign=protocols</ext-link>.</p><p>We look forward to receiving your revised manuscript.</p><p>Kind regards,</p><p>Robin Haunschild</p><p>Academic Editor</p><p>PLOS ONE</p><p>Journal requirements:&#x000a0; &#x000a0;</p><p>When submitting your revision, we need you to address these additional requirements.</p><p>1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at</p><p><ext-link xlink:href="https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf" ext-link-type="uri">https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf</ext-link> and</p><p>
<ext-link xlink:href="https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf" ext-link-type="uri">https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf</ext-link>
</p><p>2. In your Methods section, please include additional information about your dataset and ensure that you have included a statement specifying whether the collection and analysis method complied with the terms and conditions for the source of the data.&#x000a0;</p><p>Additional Editor Comments (if provided):</p><p>[Note: HTML markup is below. Please do not edit.]</p><p>Reviewers' comments:</p><p>Reviewer's Responses to Questions</p><p>
<!--<font color="black">-->
<bold>Comments to the Author</bold>
</p><p>1. Is the manuscript technically sound, and do the data support the conclusions?</p><p>The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. <!--</font>--></p><p>Reviewer #1:&#x000a0;Yes</p><p>Reviewer #2:&#x000a0;Yes</p><p>**********</p><p><!--<font color="black">-->2. Has the statistical analysis been performed appropriately and rigorously? <!--</font>--></p><p>Reviewer #1:&#x000a0;N/A</p><p>Reviewer #2:&#x000a0;Yes</p><p>**********</p><p><!--<font color="black">-->3. Have the authors made all data underlying the findings in their manuscript fully available?</p><p>The <ext-link xlink:href="http://www.plosone.org/static/policies.action#sharing" ext-link-type="uri">PLOS Data policy</ext-link> requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data&#x02014;e.g. participant privacy or use of data from a third party&#x02014;those must be specified.<!--</font>--></p><p>Reviewer #1:&#x000a0;Yes</p><p>Reviewer #2:&#x000a0;Yes</p><p>**********</p><p><!--<font color="black">-->4. Is the manuscript presented in an intelligible fashion and written in standard English?</p><p>PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.<!--</font>--></p><p>Reviewer #1:&#x000a0;Yes</p><p>Reviewer #2:&#x000a0;Yes</p><p>**********</p><p><!--<font color="black">-->5. Review Comments to the Author</p><p>Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)<!--</font>--></p><p>Reviewer #1:&#x000a0;Summary:</p><p>The manuscript proposes &#x0201c;informed default&#x0201c; prior distributions for the beta coefficient in Cox regression in nine subfields of biomedical research. The priors are based on the analysis of Cox regression coefficients in a large corpus of biomedical studies.</p><p>Review:</p><p>Finding suitable prior distributions in Bayesian modeling is challenging, and the present manuscript proposes a reasonable way to address this challenge. The methodology for prior specification followed in the manuscript has been applied in similar ways before, but to my knowledge, not for Cox regressions in biomedical science. Given the popularity of survival models and the increasing uptake of Bayesian statistics across scientific fields, I believe that the manuscript can make a valuable contribution to the literature. However, I also have several concerns about the paper, particularly about the validity of the data extraction procedure and the appropriateness of the application example and the simulation study. I will go into more detail on my concerns below and I recommend that the authors address these concerns in a revised version of the manuscript.</p><p>I appreciate that the authors used such a large corpus of studies as a basis for prior specification. However, I am concerned that the way the regression coefficients were extracted from the literature may introduce bias into the results. Specifically, estimates were extracted from articles that mentioned the method as well as estimates and confidence intervals in the abstract. This makes me wonder: How often does it happen at all that the specific statistical method is mentioned in the abstract (rather than only in the results section of the article)? To what extent do articles that mention the method (and specific estimates) in the abstract differ systematically from articles that do not mention these details in the abstract? It seems like the extraction method may give preference to articles with structured abstracts (in my view, the most minor bias since the abstract structure is often guided by journal policies rather than by article content), but potentially also to articles where a statistician/methodologist was involved (hence the stronger focus on statistical methods and outcomes), or to articles where a significant result or large effect size was found (something &#x0201c;worth mentioning&#x0201d; in an abstract). It would be good if the authors could run some robustness analyses to check the unbiasedness of extracted effect sizes (e.g., compare full-text search for Cox regression in some journal issues to abstract-only search and compare the results to get a feeling for the potential bias).</p><p>Related to my previous point, I think that there are a few details about the extraction method that could be made clearer in the manuscript. Specifically, the authors mention that they extracted articles from &#x0201c;top journals&#x0201d; in the respective fields, but the definition of a &#x0201c;top journal&#x0201d; remained vague. How did the authors ensure that no predatory (pseudo-peer reviewed) journals were part of the selection? Moreover, when explaining the search algorithm using regular expressions, the examples include different versions of &#x0201c;HR&#x0201d;. How can we be sure that &#x0201c;HR&#x0201d; always refers to a hazard ratio and isn&#x02019;t an abbreviation of something else (e.g., heart rate) and that the reported numbers hence refer to a different quantity? And finally, the extraction method for the standard error assumes two-sided confidence intervals. Intuitively, it makes sense that this would be the standard, but wouldn&#x02019;t it be possible that some articles report one-sided confidence intervals (e.g., with a one-sided test of treatment effectiveness?).</p><p>For me, the application example presented on pp. 9-12 does not fall into the intended application domain of the specified prior distributions. The prior distribution was elicited for the beta coefficient in Cox regressions, but in the presented application example, the prior distribution was applied to the fixed effect in a meta-analysis across five Cox regressions. I would argue that the specified prior distribution is not a good match for the analysis presented in the application example because the meta-analytic effect size estimate tends to be less extreme than the effect size estimate in a single study. Specifically, we can expect that due to sampling variability, the effect size in a single (potentially small) study is more extreme than the combined estimate across multiple studies (weighed by the study sample size). An appropriate prior specification procedure for meta-analytic effect size estimates in Cox regressions that is similar to the described procedure would therefore, in my view, not specify the prior based on a corpus of individual studies, but on a corpus of meta-analyses. I would therefore highly recommend to exchange the example application in the paper with a Bayesian Cox regression in a single study.</p><p>In addition to my previous point, I believe that the presented application example falls short of showcasing the advantages of the methodology and the recommended best practices for using the informed prior distribution. The authors repeatedly mention in the introduction of the manuscript that two advantages of the Bayesian statistical framework are the possibility of quantifying evidence for the null hypothesis and the possibility of flexible sequential designs. I believe that it would be a great opportunity to showcase these advantages in the application example by using a sequential hypothesis test with the specified priors and quantifying the evidence for H0 and H1. Moreover, the discussion section of the manuscript mentions that sensitivity analyses for prior distributions are considered best practice, yet the application example does not include sensitivity analyses. I think that here, too, it would be a good opportunity to showcase this best practice in the application example using the specified prior distributions of different (adjacent?) subfields as well as a default prior distribution.</p><p>If my calculations are right, the simulation study presented on p. 11 / Figure 3 is unnecessary. The authors decide to assume the same sample size for all studies. This means that Equation 10 can be drastically simplified and basically yields an analytic result for the simulations. Specifically, the index j is unnecessary to describe the sample size n (n is a constant), since all studies are assumed to have the same sample size. Therefore, the terms under the square root can be simplified to:</p><p>&#x02211;(n-1) &#x003b8;_j^2=(n-1)&#x02211;&#x003b8;_j^2</p><p>&#x02211;n(&#x003c9;_j-&#x003bc;^p )=n&#x02211;(&#x003c9;_j-0)^2=n&#x02211;&#x003c9;_j^2</p><p>&#x02211;_(i=1)^K&#x02592;n_j -1=nK-1</p><p>With this simpler form of the equation, it also becomes relatively clear that the &#x0201c;mirroring&#x0201d; process in the manuscript has no effect on the results. We can simply write the equation in terms of original effect sizes. For each study, the following is true (note that SE(beta) = SE(-beta)):</p><p>(n-1)&#x02211;&#x003b8;_j^2=(n-1)(&#x03016;SE&#x03017;_j^2+&#x03016;SE&#x03017;_j^2 )=2&#x03016;SE&#x03017;_j^2 (n-1)</p><p>n&#x02211;&#x003c9;_j^2=n(&#x003b2;_j^2+(-&#x003b2;_j )^2 )=2n&#x003b2;_j^2</p><p>This means, we can express Equation 10 as:</p><p>&#x0221a;((2(n-1)&#x02211;SE_j^2+2n&#x02211;&#x003b2;_j^2)/(n&#x022c5;2N-1))=&#x0221a;(((n-1)&#x02211;SE_j^2+n&#x02211;&#x003b2;_j^2)/(nN-1))</p><p>From this, we can see that the influence of the sample size of a single study, n, influences the comparative weighting of SE and beta in the equation: In the most extreme cases, beta gets weighed twice as much as SE (for n = 2) or beta and SE obtain equal weights (for n=Inf), respectively. We can simply plug in the assumed sample sizes (10:10000), as well as the sum of SEs and sum of betas into the equation to analyze the sensitivity of results.</p><p>In my view, a more sensible way to test the sensitivity of results to the sample sizes would be to draw sets of different sample sizes from realistic distributions (I believe that there are papers on sample size / statistical power development across time in the biomedical sciences?) and use these to determine sigma^p. This way, n would actually differ per study and different studies would be weighed differently in each iteration of the simulation. To make it more realistic, the SEs of individual studies should probably also be negatively correlated with the sample size in the simulation (higher sample size, lower SE).</p><p>In the discussion section, the authors write that &#x0201c;it is possible that certain journals were systematically underrepresented in our results&#x0201d;. To me, this sounds like an empirical question that could be answered using the extracted data? If the proportion of articles selected from each journal within a field does not decrease at the same rate throughout the selection process (e.g. the step indicated in Table 1), then there is some bias. This could for example be represented in some sort of Sankey diagram.</p><p>In the introduction, I think it could be made clearer that there is a rich tradition of sequential designs in frequentist statistics, too. In particular, in my knowledge, clinical biomedical studies are one of the key application domains of Group Sequential designs. I agree with the authors that Bayesian methods are more flexible, but I think this point may need a bit of a more nuanced discussion.</p><p>Also in the introduction, it could be made clearer that the specification of prior distributions is not only necessary in the context of Bayesian hypothesis testing with Bayes factors, but also in the context of Bayesian parameter estimation. I understand that the focus of the article is on Bayes factors, but to readers with little experience in Bayesian statistics, this might lead to misunderstandings.</p><p>Generally, I believe that in practice &#x0201c;informed default&#x0201d; priors are unfortunately often applied outside of their intended application domain (e.g., as has happened to the Oosterwijk prior that is applied outside of social psychology and wasn&#x02019;t even initially intended as a default). Of course, how the priors will be used in practice is outside of the control of the authors. However, I believe that a thorough discussion of the limitations of recommended use in the discussion section of the manuscript could be beneficial to restrict their use to reasonable applications. For example, I would argue that the specified priors are not ideal for meta-analytic effect size parameters (see my point above) and that they should not be used outside of Cox regression (this may be obvious to the authors, but maybe not to non-experts in Bayesian analyses). Moreover, if more field-specific result summaries exist (e.g., Cochrane meta-analysis on breast cancer treatments), and a new analysis is run in this particular field (e.g., new breast cancer treatment), then it might be good to create a more informed prior distribution based on these field-specific results.</p><p>Another aspect that I believe warrants further discussion is how the mix of results for the null- and alternative hypothesis in the literature influences the specified prior distributions. Specifically, the specified prior distributions are intended for use under the alternative hypothesis. However, unless there is severe publication bias, it can be assumed that the literature contains effect sizes that are generated under the null- and alternative hypothesis. From a theoretical standpoint, I am wondering: Should effect sizes that were generated under the null hypothesis really be included to specify a prior for the alternative hypothesis?</p><p>Related to my previous point, I believe that the topic of how publication bias might have influenced the specified prior distributions warrants further discussion. Ideally, it would be great to see some p-curves or z-curves together to contextualize the results, but since p-values were not extracted, I understand that this is difficult.</p><p>In the results section, it would be great if the authors could include some descriptive statistics of the betas and SEs in the different subfields, and perhaps also the sum of beta^2 and the sum of SE^2 for each discipline. Given the extent to which the results depend on these statistics (see also my earlier points), it would be great to have some more information available in the manuscript.</p><p>Reading the manuscript, I was wondering a little what prior distribution the authors would recommend for directional tests. For example, if I assume that a new treatment is better than an old treatment, I would want to test a directional test on the beta parameter. Should I just use the specified distribution for my field and truncate it at zero (e.g., a truncated Normal(0, 0.96) for cardiology)? Or would it be better to use a non-central informed prior distribution? What could be the advantages/disadvantages of each?</p><p>Signed</p><p>Angelika Stefan</p><p>Reviewer #2:&#x000a0;Motivated by the problem of facilitating Bayesian inference of Cox regression, the authors proposed a data-driven prior elicitation method. Overall, the presentation is clear and the proposed method is sensible. I believe this work can be further strengthened by more numerical results and a more thorough discussion on how we can prevent Bayes factor hacking in practice.</p><p>Numerical Results:</p><p>- Can the authors run some simulation studies to quantify the benefits of using these data-driven priors? For example, I imagine that the data-driven priors would carry information from prior studies, and hence would reduce the sample size needed to reach similar strength of evidence compared to another study with weak informative prior.</p><p>- Can the authors add a sensitivity analysis in the example application? I believe such an analysis would help better demonstrate the usefulness of the proposed method and set a good example for practitioners to follow.</p><p>Discussion on how we can prevent Bayes factor hacking:</p><p>- In frequentist statistics, there is a notion of p-value hacking (<ext-link xlink:href="https://en.wikipedia.org/wiki/Data_dredging)." ext-link-type="uri">https://en.wikipedia.org/wiki/Data_dredging</ext-link>). Following similar logic, it is natural to think that could be Bayes factor hacking in the Bayesian world. Therefore, I believe it would be important for authors to give a more thorough discussion on how we can prevent Bayes factor hacking when the prior distribution can be manipulated in the name of data-driven prior.</p><p>**********</p><p><!--<font color="black">-->6. PLOS authors have the option to publish the peer review history of their article (<ext-link xlink:href="https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history" ext-link-type="uri">what does this mean?</ext-link>). If published, this will include your full peer review and any attached files.</p><p>If you choose &#x0201c;no&#x0201d;, your identity will remain anonymous but your review may still be made public.</p><p><bold>Do you want your identity to be public for this peer review?</bold> For information about this choice, including consent withdrawal, please see our <ext-link xlink:href="https://www.plos.org/privacy-policy" ext-link-type="uri">Privacy Policy</ext-link>.<!--</font>--></p><p>Reviewer #1:&#x000a0;<bold>Yes:&#x000a0;</bold>Angelika M. Stefan</p><p>Reviewer #2:&#x000a0;No</p><p>**********</p><p>[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]</p><p>While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool,&#x000a0;<ext-link xlink:href="https://pacev2.apexcovantage.com/" ext-link-type="uri">https://pacev2.apexcovantage.com/</ext-link>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at&#x000a0;<email>figures@plos.org</email>. Please note that Supporting Information files do not need this step.</p><supplementary-material id="pone.0322144.s001" position="float" content-type="local-data"><label>Attachment</label><caption><p>Submitted filename: <named-content content-type="submitted-filename">PONE-D-24-18152_Review.pdf</named-content></p></caption><media xlink:href="pone.0322144.s001.pdf"/></supplementary-material></body></sub-article><sub-article article-type="author-comment" id="pone.0322144.r003"><front-stub><article-id pub-id-type="doi">10.1371/journal.pone.0322144.r003</article-id><title-group><article-title>Author response to Decision Letter 1</article-title></title-group><related-article ext-link-type="doi" xlink:href="10.1371/journal.pone.0322144" id="rel-obj003" related-article-type="editor-report"/><custom-meta-group><custom-meta><meta-name>Submission Version</meta-name><meta-value>1</meta-value></custom-meta></custom-meta-group></front-stub><body><p>
<named-content content-type="author-response-date">6 Dec 2024</named-content>
</p><p>Dear Dr. Haunschild,</p><p>Thank you for considering our manuscript &#x0201c;Data-driven prior elicitation for Bayes factors in Cox regression for nine subfields in biomedicine&#x0201d; for publication in PLOS ONE. We have read your and the reviewers&#x02019; comments carefully. Below you find our responses. The reviewers&#x02019; comments are shown in regular font and our responses are shown in bold font. Our revision contains a version of our manuscript without track changes (i.e., a clean version with all changes already incorporated) and a version of our manuscript with track changes. For the latter, track changes that correspond to additions are shown in blue font and track changes that correspond to removals are shown in red font.</p><p>We look forward to your comments.</p><p>Kind regards,</p><p>Maximilian Linde</p><p>Laura Jochim</p><p>Jorge N. Tendeiro</p><p>Don van Ravenzwaaij&#x02003;</p><p>Dear Dr. Linde,</p><p>Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE&#x02019;s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.</p><p>Please submit your revised manuscript by Sep 21 2024 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to <ext-link xlink:href="https://www.editorialmanager.com/pone/" ext-link-type="uri">https://www.editorialmanager.com/pone/</ext-link> and select the 'Submissions Needing Revision' folder to locate your manuscript file.</p><p>Please include the following items when submitting your revised manuscript:</p><p>&#x025cf; A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.</p><p>&#x025cf; A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.</p><p>&#x025cf; An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.</p><p>If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.</p><p>If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: <ext-link xlink:href="https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols." ext-link-type="uri">https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols</ext-link>. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at <ext-link xlink:href="https://plos.org/protocols?utm_medium=editorial-email&#x00026;utm_source=authorletters&#x00026;utm_campaign=protocols." ext-link-type="uri">https://plos.org/protocols?utm_medium=editorial-email&#x00026;utm_source=authorletters&#x00026;utm_campaign=protocols</ext-link>.</p><p>We look forward to receiving your revised manuscript.</p><p>Kind regards,</p><p>Robin Haunschild</p><p>Academic Editor</p><p>PLOS ONE</p><p>Journal requirements:</p><p>When submitting your revision, we need you to address these additional requirements.</p><p>1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at</p><p><ext-link xlink:href="https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf" ext-link-type="uri">https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf</ext-link> and</p><p>
<ext-link xlink:href="https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf" ext-link-type="uri">https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf</ext-link>
</p><p>2. In your Methods section, please include additional information about your dataset and ensure that you have included a statement specifying whether the collection and analysis method complied with the terms and conditions for the source of the data.</p><p>Additional Editor Comments (if provided):</p><p>E1-1: We are grateful for the opportunity to revise and resubmit our manuscript.</p><p>Reviewer #1: Summary:</p><p>The manuscript proposes &#x0201e;informed default&#x0201c; prior distributions for the beta coefficient in Cox regression in nine subfields of biomedical research. The priors are based on the analysis of Cox regression coefficients in a large corpus of biomedical studies.</p><p>Review:</p><p>Finding suitable prior distributions in Bayesian modeling is challenging, and the present manuscript proposes a reasonable way to address this challenge. The methodology for prior specification followed in the manuscript has been applied in similar ways before, but to my knowledge, not for Cox regressions in biomedical science. Given the popularity of survival models and the increasing uptake of Bayesian statistics across scientific fields, I believe that the manuscript can make a valuable contribution to the literature. However, I also have several concerns about the paper, particularly about the validity of the data extraction procedure and the appropriateness of the application example and the simulation study. I will go into more detail on my concerns below and I recommend that the authors address these concerns in a revised version of the manuscript.</p><p>R1-1: We thank the reviewer for the positive evaluation and the review. We address the reviewer&#x02019;s comments below.</p><p>I appreciate that the authors used such a large corpus of studies as a basis for prior specification. However, I am concerned that the way the regression coefficients were extracted from the literature may introduce bias into the results. Specifically, estimates were extracted from articles that mentioned the method as well as estimates and confidence intervals in the abstract. This makes me wonder: How often does it happen at all that the specific statistical method is mentioned in the abstract (rather than only in the results section of the article)? To what extent do articles that mention the method (and specific estimates) in the abstract differ systematically from articles that do not mention these details in the abstract? It seems like the extraction method may give preference to articles with structured abstracts (in my view, the most minor bias since the abstract structure is often guided by journal policies rather than by article content), but potentially also to articles where a statistician/methodologist was involved (hence the stronger focus on statistical methods and outcomes), or to articles where a significant result or large effect size was found (something &#x0201c;worth mentioning&#x0201d; in an abstract). It would be good if the authors could run some robustness analyses to check the unbiasedness of extracted effect sizes (e.g., compare full-text search for Cox regression in some journal issues to abstract-only search and compare the results to get a feeling for the potential bias).</p><p>R1-2: We understand the concerns of the reviewer. Therefore, we have done additional investigations regarding this potential bias. Specifically, we took our database of articles found on Scopus that matched any of the journals listed in Scimago, yielding 36,431 articles (see Table 1 in the manuscript). Of those articles, we randomly sampled 100 articles for which we could not match results in the abstract with our regular expression (no-match group); and we randomly sampled 100 articles for which we could match results in the abstract with our regular expression (match group). Then, we tried to obtain the full texts of these 200 articles. We were able to obtain 86 full texts for the no-match group and 88 full texts for the match group (some articles were not accessible to us). We transformed the PDF files into txt files using the pdftotext command from the Xpdfreader tool (<ext-link xlink:href="https://www.xpdfreader.com/)." ext-link-type="uri">https://www.xpdfreader.com/</ext-link>). The resulting txt files were not perfect but they should suffice for the current demonstration. Then we manually removed the abstracts from the txt files. Subsequently, we used the same regular expression as in our original submission to match results in the main text of the txt files. Below is a plot that compares the effect size distributions for extracted results from the abstracts (the original findings) and the main text. As can be seen, the effect size distributions look similar across the different panels, providing evidence that there is probably no strong bias. We have added the following to an Appendix: &#x0201c;To mitigate the possibility that the effect size distributions are biased, we took our database of articles found on Scopus that matched any of the journals listed in Scimago, yielding 36,431 articles (see Table 1 in the manuscript). Of those articles, we randomly sampled 100 articles for which we could not match results in the abstract with our regular expression (no-match group); and we randomly sampled 100 articles for which we could match results in the abstract with our regular expression (match group). Then, we tried to obtain the full texts of these 200 articles. We were able to obtain 86 full texts for the no-match group and 88 full texts for the match group (some articles were not accessible to us). We transformed the PDF files into txt files using the pdftotext command from the Xpdfreader tool (<ext-link xlink:href="https://www.xpdfreader.com/)." ext-link-type="uri">https://www.xpdfreader.com/</ext-link>). Then we manually removed the abstracts from the txt files. Subsequently, we used the same regular expression to match results in the main text of the txt files. Fig 5 shows a plot that compares the effect size distributions for extracted results from the abstracts and the main text. As can be seen, the effect size distributions look similar across the different panels, providing evidence that there is probably no strong bias.&#x0201d;</p><p>Related to my previous point, I think that there are a few details about the extraction method that could be made clearer in the manuscript. Specifically, the authors mention that they extracted articles from &#x0201c;top journals&#x0201d; in the respective fields, but the definition of a &#x0201c;top journal&#x0201d; remained vague. How did the authors ensure that no predatory (pseudo-peer reviewed) journals were part of the selection? Moreover, when explaining the search algorithm using regular expressions, the examples include different versions of &#x0201c;HR&#x0201d;. How can we be sure that &#x0201c;HR&#x0201d; always refers to a hazard ratio and isn&#x02019;t an abbreviation of something else (e.g., heart rate) and that the reported numbers hence refer to a different quantity? And finally, the extraction method for the standard error assumes two-sided confidence intervals. Intuitively, it makes sense that this would be the standard, but wouldn&#x02019;t it be possible that some articles report one-sided confidence intervals (e.g., with a one-sided test of treatment effectiveness?).</p><p>R1-3: In the following, we address the three points raised by the reviewer:</p><p>1) We think that it is almost impossible to be certain that all articles contained in our corpus are not connected to predatory journals. There are several databases that list predatory journals, the most famous one being Beall&#x02019;s list (<ext-link xlink:href="https://beallslist.net/)." ext-link-type="uri">https://beallslist.net/</ext-link>). However, these databases are often outdated or incomplete. Due to these drawbacks, we have decided to not filter out articles based on these lists. An alternative would have been to check the journals in our corpus manually. But with 1170 considered journals, this task would have exceeded our resources. Even more, we believe that this alternative would not be worth the effort because it would be prone to errors; false positives and false negatives would probably arise because of the uncertainties surrounding classification of journals to be predatory or non-predatory. Ultimately, we decided to not screen for predatory journals for two reasons. First, there is a workforce installed at Scopus that constantly screens for predatory journals in their database (<ext-link xlink:href="https://www.elsevier.com/connect/the-guardians-of-scopus)." ext-link-type="uri">https://www.elsevier.com/connect/the-guardians-of-scopus</ext-link>). Second, even if a small proportion of the journals in our corpus can be considered predatory, we think that their influence on our results is minimal, given the large number of non-predatory journals. To accommodate the point of the reviewer, we have added the following limitation to our Discussion section: &#x0201c;Fifth, our results are predicated on articles that have come up in the Scopus search engine. Any articles that were published in predatory journals, but that were somehow not screened out as such (see e.g., <ext-link xlink:href="https://www.elsevier.com/connect/the-guardians-of-scopus)," ext-link-type="uri">https://www.elsevier.com/connect/the-guardians-of-scopus</ext-link>), may have introduced bias in the estimate of effect size variance, because of lack of proper peer review.&#x0201d;</p><p>2) We cannot be absolutely certain that &#x0201c;HR&#x0201d; in the regular expression matches hazard ratios only. We agree that &#x0201c;HR&#x0201d; could in principle also refer to other abbreviations, such as heart rate. However, our regular expression does not only match &#x0201c;HR&#x0201d;. Instead, it also requires that &#x0201c;HR&#x0201d; is immediately followed by some form of confidence interval. This requirement drastically decreases the probability that the regular expression captures heart rate or anything else than hazard ratio. Further, all our abstracts must contain &#x0201c;Cox&#x0201d;, further decreasing the chances that HR refers to something other than hazard ratio. To mitigate this concern even more, we manually screened the 88 articles mentioned in R1-2 and added the following to the Discussion section: &#x0201c;Sixth, we assumed that HR refers to hazard ratio in the abstracts. However, HR could also be an abbreviation for other terms like heart rate. To mitigate this concern, we manually screened a random sample of 88 articles for which we could obtain a match and found that in all cases HR corresponded to hazard ratio.&#x0201d;</p><p>3) The way that our regular expression is constructed increases the probability that only articles that report two-sided confidence intervals are matched. More precisely, our regular expression has a match when both the lower and upper limits of a confidence interval are represented by a number, which is higher than 0. Importantly, this excludes 0, which would be required for upper one-sided confidence intervals. Moreover, any symbols representing infinity are also excluded, which would be required for lower one-sided confidence intervals. In addition, our regular expression method checks whether point estimates of the hazard ratio are approximately in the middle of the reported confidence interval (see paragraph &#x02018;We applied &#x02026; results of 21,598&#x02019;). Note that only a small proportion of confidence intervals was excluded as a result of this check (see Table 1), strongly suggesting that the included confidence intervals are all two-sided.</p><p>For me, the application example presented on pp. 9-12 does not fall into the intended application domain of the specified prior distributions. The prior distribution was elicited for the beta coefficient in Cox regressions, but in the presented application example, the prior distribution was applied to the fixed effect in a meta-analysis across five Cox regressions. I would argue that the specified prior distribution is not a good match for the analysis presented in the application example because the meta-analytic effect size estimate tends to be less extreme than the effect size estimate in a single study. Specifically, we can expect that due to sampling variability, the effect size in a single (potentially small) study is more extreme than the combined estimate across multiple studies (weighed by the study sample size). An appropriate prior specification procedure for meta-analytic effect size estimates in Cox regressions that is similar to the described procedure would therefore, in my view, not specify the prior based on a corpus of individual studies, but on a corpus of meta-analyses. I would therefore highly recommend to exchange the example application in the paper with a Bayesian Cox regression in a single study.</p><p>In addition to my previous point, I believe that the presented application example falls short of showcasing the advantages of the methodology and the recommended best practices for using the informed prior distribution. The authors repeatedly mention in the introduction of the manuscript that two advantages of the Bayesian statistical framework are the possibility of quantifying evidence for the null hypothesis and the possibility of flexible sequential designs. I believe that it would be a great opportunity to showcase these advantages in the application example by using a sequential hypothesis test with the s</p><supplementary-material id="pone.0322144.s002" position="float" content-type="local-data"><label>Attachment</label><caption><p>Submitted filename: <named-content content-type="submitted-filename">Response to Reviewers.docx</named-content></p></caption><media xlink:href="pone.0322144.s002.docx"/></supplementary-material></body></sub-article><sub-article article-type="aggregated-review-documents" id="pone.0322144.r004" specific-use="decision-letter"><front-stub><article-id pub-id-type="doi">10.1371/journal.pone.0322144.r004</article-id><title-group><article-title>Decision Letter 1</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Haunschild</surname><given-names>Robin</given-names></name><role>Academic Editor</role></contrib></contrib-group><permissions><copyright-statement>&#x000a9; 2025 Robin Haunschild</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Robin Haunschild</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><related-article ext-link-type="doi" xlink:href="10.1371/journal.pone.0322144" id="rel-obj004" related-article-type="reviewed-article"/><custom-meta-group><custom-meta><meta-name>Submission Version</meta-name><meta-value>1</meta-value></custom-meta></custom-meta-group></front-stub><body><p>
<named-content content-type="letter-date">15 Jan 2025</named-content>
</p><p><!--<div>-->PONE-D-24-18152R1<!--</div>--><!--<div>-->Data-driven prior elicitation for Bayes factors in Cox regression for nine subfields in biomedicine<!--</div>--><!--<div>-->PLOS ONE</p><p>Dear Dr. Linde,</p><p>Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE&#x02019;s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.</p><p>Please submit your revised manuscript by Mar 01 2025 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at&#x000a0;<email>plosone@plos.org</email>. When you're ready to submit your revision, log on to <ext-link xlink:href="https://www.editorialmanager.com/pone/" ext-link-type="uri">https://www.editorialmanager.com/pone/</ext-link> and select the 'Submissions Needing Revision' folder to locate your manuscript file.</p><p>Please include the following items when submitting your revised manuscript:<!--</div>--></p><p><list list-type="bullet"><list-item><p>A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.</p></list-item><list-item><p>A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.</p></list-item><list-item><p>An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.</p></list-item></list>
</p><p><!--<div>-->If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.</p><p>If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: <ext-link xlink:href="https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols" ext-link-type="uri">https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols</ext-link>. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at <ext-link xlink:href="https://plos.org/protocols?utm_medium=editorial-email&#x00026;utm_source=authorletters&#x00026;utm_campaign=protocols" ext-link-type="uri">https://plos.org/protocols?utm_medium=editorial-email&#x00026;utm_source=authorletters&#x00026;utm_campaign=protocols</ext-link>.</p><p>We look forward to receiving your revised manuscript.</p><p>Kind regards,</p><p>Robin Haunschild</p><p>Academic Editor</p><p>PLOS ONE</p><p>Journal Requirements:</p><p>Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article&#x02019;s retracted status in the References list and also include a citation and full reference for the retraction notice.</p><p>[Note: HTML markup is below. Please do not edit.]</p><p>Reviewers' comments:</p><p>Reviewer's Responses to Questions</p><p>
<!--<font color="black">-->
<bold>Comments to the Author</bold>
</p><p>1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the &#x0201c;Comments to the Author&#x0201d; section, enter your conflict of interest statement in the &#x0201c;Confidential to Editor&#x0201d; section, and submit your "Accept" recommendation.<!--</font>--></p><p>Reviewer #1:&#x000a0;(No Response)</p><p>Reviewer #2:&#x000a0;All comments have been addressed</p><p>**********</p><p><!--<font color="black">-->2. Is the manuscript technically sound, and do the data support the conclusions?</p><p>The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. <!--</font>--></p><p>Reviewer #1:&#x000a0;Yes</p><p>Reviewer #2:&#x000a0;Yes</p><p>**********</p><p><!--<font color="black">-->3. Has the statistical analysis been performed appropriately and rigorously? <!--</font>--></p><p>Reviewer #1:&#x000a0;Yes</p><p>Reviewer #2:&#x000a0;Yes</p><p>**********</p><p><!--<font color="black">-->4. Have the authors made all data underlying the findings in their manuscript fully available?</p><p>The <ext-link xlink:href="http://www.plosone.org/static/policies.action#sharing" ext-link-type="uri">PLOS Data policy</ext-link> requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data&#x02014;e.g. participant privacy or use of data from a third party&#x02014;those must be specified.<!--</font>--></p><p>Reviewer #1:&#x000a0;Yes</p><p>Reviewer #2:&#x000a0;No</p><p>**********</p><p><!--<font color="black">-->5. Is the manuscript presented in an intelligible fashion and written in standard English?</p><p>PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.<!--</font>--></p><p>Reviewer #1:&#x000a0;Yes</p><p>Reviewer #2:&#x000a0;Yes</p><p>**********</p><p><!--<font color="black">-->6. Review Comments to the Author</p><p>Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)<!--</font>--></p><p>Reviewer #1:&#x000a0;I think the manuscript is in a very good shape in its current form and the authors have done an excellent job to address the points I raised in my previous review. I particularly want to praise the thorough robustness analyses that have been conducted in response to my earlier comments and the introduction of a new example that much better demonstrates the application of the methodology. I do have a few really minor comments on the current version, particularly on the new example application, but in my view, these should not impede the publication of the manuscript.</p><p>&#x02022; In the application example, the manuscript reads &#x0201c;It can be seen that all Bayes factor trajectories cross the upper threshold of 30 at some point&#x0201d;. However, Figure 4 seems to suggest that the trajectories cross the threshold of 20, but not of 30? Is there potentially an issue with the axis labels? Furthermore, it may be helpful to very briefly discuss the definition of stopping thresholds in the new paragraph about the sequential design (i.e., why is 30 a good choice?)</p><p>&#x02022; In the example application, is there any benefit of using the data-driven priors compared to the default priors? Judging based on Figure 4, it looks a bit like the data-driven priors yield Bayes factors in the upper third of the distribution, which would indicate at least some efficiency benefit over the default priors. I understand that the authors are reluctant to point to the potential efficiency benefits of informed priors (I&#x02019;ve gathered as much from the response to the second reviewer). However, I think the application example shows that at least IF the parameter in the present study is similar to the corpus of literature used for deriving the prior, then efficiency gains can be expected compared to SOME default priors. Moreover, the variability in data-driven priors is much smaller than in the other priors, potentially indicating greater stability of results if priors are chosen in a principled manner.</p><p>&#x02022; In Figure 4, it is difficult to distinguish the red and blue lines. Is there any way to overcome this issue (perhaps decreasing the line width and/or making the grey lines in the background brighter would help?), or if not, could the authors perhaps briefly note the overlap in the figure caption so that readers don&#x02019;t get confused?</p><p>&#x02022; In response to my earlier comment R1-7, the authors added a section to the introduction that contains the sentence &#x0201c;A prominent way to deal with this issue within the frequentist framework is the use of sequential designs&#x0201d; &#x02013; I think this should be group sequential designs?</p><p>&#x02022; I thought the new figure illustrating the article retention rate across processing steps was interesting &#x02013; will this be included in the appendix / supplementary materials?</p><p>Signed,</p><p>Angelika Stefan</p><p>Reviewer #2:&#x000a0;(No Response)</p><p>**********</p><p><!--<font color="black">-->7. PLOS authors have the option to publish the peer review history of their article (<ext-link xlink:href="https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history" ext-link-type="uri">what does this mean?</ext-link>). If published, this will include your full peer review and any attached files.</p><p>If you choose &#x0201c;no&#x0201d;, your identity will remain anonymous but your review may still be made public.</p><p><bold>Do you want your identity to be public for this peer review?</bold> For information about this choice, including consent withdrawal, please see our <ext-link xlink:href="https://www.plos.org/privacy-policy" ext-link-type="uri">Privacy Policy</ext-link>.<!--</font>--></p><p>Reviewer #1:&#x000a0;<bold>Yes:&#x000a0;</bold>Angelika M. Stefan</p><p>Reviewer #2:&#x000a0;No</p><p>**********</p><p>[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]</p><p>While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool,&#x000a0;<ext-link xlink:href="https://pacev2.apexcovantage.com/" ext-link-type="uri">https://pacev2.apexcovantage.com/</ext-link>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at&#x000a0;<email>figures@plos.org</email>. Please note that Supporting Information files do not need this step.<!--</div>--></p></body></sub-article><sub-article article-type="author-comment" id="pone.0322144.r005"><front-stub><article-id pub-id-type="doi">10.1371/journal.pone.0322144.r005</article-id><title-group><article-title>Author response to Decision Letter 2</article-title></title-group><related-article ext-link-type="doi" xlink:href="10.1371/journal.pone.0322144" id="rel-obj005" related-article-type="editor-report"/><custom-meta-group><custom-meta><meta-name>Submission Version</meta-name><meta-value>2</meta-value></custom-meta></custom-meta-group></front-stub><body><p>
<named-content content-type="author-response-date">12 Mar 2025</named-content>
</p><p>Dear Dr. Haunschild,</p><p>Thank you for considering our manuscript &#x0201c;Data-driven prior elicitation for Bayes factors in Cox regression for nine subfields in biomedicine&#x0201d; for publication in PLOS ONE. We have read your and the reviewers&#x02019; comments carefully. Below you find our responses. The reviewers&#x02019; comments are shown in regular font and our responses are shown in bold font. Our revision contains a version of our manuscript without track changes (i.e., a clean version with all changes already incorporated) and a version of our manuscript with track changes. For the latter, track changes that correspond to additions are shown in blue font and track changes that correspond to removals are shown in red font.</p><p>We look forward to your comments.</p><p>Kind regards,</p><p>Maximilian Linde</p><p>Laura Jochim</p><p>Jorge N. Tendeiro</p><p>Don van Ravenzwaaij&#x02003;</p><p>PONE-D-24-18152R1</p><p>Data-driven prior elicitation for Bayes factors in Cox regression for nine subfields in biomedicine</p><p>PLOS ONE</p><p>Dear Dr. Linde,</p><p>Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE&#x02019;s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.</p><p>Please submit your revised manuscript by Mar 01 2025 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to <ext-link xlink:href="https://www.editorialmanager.com/pone/" ext-link-type="uri">https://www.editorialmanager.com/pone/</ext-link> and select the 'Submissions Needing Revision' folder to locate your manuscript file.</p><p>Please include the following items when submitting your revised manuscript:</p><p>A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.</p><p>A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.</p><p>An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.</p><p>If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.</p><p>If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: <ext-link xlink:href="https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols." ext-link-type="uri">https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols</ext-link>. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at <ext-link xlink:href="https://plos.org/protocols?utm_medium=editorial-email&#x00026;utm_source=authorletters&#x00026;utm_campaign=protocols." ext-link-type="uri">https://plos.org/protocols?utm_medium=editorial-email&#x00026;utm_source=authorletters&#x00026;utm_campaign=protocols</ext-link>.</p><p>We look forward to receiving your revised manuscript.</p><p>Kind regards,</p><p>Robin Haunschild</p><p>Academic Editor</p><p>PLOS ONE</p><p>Journal Requirements:</p><p>Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article&#x02019;s retracted status in the References list and also include a citation and full reference for the retraction notice.</p><p>E1-1: We thank the editor for the positive evaluation of our manuscript and for the opportunity to resubmit our manuscript.&#x02003;</p><p>Reviewer 1:</p><p>I think the manuscript is in a very good shape in its current form and the authors have done an excellent job to address the points I raised in my previous review. I particularly want to praise the thorough robustness analyses that have been conducted in response to my earlier comments and the introduction of a new example that much better demonstrates the application of the methodology. I do have a few really minor comments on the current version, particularly on the new example application, but in my view, these should not impede the publication of the manuscript.</p><p>R1-1: We thank the reviewer for the very positive evaluation of our revised manuscript.</p><p>In the application example, the manuscript reads &#x0201c;It can be seen that all Bayes factor trajectories cross the upper threshold of 30 at some point&#x0201d;. However, Figure 4 seems to suggest that the trajectories cross the threshold of 20, but not of 30? Is there potentially an issue with the axis labels? Furthermore, it may be helpful to very briefly discuss the definition of stopping thresholds in the new paragraph about the sequential design (i.e., why is 30 a good choice?)</p><p>R1-2: We are grateful that the reviewer caught this error. It turned out that the figure is correct but the text is wrong. That is, we used a threshold of 20. We have corrected the text accordingly. Further, we followed the reviewer's request to give some additional explanation about stopping thresholds. We wrote the following: &#x0201c;In general, the choice for a specific decision threshold should be tailored to the research at hand. There are scenarios where more certainty is desired compared to other scenarios. However, researchers should be aware of the tradeoff between certainty and resource demands; the more certain we want to be, the more cases must be sampled.&#x0201d;. We think that a more detailed discussion about this extensive topic is beyond the scope of our article.</p><p>In the example application, is there any benefit of using the data-driven priors compared to the default priors? Judging based on Figure 4, it looks a bit like the data-driven priors yield Bayes factors in the upper third of the distribution, which would indicate at least some efficiency benefit over the default priors. I understand that the authors are reluctant to point to the potential efficiency benefits of informed priors (I&#x02019;ve gathered as much from the response to the second reviewer). However, I think the application example shows that at least IF the parameter in the present study is similar to the corpus of literature used for deriving the prior, then efficiency gains can be expected compared to SOME default priors. Moreover, the variability in data-driven priors is much smaller than in the other priors, potentially indicating greater stability of results if priors are chosen in a principled manner.</p><p>R1-3: In general, we are very much in favour of using informed priors when relevant information is available. In our case, however, we did not observe efficiency gains of the data-driven priors. Although based on eyeballing, it appears that the data-driven priors result in Bayes factors in the upper third of the distribution generated by the default priors used in the sensitivity analyses, numerical confirmation revealed that it is closer to the median. In an additional analysis, we looked at potential Bayes factor decision thresholds of {3, 4, &#x02026;, 60}. For almost all of these Bayes factor decision thresholds, the rank of the data-driven priors, in terms of the speed of reaching that threshold, was in the middle, compared to the default priors we used in our sensitivity analysis. In other words, roughly 50% of the priors reached the decision thresholds faster and 50% slower. We observed that in our scenario, priors that are more concentrated at 0 (i.e., smaller standard deviation) reached the decision thresholds faster.</p><p>In Figure 4, it is difficult to distinguish the red and blue lines. Is there any way to overcome this issue (perhaps decreasing the line width and/or making the grey lines in the background brighter would help?), or if not, could the authors perhaps briefly note the overlap in the figure caption so that readers don&#x02019;t get confused?</p><p>R1-4: To mitigate this issue, we have now decreased the line width and increased the transparency of lines. These steps improved the visibility of the lines. However, since the blue and red lines overlap so heavily, the visual distinction is still not perfect. Therefore, we added another note to the caption of Figure 4: &#x0201c;The blue and red lines heavily overlap, so the blue line is hardly visible.&#x0201d;</p><p>In response to my earlier comment R1-7, the authors added a section to the introduction that contains the sentence &#x0201c;A prominent way to deal with this issue within the frequentist framework is the use of sequential designs&#x0201d; &#x02013; I think this should be group sequential designs?</p><p>R1-5: We have now corrected this sentence according to the reviewer's request.</p><p>I thought the new figure illustrating the article retention rate across processing steps was interesting &#x02013; will this be included in the appendix / supplementary materials?</p><p>R1-6: We have now included and explained the figure in an appendix.</p><supplementary-material id="pone.0322144.s003" position="float" content-type="local-data"><label>Attachment</label><caption><p>Submitted filename: <named-content content-type="submitted-filename">Response_to_Reviewers_auresp_2.docx</named-content></p></caption><media xlink:href="pone.0322144.s003.docx"/></supplementary-material></body></sub-article><sub-article article-type="aggregated-review-documents" id="pone.0322144.r006" specific-use="decision-letter"><front-stub><article-id pub-id-type="doi">10.1371/journal.pone.0322144.r006</article-id><title-group><article-title>Decision Letter 2</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Haunschild</surname><given-names>Robin</given-names></name><role>Academic Editor</role></contrib></contrib-group><permissions><copyright-statement>&#x000a9; 2025 Robin Haunschild</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Robin Haunschild</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><related-article ext-link-type="doi" xlink:href="10.1371/journal.pone.0322144" id="rel-obj006" related-article-type="reviewed-article"/><custom-meta-group><custom-meta><meta-name>Submission Version</meta-name><meta-value>2</meta-value></custom-meta></custom-meta-group></front-stub><body><p>
<named-content content-type="letter-date">18 Mar 2025</named-content>
</p><p>Data-driven prior elicitation for Bayes factors in Cox regression for nine subfields in biomedicine</p><p>PONE-D-24-18152R2</p><p>Dear Dr. Linde,</p><p>We&#x02019;re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.</p><p>Within one week, you&#x02019;ll receive an e-mail detailing the required amendments. When these have been addressed, you&#x02019;ll receive a formal acceptance letter and your manuscript will be scheduled for publication.</p><p>An invoice will be generated when your article is formally accepted. Please note, if your institution has a publishing partnership with PLOS and your article meets the relevant criteria, all or part of your publication costs will be covered. Please make sure your user information is up-to-date by logging into Editorial Manager at <ext-link xlink:href="https://www.editorialmanager.com/pone/" ext-link-type="uri">Editorial Manager&#x000ae;</ext-link>&#x000a0;and clicking the &#x02018;Update My Information' link at the top of the page. If you have any questions relating to publication charges, please contact our Author Billing department directly at authorbilling@plos.org.</p><p>If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they&#x02019;ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.</p><p>Kind regards,</p><p>Robin Haunschild</p><p>Academic Editor</p><p>PLOS ONE</p><p>Additional Editor Comments (optional):</p><p>Reviewers' comments:</p><p>Reviewer's Responses to Questions</p><p>
<!--<font color="black">-->
<bold>Comments to the Author</bold>
</p><p>1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the &#x0201c;Comments to the Author&#x0201d; section, enter your conflict of interest statement in the &#x0201c;Confidential to Editor&#x0201d; section, and submit your "Accept" recommendation.<!--</font>--></p><p>Reviewer #1:&#x000a0;All comments have been addressed</p><p>**********</p><p><!--<font color="black">-->2. Is the manuscript technically sound, and do the data support the conclusions?</p><p>The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. <!--</font>--></p><p>Reviewer #1:&#x000a0;Yes</p><p>**********</p><p><!--<font color="black">-->3. Has the statistical analysis been performed appropriately and rigorously? <!--</font>--></p><p>Reviewer #1:&#x000a0;Yes</p><p>**********</p><p><!--<font color="black">-->4. Have the authors made all data underlying the findings in their manuscript fully available?</p><p>The <ext-link xlink:href="http://www.plosone.org/static/policies.action#sharing" ext-link-type="uri">PLOS Data policy</ext-link> requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data&#x02014;e.g. participant privacy or use of data from a third party&#x02014;those must be specified.<!--</font>--></p><p>Reviewer #1:&#x000a0;Yes</p><p>**********</p><p><!--<font color="black">-->5. Is the manuscript presented in an intelligible fashion and written in standard English?</p><p>PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.<!--</font>--></p><p>Reviewer #1:&#x000a0;Yes</p><p>**********</p><p><!--<font color="black">-->6. Review Comments to the Author</p><p>Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)<!--</font>--></p><p>Reviewer #1:&#x000a0;All my comments were addressed. I thank the authors for considering the concerns that I previously raised and for their thoughtful responses. In my view, this manuscript is ready to be published.</p><p>**********</p><p><!--<font color="black">-->7. PLOS authors have the option to publish the peer review history of their article (<ext-link xlink:href="https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history" ext-link-type="uri">what does this mean?</ext-link>). If published, this will include your full peer review and any attached files.</p><p>If you choose &#x0201c;no&#x0201d;, your identity will remain anonymous but your review may still be made public.</p><p><bold>Do you want your identity to be public for this peer review?</bold> For information about this choice, including consent withdrawal, please see our <ext-link xlink:href="https://www.plos.org/privacy-policy" ext-link-type="uri">Privacy Policy</ext-link>.<!--</font>--></p><p>Reviewer #1:&#x000a0;<bold>Yes:&#x000a0;</bold>Angelika M. Stefan</p><p>**********</p></body></sub-article><sub-article article-type="editor-report" id="pone.0322144.r007" specific-use="acceptance-letter"><front-stub><article-id pub-id-type="doi">10.1371/journal.pone.0322144.r007</article-id><title-group><article-title>Acceptance letter</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Haunschild</surname><given-names>Robin</given-names></name><role>Academic Editor</role></contrib></contrib-group><permissions><copyright-statement>&#x000a9; 2025 Robin Haunschild</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Robin Haunschild</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><related-article ext-link-type="doi" xlink:href="10.1371/journal.pone.0322144" id="rel-obj007" related-article-type="reviewed-article"/></front-stub><body><p>PONE-D-24-18152R2</p><p>PLOS ONE</p><p>Dear Dr. Linde,</p><p>I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now being handed over to our production team.</p><p>At this stage, our production department will prepare your paper for publication. This includes ensuring the following:</p><p>* All references, tables, and figures are properly cited</p><p>* All relevant supporting information is included in the manuscript submission,</p><p>* There are no issues that prevent the paper from being properly typeset</p><p>If revisions are needed, the production department will contact you directly to resolve them. If no revisions are needed, you will receive an email when the publication date has been set. At this time, we do not offer pre-publication proofs to authors during production of the accepted work. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few weeks to review your paper and let you know the next and final steps.</p><p>Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.</p><p>If we can help with anything else, please email us at customercare@plos.org.</p><p>Thank you for submitting your work to PLOS ONE and supporting open access.</p><p>Kind regards,</p><p>PLOS ONE Editorial Office Staff</p><p>on behalf of</p><p>Dr. Robin Haunschild</p><p>Academic Editor</p><p>PLOS ONE</p></body></sub-article></article>